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Abstract
The monitoring of central hemodynamic parameters such as cardiac output (CO) and
pulmonary artery pressure (PAP) is of paramount clinical importance to assess the
health status of the cardiovascular system. However, their measurement requires the
insertion of a pulmonary artery catheter, a highly invasive procedure associated with
non-negligible morbidity and mortality rates. In this thesis, we investigated the clinical
potential of electrical impedance tomography (EIT) – a radiation-free medical imaging
technique – as a non-invasive alternative for the measurement of CO and PAP.
In a ﬁrst phase, we investigated the potential of EIT for the measurement of CO. This
measurement is implicitly based on the hypothesis that the EIT heart signal (the ventricu-
lar component of the EIT signals) is induced by ventricular blood volume changes. This
hypothesis has never been formally investigated, and the exact origins of the EIT heart
signal remain subject to interpretation. Therefore, using a model, we investigated the
genesis of this signal by identifying its various sources and their respective contributions.
The results revealed that the EIT heart signal is dominated by cardioballistic effects
(heart motion). However, although of prominently cardioballistic origin, the amplitude
of the signal has shown to be strongly correlated to stroke volume (r = 0.996, p < 0.001;
error of 0.57± 2.19 mL). We explained these observations by the quasi-incompressibility
of myocardial tissue and blood. We further identiﬁed several factors and conditions
susceptible to affect the accuracy of the measurement. Finally, we investigated the
inﬂuence of the EIT sensor belt position on the measured heart signal. We observed that
small belt displacements – likely to occur in clinical settings during patient handling –
can induce errors of up to 30 mL on stroke volume estimation.
In a second phase, we investigated the feasibility of a novel method for the non-invasive
measurement of PAP by EIT. The method is based on the physiological relation linking
the PAP to the velocity of propagation of the pressure waves in the pulmonary arteries.
We hypothesized that the variations of this velocity, and therefore of the PAP, could be
measured by EIT. In a bioimpedance model of the human thorax, we demonstrated the
feasibility of our method in various types of pulmonary hypertensive disorders. Our EIT-
derived parameter has shown to be particularly well-suited for predicting early changes
in pulmonary hemodynamics due to its physiological link with arterial compliance.
Finally, we validated experimentally our method in 14 subjects undergoing hypoxia-
induced PAP changes. Signiﬁcant correlation coefﬁcients (r ∈ [0.70, 0.98], average: 0.89)
and small standard errors of the estimate (SEE ∈ [0.9, 6.3] mmHg, average: 2.4 mmHg)
i
were found between our EIT-derived systolic PAP and reference systolic PAP values
obtained by Doppler echocardiography.
In conclusion, there is a promising outlook for EIT in non-invasive hemodynamic moni-
toring. Our observations provide novel insights for the interpretation and understanding
of EIT heart signals, and detail the physiological and metrological requirements for an
accurate measurement of CO by EIT. Our novel PAP monitoring method, validated
in vivo, allows a reliable tracking of PAP changes, thereby paving the way towards the
development of a new branch of non-invasive hemodynamic monitors based on the use
of EIT.
Keywords: non-invasive hemodynamic monitoring, electrical impedance tomography,
cardiac output, pulmonary artery pressure, cardiovascular diseases.
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Résumé
Le monitorage de paramètres hémodynamiques centraux tels que le débit cardiaque (DC)
et la pression artérielle pulmonaire (PAP) est d’une importance clinique primordiale pour
évaluer l’état du système cardiovasculaire. Cependant, leur mesure nécessite l’insertion
d’un cathéter artériel pulmonaire, une procédure hautement invasive et associée à des
taux de morbidité et mortalité non-négligeables. Dans cette thèse, nous avons étudié
le potentiel clinique de la tomographie d’impédance électrique (TIE) – une technique
d’imagerie médicale sans radiation – comme alternative non-invasive pour la mesure
du DC et de la PAP.
Dans un premier temps, nous avons étudié le potentiel de la TIE pour la mesure du DC.
Cette mesure est implicitement basée sur l’hypothèse selon laquelle le signal TIE du
coeur (la composante ventriculaire des signaux TIE) est induit par des changements de
volume sanguin ventriculaire. Cette hypothèse n’a jamais été formellement examinée, et
les origines exactes du signal TIE du coeur demeurent, à ce jour, sujettes à interprétation.
Pour cette raison, au moyen d’un modèle, nous avons étudié la genèse de ce signal
en identiﬁant ses diverses sources et leurs contributions respectives. Les résultats ont
révélé que le signal TIE du coeur est dominé par des effets cardiobalistiques (mou-
vements cardiaques). Cependant, bien que principalement d’origine cardiobalistique,
l’amplitude du signal s’est montrée fortement corrélée au volume d’éjection systolique
(r = 0.996, p < 0.001 ; erreur de 0.57± 2.19 mL). Nous avons expliqué ces résultats
par la quasi-incompressibilité du tissu du myocarde et du sang. Nous avons également
identiﬁé plusieurs facteurs et pathologies susceptibles d’affecter la précision de la me-
sure. Enﬁn, nous avons étudié l’inﬂuence de la position de la ceinture de TIE sur le
signal cardiaque mesuré. Nous avons observé que de petits déplacements de la ceinture
– probables en milieu clinique lors de la manutention du patient – peuvent produire des
erreurs allant jusqu’à 30 mL sur l’estimation du volume d’éjection systolique.
Dans un second temps, nous avons étudié la faisabilité d’une nouvelle méthode pour la
mesure non-invasive de la PAP par TIE. La méthode se base sur la relation physiologique
liant la PAP à la vitesse de propagation des ondes de pression dans les artères pulmo-
naires. Nous avons fait l’hypothèse que les variations de cette vitesse, et donc de la PAP,
peuvent être mesurées par TIE. Nous avons démontré la faisabilité de notre méthode
dans un modèle de bio-impédance du thorax humain pour divers types d’hypertensions
pulmonaires. Le paramètre que nous estimons par TIE s’est montré particulièrement bien
adapté pour la prédiction de changements précoces dans l’hémodynamique pulmonaire,
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en raison de son lien physiologique à la compliance artérielle. Enﬁn, nous avons validé
expérimentalement notre méthode dans 14 sujets soumis à des variations de PAP induites
par hypoxie. Des coefﬁcients de corrélation signiﬁcatifs (r ∈ [0.70, 0.98], moyenne : 0.89)
et des erreurs-types d’estimation petites (Se ∈ [0.9, 6.3] mmHg, moyenne : 2.4 mmHg)
ont été obtenus entre nos estimations de PAP systolique et les valeurs de PAP systolique
de référence obtenues par échocardiographie Doppler.
En conclusion, les perspectives de la TIE pour le monitorage hémodynamique non-
invasif sont prometteuses. Nos observations apportent de nouveaux éléments quant à
l’interprétation et la compréhension des signaux TIE du coeur, et détaillent les conditions
physiologiques et métrologiques nécessaires à une mesure précise du DC par TIE. Notre
nouvelle méthode de monitorage de la PAP, validée in vivo, permet un suivi ﬁable des
variations de PAP, ouvrant ainsi la voie au développement d’une nouvelle branche de
moniteurs hémodynamiques non-invasifs basés sur l’utilisation de la TIE.
Mots-clefs : monitorage hémodynamique non-invasif, tomographie d’impédance élec-
trique, débit cardiaque, pression artérielle pulmonaire, maladies cardiovasculaires.
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Part IIntroduction and background
1

1 Introduction
1.1 Motivation and problem statement
1.1.1 Monitoring of hemodynamic parameters
The circulation of blood in the body is vital. This function is performed by the cardio-
vascular system, which comprises the heart and blood vessels. Similarly to an hydraulic
circuit controlled by parameters such as pressure and ﬂow rate, the cardiovascular
system is governed by so-called hemodynamic parameters (from Greek haima, “blood”,
and dynamis, “power”). Being able to reliably measure hemodynamic parameters is
therefore of paramount clinical importance to assess the health of the cardiovascular
system. However, since most hemodynamic parameters are central (as opposed to pe-
ripheral), their measurement often represents a great technical challenge. In particular,
the measurement of parameters such as cardiac output (CO) or pulmonary artery pres-
sure (PAP) still requires, to this day, a highly invasive procedure known as right heart
catheterization, which consists in the insertion of a so-called pulmonary artery catheter
(PAC) into the pulmonary arteries via the right cardiac chambers (Figure 1.1).
1.1.2 Pulmonary artery catheter: beneﬁts and risks
Introduced in 1970 [162] and commercialized soon after, the PAC quickly became ex-
tensively used in operating rooms and intensive care units, not only as a diagnostic
tool, but also for the determination and guidance of therapy in critically ill and hemo-
dynamically unstable patients [38, 107]. However, in 1996, a prospective cohort study
by Connors et al [34] in 5,735 patients demonstrated a 24 % increased 30-day mortality
in patients who underwent right heart catheterization during the ﬁrst 24 hours of care
in an intensive care unit, in comparison with non-catheterized patients. Their ﬁndings
were further conﬁrmed over the next decade, when several randomized control trials
failed to demonstrate any decrease in morbidity and mortality following the use of
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Figure 1.1 – Pulmonary artery catheter inserted into the pulmonary arteries via the right
cardiac chambers for the measurement of central hemodynamic parameters such as
CO and PAP. RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle.
PA: pulmonary artery; AO: aorta. Adapted from [86].
the PAC in critically ill and hemodynamically unstable patients [67, 143, 147]. The
risks associated with the insertion and maintenance of the PAC (e.g. pulmonary artery
rupture), as well as measurement inaccuracies (particularly for CO) and the difﬁculty
for the clinicians to correctly interpret the data measured, are some of the explanations
that have been proposed to interpret these outcomes [107]. Since then, the use of the
PAC has been strongly reduced and right heart catheterization is only performed when
the beneﬁts/safety ratio is considered clearly favorable by the clinicians.
1.1.3 Clinical need for non-invasive alternatives
The controversy associated with the use of the PAC has paved the way for the introduc-
tion of non-invasive alternative solutions to monitor central hemodynamics, in particular
for CO and PAP.
For instance, although non-invasive continuous CO monitors generally cannot provide
absolute values, they are of particular importance in events of circulatory shock – a
common and potentially fatal condition affecting about one third of patients in inten-
sive care units – where beat-to-beat trends in CO (rather than absolute values) have
a strong impact for guiding and optimizing the therapy [106, 169]. Continuous CO
monitors are also useful as complementary solutions to the PAC, by providing beat-to-
beat readings in-between PAC measurements, possibly using the latter for intermittent
recalibration [36, 131]. However, the reliability of current non-invasive beat-to-beat CO
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monitors is strongly limited by their sensitivity to physiological phenomena unrelated to
CO, thus requiring frequent recalibration maneuvers, whenever changes in the patient’s
hemodynamic status may have occurred [91, 131, 177].
For monitoring PAP, the PAC remains the only solution for reliable beat-to-beat measure-
ment. Non-invasive and continuous PAP monitors could therefore prove themselves
particularly useful, for instance in patients undergoing acute changes in pulmonary
hemodynamics but for whom the placement of a PAC was not indicated. Furthermore,
in patients requiring right heart catheterization, such devices would allow extending
the monitoring after removal of the PAC, as the latter should be left in place as brieﬂy
as possible to minimize the risks of complications [38, 184]. In patients with chronic
pulmonary hypertension (sustained and abnormally elevated PAP), a condition affect-
ing at least 0.3 % of the general population [160] and more than 60 % of patients with
moderate or severe heart failure [58], reliable non-invasive means of assessing changes
in PAP at regular intervals of days or weeks have shown to improve patient outcomes
and allow anticipating worsening conditions, as increases in PAP occur days or weeks
before the onset of symptoms [1, 111]. However, the currently existing reliable and
non-invasive PAP measuring techniques – based on Doppler ultrasounds – are unsuited
for frequent or continuous monitoring. They depend on medical doctors to perform the
measurement and are inapplicable in 20–50 % of patients due to unmeasurable tricuspid
regurgitation [37, 40].
In summary, reliable and non-invasive solutions for the continuous monitoring of CO
and PAP are currently still lacking.
1.1.4 Non-invasive monitoring by electrical impedance tomography
Electrical impedance tomography (EIT) is a non-invasive and radiation-free medical
imaging technique for continuous monitoring at the bedside [73]. The main strength of
EIT resides in its ability to monitor changes in the intra-thoracic distribution of electrical
impedance with a high time resolution. In particular, impedance changes induced by
respiratory and cardiovascular activity (e.g. changes in air volume in the lungs or in
blood volume in the heart) can be monitored in real-time, providing valuable functional
information about the cardiorespiratory system.
Signiﬁcant advances have been achieved in EIT research in recent years, in particular for
the monitoring and guidance of mechanical ventilation [6, 51, 52]. In parallel, over the
last two decades, the clinical potential of EIT for the monitoring of central hemodynamic
parameters has been a growing focus of attention [104, 120, 129, 157]. For instance,
changes in blood volume during ventricular ejection have shown to produce variations
in EIT images in the heart region, suggesting the possibility of tracking changes in
CO [129, 174]. Similarly, changes in the pulsatility of the pulmonary arteries have shown
5
Chapter 1. Introduction
to produce variations in EIT images in the pulmonary region, suggesting the possibility
of assessing PAP-related information [155].
In this context, the purpose of the present thesis is to investigate the clinical potential of
EIT as a hemodynamic monitor for the non-invasive measurement of CO and PAP.
1.2 Objectives
More speciﬁcally, the present thesis aims at fulﬁlling the following objectives:
a) To determine the inﬂuence of heart motion on the accuracy of the EIT-based
measurement of CO;
b) To determine the inﬂuence of sensor belt position and displacement on the accuracy
of the EIT-based measurement of CO;
c) To propose and determine the feasibility of a novel method for the EIT-based
measurement of PAP;
d) To validate and determine the accuracy of the proposed method for the EIT-based
measurement of PAP in vivo.
1.3 Organization of the manuscript
This manuscript is organized into four parts. Part I introduces the problem and moti-
vation behind the present thesis (Chapter 1), as well as the physiological (Chapter 2)
and technical (Chapters 3 and 4) background related to it. Part II investigates, via sim-
ulations, the accuracy of EIT-based CO estimation, while quantifying the inﬂuence of
heart motion (Chapter 5) and EIT sensor position and displacement on the measurement
(Chapter 6). Part III proposes a novel method to estimate the PAP by EIT, evaluates it in
various forms of pulmonary hypertension via simulations (Chapter 7), and validates it
experimentally in vivo (Chapter 8). Finally, Part IV concludes this dissertation with a
synthesis and suggestion of future work (Chapter 9). In Appendix A, models relevant to
the work performed in this thesis are described.
6
2 Concepts on cardiovascular
physiology
The purpose of this chapter is to provide an overview of the physiological concepts
related to the work performed during this thesis.
2.1 Overview of the cardiovascular system
The cardiovascular system is a circulatory system comprising the heart and the blood
vessels (Figure 2.1). It can be divided into two circulations: the systemic circulation,
perfused by the left heart, and the pulmonary circulation, perfused by the right heart.
The systemic circulation receives oxygenated blood from the pulmonary circulation and
transports it (along with other substances, such as nutriments and hormones) from the
left heart to the peripheral tissues of the body (organs and muscles) via the systemic
arteries. The oxygen is then diffused from the blood into the tissues via the systemic
capillaries. Conversely, metabolic waste products (such as carbon dioxide) are diffused
from the tissues into the blood. The partly deoxygenated blood then returns to the heart
via the systemic veins.
The pulmonary circulation receives partly deoxygenated blood from the systemic cir-
culation and transports it from the right heart to the lungs via the pulmonary arteries.
Oxygen brought by respiration into the pulmonary alveoli is then diffused into the blood
via the pulmonary capillaries. Conversely, carbon dioxide is diffused from the blood
into the alveoli in order to be expelled. The reoxygenated blood returns to the heart via
the pulmonary veins and reenters the systemic circulation.
Understanding the circulatory aspects of the cardiovascular system requires introducing
the key parameters that control it from a hemodynamic viewpoint: blood pressure,
cardiac output, vascular resistance, and vascular compliance.
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Figure 2.1 – Schematic representation of the cardiovascular system. The arrows indicate
the direction of blood ﬂow. The left ventricle (LV) pumps oxygenated blood (red color)
via the aorta into the systemic circulation. After its passage through the systemic
capillaries, the partly deoxygenated blood (blue color) returns to the heart via the venae
cavae. It is then pushed by the right atrium (RA) into the right ventricle (RV), before
being expelled towards the lungs via the pulmonary arteries. After its passage through
the pulmonary capillaries, the reoxygenated blood returns to the heart via the pulmonary
veins. It is then pushed by the left atrium (LA) into the LV, and the whole cycle starts
again. Adapted from [97].
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2.2 Key cardiovascular parameters
2.2.1 Blood pressure
From a hemodynamic viewpoint, the heart works as a cyclic pump: the ventricles
eject blood during systole and reﬁll during diastole. Arterial blood pressure (BP) is
therefore pulsatile, and is usually expressed in terms of its systolic (maximum) and
diastolic (minimum) values. In a resting adult, BP oscillates between ∼120 mmHg and
∼ 80 mmHg, conventionally written 120/80 mmHg [97]. BP is commonly expressed
in millimeters of mercury (1 mmHg ≈ 133 Pa) and relative to atmospheric pressure
(760 mmHg): thus a BP of 100 mmHg is 100 mmHg above atmospheric pressure. In the
pulmonary arteries, BP is commonly referred to as pulmonary artery pressure (PAP)
and is much lower than systemic BP (approximately by a 7-fold factor) [97]. In a resting
adult, a normal value for PAP is typically 21/9 mmHg [88].
2.2.2 Cardiac output
In the large veins, BP is close to atmospheric pressure and therefore a gradient of
pressure exists between the arterial and venous trees and allows the blood to ﬂow. At
each heartbeat, the small amount of blood ejected by each ventricle into the arteries – the
so-called stroke volume (SV) – is driven by this pressure gradient from the arteries down
to the capillaries and the veins, and back to the heart. Cardiac output (CO) is deﬁned as
the amount of blood ejected by one ventricle in one minute. Thus, CO is the product of
SV and heart rate (HR), and is commonly expressed in liters per minute (L/min):
CO = SV ·HR. (2.1)
In a resting adult, a normal value for CO is typically 4-7 L/min [97]. As the systemic
and pulmonary circulations form a closed-loop system, CO is virtually equal in both
circulations.
2.2.3 Vascular resistance
BP and CO are related through the concept of vascular resistance. By analogy with
Ohm’s law in electrical circuit theory (resistance equals voltage divided by current), the
resistance R opposing the ﬂow between two locations in the vasculature is:
R =
ΔP
CO
, (2.2)
where ΔP is the mean pressure gradient between both locations. When involving
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central and global parameters in equation (2.2), we ﬁnd one of the main relations of the
cardiovascular system:
MAP = CO · Rt +CVP, (2.3)
where MAP stands for mean arterial pressure (the mean component of BP), CVP stands
for central venous pressure, and Rt for total vascular resistance.
Through Poiseuille’s law, vascular resistance in a vessel of radius r and length l is known
to be proportional to l/r4, and thus mainly to 1/r4 [180]. Therefore resistance is low in
large vessels, and becomes exponentially larger as the vessels narrow. In the systemic
circulation, the large arteries only account for ∼ 2 % of Rt, whereas ∼ 60 % of Rt is
due to the smallest arteries and the arterioles (often called, quite pertinently, resistance
vessels) [97]. In the pulmonary circulation, this effect is less marked and Rt is much
lower (∼1/7th of systemic), hence the aforementioned 7-fold factor between systemic
BP and PAP [97, 121]. This lower pulmonary Rt is due to the fact that pulmonary vessels
are shorter and wider than their systemic counterparts (thus l/r4 is smaller) [97].
The relation between pressure and ﬂow in the cardiovascular system is of course more
complex than equation (2.2) or (2.3), which only accounts for their average values. Both
pressure and ﬂow are pulsatile, and their relation is governed by equations of ﬂuid
dynamics (see Section A.2). A key parameter in their relation is vascular compliance.
2.2.4 Vascular compliance
If the arteries were perfectly rigid, blood ﬂow would drop to zero during diastole as the
heart only ejects blood during systole. This potential problem is avoided thanks to the
distension capability, or distensibility, of the arteries, caused by the presence of a protein
known as elastin in their wall [180]. By distending when subjected to a local pressure
increase ΔP, the arteries allow the temporary storage of a small volume of blood ΔV [97].
As elastin stores mechanical energy (tension) when stretched, arterial BP does not drop
to zero during diastole as it does in the ventricles; it keeps driving the blood towards
the periphery. This capacitive capability of the arteries (by analogy with capacitors in
electrical circuits), or blood vessels in general, is precisely what vascular compliance (C)
characterizes:
C =
ΔV
ΔP
. (2.4)
When involving central and global parameters in equation (2.4), we ﬁnd a second
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important relation of the cardiovascular system:
PP =
SV−Vrunoff
Ct
≈ SV
Ct
, (2.5)
where PP is the pressure pulse (the pulsatility-related component of BP, deﬁned as
systolic minus diastolic BP), Vrunoff is the volume of blood drained away during ejection,
and Ct is total vascular compliance [97]. In the systemic arterial tree, ∼ 80 % of Ct is
provided by the aorta alone [149]. The systemic arteries become increasingly stiffer and
muscular as one moves away from the heart. Conversely, the pulmonary arteries do not
exhibit increased stiffness between central and peripheral sites [121]. Pulmonary arterial
compliance is distributed over the entire tree [149]. This particularity stands at the basis
of several remarkable characteristics of the pulmonary circulation, as will later be seen
in Section 2.3.
2.2.5 Regulation aspects of the systemic circulation
Figure 2.2 illustrates the mechanisms involved in the regulation of arterial BP and the
various parameters related to it.
As seen from equations (2.3) and (2.5), one of the main factors affecting the regulation of
BP is CO, and therefore HR and SV. HR is controlled by the autonomic nervous system,
which is subdivided into the sympathetic nervous system (SNS) and the parasympa-
thetic nervous system (PSNS). Activation of the SNS increases HR, e.g. during exercise,
emotional stress, or hemorrhagic shock, whereas activation of the PSNS decreases it [97].
On the other hand, changes in SV are mainly induced by three factors [86]:
a) Preload. In case of an increased venous return (venous ﬂow returning to the heart),
ventricular ﬁlling increases. The increase in volume leads to an increased tension
in the cardiac muscle (by stretching the cardiac myocytes). The resulting increase
in ejection force allows the heart to eject the additional volume, thereby increasing
SV.
b) Afterload. Afterload describes the load “seen” by the heart, against which it must
eject blood. Afterload is closely related to Rt (or MAP). An increased afterload
leads to a decreased SV.
c) Inotropy. Cardiac inotropy (contractility) is controlled by the autonomic nervous
system. The SNS increases cardiac inotropy, which allows the heart to eject more
blood and increases SV. Conversely, the PSNS decreases SV via the opposite mech-
anism.
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Figure 2.2 – Regulation of arterial BP in the systemic circulation. The ﬁgure is explained
in detail in the text. For simplicity, Rt is entirely attributed to the small arteries in the
ﬁgure, whereas Ct is entirely attributed to the large arteries. Also, the dependence of
SV on ventricular afterload, which would take the form of a feedback arrow from Rt (or
MAP) to “Heart”, is not depicted. BP: blood pressure; MAP: mean arterial pressure; PP:
pulse pressure; CO: cardiac output; SV: stroke volume; CVP: central venous pressure;
Rt: total vascular resistance; Ct: total vascular compliance; (P)SNS: (para)sympathetic
nervous system.
The SNS is also involved – along with circulating vasoactive hormones such as adrenaline,
angiotensin II and vasopressin – for the control of vascular tone (the tension exerted
by the vascular smooth muscle) [97]. Vascular tone determines Rt and venous return,
and thus its continuous adjustment plays an important role in the regulation of BP.
Increasing vascular tone – and thus Rt – occurs through the vasoconstriction (narrow-
ing) of blood vessels, mainly the small arteries (resistance vessels). Venous return is
increased by peripheral venous vasoconstriction, which displaces the blood towards
the central veins, thereby increasing CVP and SV. These neural and hormonal factors
are extrinsic mechanisms in the control of vascular tone. Two intrinsic factors allow the
local regulation of blood ﬂow in the small arteries. The ﬁrst one is autoregulation, a
vascular myogenic response inducing a fast vasoconstriction in case of acute BP increase
(see Figure 2.3). Autoregulation allows maintaining local ﬂow and capillary pressure
constant. Autoregulated vascular tone can further be controlled by a second intrinsic
factor: local metabolic vasoactive agents produced within the vascular tissue allow
autoregulated arteries to operate at a different level of ﬂow [97].
The control of the neural and hormonal mechanisms that regulate BP is carried out by the
so-called baroreﬂex (see dotted line in Figure 2.2), a rapid negative feedback mechanism
operating within fractions of a second and maintaining BP at a nearly constant level. The
baroreﬂex relies on so-called baroreceptors (stretch receptors sensitive to BP-induced
distensions). The two main baroreceptors locations are found in the aortic arch and the
carotid sinus.
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2.3 Particularities of the pulmonary circulation
Some important differences exist between the systemic and pulmonary circulations. We
have mentioned that PAP and pulmonary Rt are ∼1/7th of their systemic counterparts.
We have also mentioned that pulmonary arterial compliance is distributed over the entire
pulmonary arterial tree, as opposed to systemic arterial compliance which is mainly
located in the aorta. Another important difference concerns the factors inﬂuencing
Rt. Hereafter we will start by addressing this topic. We will then mention the various
implications of a well-distributed pulmonary compliance.
2.3.1 Factors inﬂuencing pulmonary vascular resistance
With baroreceptors present in the pulmonary arteries, pulmonary Rt is controlled – in
part – by neural and hormonal mechanisms similar to its systemic counterpart. However,
Rt in the lungs is not affected by autoregulation or local vasoactive agents (left part
of Figure 2.2). As a consequence, the pressure-ﬂow relation is passive in the lungs:
an increase in pressure leads to a quasi-proportional increase in ﬂow, as detailed in
Figure 2.3. Other factors, however, do affect pulmonary Rt, namely:
a) Lung volume. Rt is known to be modulated by respiratory activity. The physiologi-
cal aspects governing this phenomenon are explained in Figure 2.4.
b) Cardiac output. An increased CO will distend the (highly compliant) pulmonary
arteries and recruit previously closed/underperfused vessels, thus decreasing Rt
(without signiﬁcantly affecting the PAP) [46].
c) Gravity. Rt is distributed unevenly when an upright position is adopted. Vessels at
the apex (upper part) of the lungs (∼16 cm above the heart) are barely perfused
and collapse during diastole (low PAP, high R), whereas vessels at the bases of the
lungs are hyperdistended and highly perfused (high PAP, low R) [97].
d) Hypoxia. Hypoxic pulmonary vasoconstriction (HPV) is a mechanism that helps to
maintain an efﬁcient oxygenation of the blood. In case of hypoxia (lower oxygen
supply), arteries leading to under-ventilated alveoli constrict in order to redirect
the blood ﬂow towards better-ventilated alveoli [97]. Rt increases as a result of this
vasoconstriction.
2.3.2 Consequences of a well-distributed pulmonary vascular compliance
We have mentioned that ∼80 % of vascular compliance is located in the aorta alone in
the systemic circulation [149]. A remarkable characteristic of the pulmonary circulation
is that only a small portion (15–20 %) of Ct is located in the major (main, left and right)
13
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Figure 2.3 – Pressure-ﬂow relationship in the systemic and pulmonary circulations
(assuming zero venous pressure for simplicity). In the systemic circulation, a process
known as autoregulation, illustrated here with gray arrows, allows maintaining local
blood ﬂow at a constant level through fast adaptation of the vascular tone in case of
acute changes in BP. Autoregulation is absent of the pulmonary circulation, where the
pressure-ﬂow relationship is passive and almost linear. The curve steepens slightly
with pressure due to ﬂow-induced arterial distension (and related resistance decrease).
Adapted from [97].
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Figure 2.4 – Characteristic U-shaped relationship between pulmonary Rt and lung
volume. At residual volume (RV), the increase in intrathoracic pressure compresses the
arteries and veins (extra-capillary vessels), thereby increasing Rt. At total lung capacity
(TLC), the increase in alveolar volume compresses the capillaries, thereby increasing Rt.
The minimum of Rt is found at functional residual capacity (FRC), i.e. at end of passive
expiration. Adapted from [46].
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pulmonary arteries. A considerable part (∼ 50 %) of pulmonary Ct is located in the
arterioles [149]. Compliance and resistance are thus distributed in a similar fashion, and
this anatomic distribution is unaltered in disease [164]. This special connection between
Rt and Ct stands at the basis of several particular features of the pulmonary circulation:
a) The so-called RC time τRC (the product of Rt and Ct) is constant in both health and
disease [93, 94, 164]. In other words, an increase in arterial resistance is always
accompanied by an inversely proportional decrease in arterial compliance, and
vice versa, as illustrated in Figure 2.5. This means that the vessels responsible for
resistance and compliance are the same in both health and disease [164]. This is not
true for the systemic circulation, where τRC is highly variable due to the anatomic
separation of Ct (central) and Rt (peripheral) [149, 164].
b) The diastolic and systolic values of PAP are linearly related to the mean value of
PAP (PA) in both health and disease. In a retrospective study, Syyed et al [163]
found the following relationships:
Diastolic PAP = 0.71 · PA − 0.66, Systolic PAP = 1.50 · PA + 0.46.
The reason for this linearity is a consequence of τRC being constant. Indeed,
combining (2.3) and (2.5) and neglecting venous pressure, we ﬁnd that PA ≈
τRC ·HR · PP. With τRC constant and HR similar in health and disease, we ﬁnd
PA to be proportional to PP [149]. As both quantities depend on the diastolic and
systolic values of PAP, it can be derived that a linear relationship exists between
these values and PA [149]. This property does not hold true for the systemic
circulation, where τRC is not constant.
c) The ratio of right ventricular oscillatory power over total power is constant. The
hydraulic power required by the heart for propelling blood to the arterial circu-
lation consists in a mean power (the product of the mean pressure gradient and
CO) and an oscillatory power, which can be considered as wasted power as it
does not contribute to the transport of blood [149]. Because of the aforementioned
linearity between diastolic and systolic PAP with PA, the ratio of right ventricular
oscillatory power over total power is constant in health and disease, and has found
to be ∼ 23 % [150]. This contrasts with the systemic circulation, where the left
ventricular ratio is ∼10–13 % in health and increases with BP [149].
d) Finally, another consequence of a well-distributed pulmonary Ct is that arterial
distensibility δ is uniform in the pulmonary circulation [90]. By deﬁnition, the
distensibility of an arterial segment of volume V and compliance C is given by
δ = C/V, and is expressed in mmHg−1 [180]. (For instance, with a distensibility
δ = 0.01 mmHg−1, an increase in distending pressure of 15 mmHg will increase
the volume of the artery by 15 %.) This property is unique to the pulmonary
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Figure 2.5 – Illustration of the consequence of a constant RC time τRC in the pulmonary
circulation. Consider two patients (A and B) whose vascular resistance Rt is decreased
through therapy by the same amount ΔRt. Both will experience the same decrease
in steady (resistive) afterload. However, only patient A will experience a signiﬁcant
decrease in pulsatile (capacitive) afterload. Adapted from [94].
circulation and has a remarkable consequence: the propagation velocity of the
pressure waves in the arterial tree is uniform, as it directly depends on δ [180].
This will be further detailed in Section 2.5. Again, this property does not hold true
for the systemic circulation, as systemic arteries become increasingly stiffer and
muscular (i.e. δ decreases) as one moves away from the heart [121].
2.4 Cardiovascular pathologies
The present thesis tackles the subject of hemodynamic monitoring in general, but fo-
cuses in particular on two major hemodynamic parameters: cardiac output (CO) and
pulmonary artery pressure (PAP). The purpose of this section is therefore to explain the
clinical importance of CO and PAP, particularly in hemodynamically unstable patients,
where both of these parameters are subjects to signiﬁcant variations.
In Section 2.4.1, hemodynamic instability – and more speciﬁcally the underlying medical
condition known as circulatory shock – is described in terms of its clinical and hemody-
namic characteristics. Particular emphasis is put on the current clinical need for reliable
non-invasive beat-to-beat CO monitoring solutions. Then, Section 2.4.2 introduces pul-
monary hypertension (PH), its clinical subgroups and hemodynamic characteristics. Here,
the emphasis will be put on the need for reliable non-invasive PAP monitoring solutions,
both for events of acute PH that can arise in hemodynamically unstable patients and for
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the monitoring of patients with chronic PH.
2.4.1 Circulatory shock
Clinical and hemodynamic characteristics
Circulatory shock (or simply shock) is a serious medical condition associated with high
mortality rates and characterized by an inadequate oxygen delivery to body tissues
(tissue hypoperfusion), usually resulting from inadequate CO [65]. Shock is common
in critical care, and affects about one third of patients in intensive care units [169]. The
clinical signs of shock are mainly cutaneous (e.g. mottled and clammy skin), renal (de-
creased urine output) and neurological (e.g. anxiety, confusion, disorientation). From a
hemodynamic viewpoint, shock is characterized by a severely decreased BP (typically
less than 70 mmHg in mean BP) and an increased heart rate (tachycardia). Depending on
the type of shock (see below), CO can either be signiﬁcantly decreased or increased. Fi-
nally, blood lactate levels are known to be abnormally high in shock, reﬂecting abnormal
cellular function [169].
Diagnosis and clinical classiﬁcation
The most common sign of shock is arterial hypotension, although a decreased BP is
not sufﬁcient to diagnose shock. Tachycardia, elevated blood lactate levels and the
aforementioned clinical signs of tissue hypoperfusion are necessary to conﬁrm the
diagnosis [169]. Shock is clinically classiﬁed into four groups: distributive, hypovolemic,
cardiogenic, and obstructive shock.
Distributive shock is characterized by a bacterial infection widely disseminated through-
out the body, causing extensive damage and a marked vasodilation in the infected
tissues [65]. As a result, CO is usually high in distributive shock (a unique feature for
its diagnosis as CO typically decreases in all other types of shock). Echocardiographic
signs in distributive shock are normal, i.e. normal cardiac chamber size and preserved
contractility [169].
Hypovolemic shock, which occurs after a severe decrease in blood volume, is most often
caused by hemorrhage [65]. Hypovolemic shock is characterized by a low CO (just as
cardiogenic and obstructive shock) but a low central venous pressure (as opposed to
cardiogenic and obstructive shock), as hypovolemia does not induce venous congestion.
Echocardiographic signs usually shows small cardiac chambers, and normal or high
contractility [169].
Cardiogenic shock can occur as a result of various cardiopathologies, e.g. acute myocar-
dial infarction or advanced valvular diseases. It is characterized by a failure of the left
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ventricle to pump blood efﬁciently, resulting in a low CO and progressively leading to
venous congestion and an elevation in central venous pressure. Echocardiographic signs
include enlarged ventricles and poor contractility [169].
Obstructive shock is characterized by an obstruction of blood ﬂow in the large vessels or
the heart itself, such as in case of pulmonary embolism (blockage of a pulmonary artery)
or pericardial tamponade (accumulation of ﬂuid in the pericardial cavity affecting heart
function) [131, 169]. From a hemodynamic viewpoint, obstructive shock is somewhat
similar to cardiogenic shock, i.e. decreased CO and elevated central venous pressure.
Echocardiographic signs depend on the cause of the shock: enlarged right ventricle
and small left ventricle in case of pulmonary embolism, and small ventricles in case of
pericardial tamponade [169].
Therapy
In the event of shock, resuscitation should be started as soon as possible, even if the
cause of the shock is still unknown [169]. The primary objective is to perform life-saving
measures and to restore BP to an acceptable level. Oxygen should be administered
immediately to improve oxygen delivery and prevent hypoxia-induced pulmonary
hypertension. Once the underlying cause of the shock is identiﬁed, it must be corrected
rapidly (e.g. control of bleeding in case of injury-induced hypovolemic shock). If the
situation does not improve, an arterial catheter should be inserted for BP monitoring
and blood sampling, and a central venous catheter for ﬂuid resuscitation (replacement
of lost bodily ﬂuids) and injection of vasoactive agents. Fluid resuscitation mainly
aims at improving CO and blood ﬂow in the microvasculature through intravenous
injections of ﬂuids. A common difﬁculty in ﬂuid resuscitation is the assessment of the
patient’s responsiveness to therapy. In mechanically-ventilated patients, signs of ﬂuid
responsiveness may be identiﬁed from beat-by-beat SV measurements. So-called ﬂuid
challenges are indicated to help assessing the patient’s responsiveness, but must be
rapidly stopped in absence of response to avoid ﬂuid overload. The third component of
resuscitation (along with oxygen administration and ﬂuid therapy) is the intravenous
injection of vasoactive agents. In particular, vasopressors (anti-hypotensive agents)
such as norepinephrine are indicated to help increasing BP through vasoconstriction,
while maintaining HR and CO. Conversely, inotropic agents such as dobutamine help
increasing CO through increased myocardial contractility, with limited effects on BP.
The primary goal of resuscitation is to restore tissue perfusion by correcting arterial
hypotension. Although a restored mean BP value of 65 to 70 mmHg is a good indicator,
tissue perfusion should be assessed from the aforementioned signs of tissue hypoperfu-
sion, namely skin appearance, urine output and mental state. CO is the main indicator
for determining oxygen delivery, but no optimal CO value can be deﬁned. In that
sense, trends in CO rather than absolute values are of clinical importance to monitor the
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patient’s hemodynamic status, particularly during ﬂuid challenges [169].
Prevalence
In a trial involving 1679 patients in intensive care units, septic shock (the most common
form of distributive shock) was found in 62 % of cases. Non-septic distributive shock
accounted for 4 % of all cases. Both hypovolemic and cardiogenic accounted for 16 % of
all cases, and obstructive shock for 2 % [39, 169].
Current clinical need in terms of CO monitoring
There is a strong clinical need for practical, safe and continuous solutions for monitoring
CO, in particular to assess reliable beat-to-beat trends in events of circulatory shock.
However, as will be detailed in the next chapter, there is currently no safe, operator-
independent and reliable way to monitor beat-to-beat CO values in hemodynamically
unstable patients.
2.4.2 Pulmonary hypertension
Hypertension is a pathophysiological condition characterized by a persistent and ab-
normal elevation of BP. In the pulmonary circulation, pulmonary hypertension (PH) is
formally deﬁned as PA ≥ 25 mmHg at rest as assessed by right heart catheterization [56].
Untreated or inadequately treated PH is fatal as it increases the right cardiac afterload
and thus ultimately leads to right heart failure (cor pulmonale) [97]. We have mentioned
in the previous section the risk of acute PH in patients in circulatory shock in case of
unmanaged hypoxia. This risk is even more increased in patients already suffering from
chronic PH, which can arise from a wide variety of different pathophysiological causes.
The exact prevalence of chronic PH remains unclear as the condition is considerably
under-diagnosed due to the lack of speciﬁcity of the symptoms (e.g. shortness of breath,
fatigue, weakness) [56]. Large discrepancies exist between prevalence estimates. In
the UK, a prevalence of 10 cases/100,000 was reported; in contrast, a minimum indica-
tive prevalence of 326 cases/100,000 was found in an Australian echocardiographic
study [160].
Hemodynamic deﬁnitions
Multiple clinical conditions can lead to PH, left-sided heart diseases being the most com-
mon of them [56, 160]. In this situation, the failure of the left heart to pump blood leads
to an elevation of left atrial pressure, which in turn causes an elevation of PAP upstream:
therefore, PH is described as post-capillary. Conversely, most of the remaining forms of
PH are induced by conditions or pathologies taking place before (i.e. upstream of) the
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Table 2.1 – Hemodynamic deﬁnitions of pulmonary hypertension. PH: pulmonary
hypertension; PA: mean pulmonary artery pressure; PW: (mean) pulmonary capillary
wedge pressure. Adapted from [56].
Deﬁnition Characteristics Clinical groups
PH PA ≥ 25 mmHg All
Pre-capillary PH PW ≤ 15 mmHg 1, 3, 4, 5
Post-capillary PH PW > 15 mmHg 2, 5
pulmonary capillary bed. In these situations, PH is described as pre-capillary. Clinically,
pre- and post-capillary PH are distinguished from one another by measuring pulmonary
capillary wedge pressure (PW), an indirect estimate of left atrial pressure. PW remains
unaffected in pre-capillary PH and is markedly increased in post-capillary PH (central
column of Table 2.1).
Clinical classiﬁcation
Based on a consensus agreement of experts worldwide, PH is clinically classiﬁed into
ﬁve groups, depending on clinical, pathological, hemodynamic and therapeutic consid-
erations (Table 2.1): pulmonary arterial hypertension (Group 1), PH due to left heart
disease (Group 2), PH due to lung diseases and/or hypoxia (Group 3), chronic throm-
boembolic PH and other pulmonary artery obstructions (Group 4), and PH with unclear
and/or multifactorial mechanisms (Group 5) [56]. The diagnosis of PH and its classiﬁca-
tion into one of the ﬁve groups are carried out together. The diagnostic process starts
with the suspicion of the presence of PH based on symptoms, signs or history [56]. An
exam using transthoracic echocardiography is then performed in order to evaluate the
likelihood of PH. In case of intermediate or high probability, further examinations are
performed in order to conﬁrm the diagnosis and assess the classiﬁcation of PH. The
following section presents each PH group in terms of its clinical and hemodynamic
characteristics, diagnosis, therapy, and prevalence.
Group 1: Pulmonary arterial hypertension
Clinical and hemodynamic characteristics. Pulmonary arterial hypertension (PAH) is a
form of pre-capillary PH that begins with endothelial dysfunction in the small pulmonary
arteries. The endothelium (internal layer of blood vessels) regulates vascular tone and
inhibits smooth muscle cell proliferation [92, 97]. Endothelial dysfunction thus leads
to vasoconstriction and smooth muscle cell proliferation. A process known as vascular
remodeling ensues, characterized by the muscularization, wall thickening and ﬁbrosis
of the small pulmonary arteries [92]. The later stages of PAH are characterized by the
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appearance of local thrombi and so-called plexiform lesions, which further aggravate
arterial occlusion [92].
Diagnosis. PAH is suspected when the main other forms of PH (Groups 2, 3, and 4)
have been ruled out. The last group (Group 5) is associated with poorly understood
mechanisms, as will be detailed later; its diagnosis is similar to that of Group 1 (PAH).
The diagnosis of PAH or a rarer condition of Group 5 is conﬁrmed by right heart
catheterization if PA ≥ 25 mmHg and PW ≤ 15 mmHg (pre-capillary PH, see Table 2.1),
and if Rt > 0.18 mmHg·s/mL [56]. Additional speciﬁc diagnostic tests (e.g. hematology,
biochemistry, immunology) allows the ﬁnal diagnosis to be reﬁned (e.g. idiopathic PAH,
heritable PAH, or a rarer condition of Group 5).
Therapy. The current treatment strategy for patients with PAH follows three main
steps [56]: (1) general measures (e.g. encouraging patients to be active to improve
cardiorespiratory function) and supportive therapy (e.g. anticoagulants or oxygen ad-
ministration when appropriate); (2) speciﬁc drug therapy (vasodilator therapy with a
treatment strategy depending on the patient’s vasoreactivity and prognostic risk); (3)
combination therapy (simultaneous use of two or more drugs) and consideration of lung
transplantation in case of inadequate clinical response.
Prevalence. In Europe, PAH prevalence estimates stemming from epidemiological
studies are in the range 15–60 cases per million population [56]. In an echocardiographic
study, a prevalence of 15 cases/100,000 was reported [160].
Group 2: PH due to left heart disease
Clinical and hemodynamic characteristics. In Group 2, so-called PH due to left heart
disease (PH-LHD) occurs as a secondary symptom to an underlying left heart condition
(e.g. valvular diseases or advanced stages of heart failure). The failure of the left heart
to pump blood efﬁciently leads to an elevation of left heart pressures. This pressure
elevation is passively transmitted backwards and PAP increases in response, resulting in
PH-LHD. In some cases, this passive elevation in PAP gives rise to vascular remodeling
of the small pulmonary arteries, which further worsens the condition by increasing Rt.
Diagnosis. The diagnosis of PH-LHD is considered in a stepwise approach, by combin-
ing clinical presentation (e.g. symptoms of left heart failure, age, history), echocardio-
graphic signs (e.g. structural left heart abnormality), and other modalities and imaging
techniques [56]. The presence of post-capillary PH is formally conﬁrmed by right heart
catheterization with PA ≥ 25 mmHg and PW > 15 mmHg (Table 2.1).
Therapy. As PH-LHD is secondary to an underlying condition, PH therapy in Group 2
focuses on managing said condition (e.g. repair of valvular heart disease when indicated).
PAH therapy (vasodilator therapy) is not recommanded as there is currently not enough
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evidence demonstrating its beneﬁts in the treatment of PH-LHD [56].
Prevalence. In an echocardiographic study, a prevalence of 250 cases/100,000 was
reported, which makes of PH-LHD the most common form of PH (77 % of all cases) [160].
PH-LHD affects 60 % of patients with moderate or severe heart failure [58].
Group 3: PH due to lung diseases and/or hypoxia
Clinical and hemodynamic characteristics. As in Group 2, PH in Group 3 is secondary
to an underlying condition, such as the very common chronic obstructive pulmonary
disease. The mechanisms that lead to an abnormal and persistent elevation of PAP
are speciﬁc to each condition. In chronic obstructive pulmonary disease for instance,
the obstruction of small airways and the destruction of alveoli greatly decreases the
diffusing capacity of the lungs (poor gaseous exchange), causing hypoxic pulmonary
vasoconstriction [65]. As a result, a severe increase in Rt (and thus in PAP) occurs, as
explained earlier (Section 2.3.1), progressively leading to PH.
Diagnosis. As for PH-LHD, the diagnosis of PH in Group 3 relies on a wide variety of
modalities, such as chest radiography, pulmonary function tests and arterial blood gases.
After conﬁrmation of the diagnosis of a lung disease and when considered necessary
(e.g. for surgical considerations), right heart catheterization is performed for the formal
diagnosis of PH [56].
Therapy. As for PH-LHD, therapy in Group 3 focuses on managing the underlying
condition, and not PH directly. Vasodilator therapy is thus not advised, all the more so
as it may inhibit hypoxic pulmonary vasoconstriction and impair gaseous exchange. An
example of therapy is the long-term administration of oxygen in case of COPD, which
has shown to partially reduce PH [56].
Prevalence. In an echocardiographic study, a prevalence of 37 cases/100,000 (11 % of
all cases) was reported, which makes of Group 3 the second most common form of PH
after Group 2 [160].
Group 4: Chronic thromboembolic PH and other pulmonary artery obstructions
Clinical and hemodynamic characteristics. Chronic thromboembolic PH (CTEPH) is
characterized by the partial or complete obliteration of one or several pulmonary arterial
segments [128]. As a consequence, a part or the entirety of the ﬂow is redirected
towards the nonoccluded areas, thereby exposing them to higher wall shear stresses [72].
An arteriopathy similar to that encountered in PAH (vasoconstriction and vascular
remodeling) progressively develops in these segments, while the arteries downstream
of the occluded areas typically remain unaffected [72, 128].
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Diagnosis. In the PH diagnostic process, CTEPH is considered after Group 2 and
3 have been ruled out. CTEPH is considered possible in case of perfusion defects
in ventilation/perfusion scans, and conﬁrmed by right heart catheterization and CT
pulmonary angiography [56].
Therapy. Anticoagulation treatment is recommended in all patients with CTEPH. If
the patient is found to be technically operable with an acceptable risk/beneﬁt ratio,
pulmonary thromboendarterectomy (surgical blood clot removal) is performed [56].
Otherwise, as an arteriopathy similar to that encountered in PAH develops in CTEPH,
targeted vasodilator therapy is recommended [56, 72]. In case of severe and persistent
PH, lung transplantation is considered [56].
Prevalence. CTEPH is notoriously under-diagnosed and its exact prevalence unclear [72].
An estimate of 3.2 cases per million population was reported in a PH Spanish reg-
istry [43]. A signiﬁcantly larger prevalence of 9/100,000 was found in an Australian
echocardiographic study [160].
Group 5: PH with unclear and/or multifactorial mechanisms
Clinical and hemodynamic characteristics. The exact mechanisms that lead to the
development of PH are poorly understood in Group 5. PH is secondary to an underlying
rare condition such as hematological, systemic or metabolic disorder [56].
Diagnosis. As detailed earlier for PAH, the diagnosis of PH in Group 5 is similar to that
of Group 1, and thus not repeated here.
Therapy. As for the other types of PH secondary to an underlying condition, therapy in
Group 5 focuses on managing the condition, and not PH directly. Vasodilator therapy is
not advised in Group 5, due to the absence of randomized control trials demonstrating
its beneﬁts. It may even be harmful in case of disorders affecting the venous tree, such
as the pulmonary veno-occlusive disease [56].
Prevalence. In an echocardiographic study, a prevalence of 15 cases/100,000 (4.6 % of all
cases) was reported, which is similar to that of PAH [160].
Current clinical need in terms of PAP monitoring
There is a strong clinical need for risk-free and continuous solutions for monitoring the
PAP, particularly in hemodynamically unstable patients. Similarly, the follow-up of
patients with chronic PH currently lacks a proper monitoring tool to assess the patient’s
health status on a regular basis. Indeed, the follow-up of PH patients is often limited to
clinic visits at intervals of several months. The risk (in case of right heart catheterization)
and cost associated with more frequent measurements (e.g. weekly measurements) of
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the patient’s PAP strongly hinders the identiﬁcation of short-term trends in pulmonary
hemodynamics, and therefore the anticipation of worsening conditions or treatment inef-
ﬁciency [111]. Increases in PAP have been shown to occur days to weeks before the onset
of worsening signs and symptoms [1]. The beneﬁts of frequent PAP measurements over
intermittent clinic visits have been demonstrated in several previous studies, notably in
terms of prediction of therapy outcomes [48], anticipation of worsening heart failure [3],
feedback rapidity during vasodilator therapy [53], or decline in hospitalization rates [15].
Here again, a simple non-invasive means of monitoring the PAP in patients with chronic
PH is currently lacking.
2.5 Pulse wave velocity
In this thesis, a novel method for measuring changes in PAP will be proposed and
evaluated. We introduce hereafter the physiological principle on which this method is
based.
At each heartbeat, pressure waves are produced by the heart at the aortic and pulmonary
valves, and propagate along the wall of the arteries towards the periphery. The so-called
pulse wave velocity (PWV) is the velocity at which these BP waves travel along the
arterial wall. This velocity is higher in stiffer arteries. Thus, as stiffer arteries require a
higher pulse pressure to expand, it follows that BP and PWV are intrinsically linked. In
other words, arterial stiffness induces rises in both BP and PWV [180]:
Arterial Stiffness ↗ ⇒ Blood Pressure ↗
Pulse Wave Velocity ↗.
2.5.1 Relation to arterial stiffness and compliance
The relations linking arterial stiffness, compliance and the PWV are described via two
equations. The ﬁrst one is known as the Moens-Korteweg equation:
PWV =
√
hEinc
ρd
, (2.6)
where arterial stiffness is embodied by the incremental Young’s modulus Einc [180]
and where h/d is the wall thickness to diameter ratio of the arteries, a quantity that
remains almost invariable in elastic arteries [158]. Therefore, with ρ (density of blood)
constant, the Moens-Korteweg equation directly links PWV to arterial stiffness in elastic
arteries. The relation of PWV with compliance (C) and distensibility (δ) is described by
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the Bramwell-Hill equation [180]:
PWV =
√
V
ρC
=
√
1
ρδ
(2.7)
where V is the arterial blood volume. It stems from (2.7) that the PWV depends directly
on δ alone. As mentioned earlier in Section 2.3.2, a remarkable property of the pulmonary
circulation is the uniformity of δ in the entire arterial tree, irrespective of vessel size.
Therefore, via (2.7), PWV is also found to be uniform in the pulmonary arterial tree.
This strongly contrasts with the systemic circulation, where the PWV increases in the
periphery due to the smaller distensibility of resistance vessels [121].
2.5.2 Clinical signiﬁcance
Before being a correlate of BP, PWV is a clinical surrogate of arterial stiffness, the
best independent predictor of cardiovascular and all-cause mortality [158]. In the
pulmonary circulation in particular, arterial compliance (which is inversely related to
arterial stiffness and PWV, as seen hereabove) has shown to be a stronger predictor of
outcome than vascular resistance or PAP itself in patients with PH [94, 102]. This aspect
can easily be understood via Figure 2.5. A patient who is developing PH starts on the
left-most part of the curve and progressively moves from left to right as the disease
worsens. Therefore, in the early stages of PH, a large loss of compliance can occur before
any noticeable increase in resistance or pressure takes place, making of pulmonary
arterial compliance (or stiffness, or PWV) a strong predictor of survival [94, 95].
2.5.3 Typical values
In the aorta, PWV values typically range from 4 m/s in normotension, to 15 m/s
in hypertension [121]. These values are noticeably lower in the pulmonary arteries,
ranging from 2 m/s in normotension to 7 m/s in hypertension [96, 148]. Using (2.7), this
translates to pulmonary distensibility values larger by a 4-fold factor than their systemic
counterparts, as expected from the highly-compliant nature of the pulmonary arteries.
Figure 2.6 illustrates the relationship between mean PAP and pulmonary PWV.
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Figure 2.6 – Relationship between mean pulmonary artery pressure and pulmonary
pulse wave velocity (PWV). From ∼ 40 mmHg and above, the curve starts reaching
a plateau level, as the arteries are approaching their elastic limit [96]. In other words,
as pressure keeps increasing, the arterial wall cannot distend to the same extent: δ is
approaching its lower limit, which translates to a higher limit in PWV via (2.7). Curve
compiled with data from [96] and [148].
2.5.4 Measurement principle
The PWV in an arterial pathway going from a proximal point a to a distal point b can be
calculated as:
PWV = D/PTT, (2.8)
where D is the distance between a and b, and PTT is the so-called pulse transit time,
i.e. the time required for a pressure wave traveling along the arterial wall to go from
a to b. Depending on the arterial pathway considered, D can usually only be roughly
estimated from surface measurements and anthropometric data. However, for blood
pressure-related applications, estimating D is unnecessary as a calibration function
f (·) is eventually required for converting the estimated PWV values to pressure units.
Therefore, monitoring changes in BP via the PWV principle directly relies on monitoring
changes in PTT and considering D to be constant:
BP = f (1/PTT). (2.9)
Estimating the PTT requires choosing two distinct (and distant) arterial sites a and b,
and detecting the time of arrival of the pressure wave – the so-called pulse arrival time
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Figure 2.7 – Measurement of the pulmonary pulse transit time (PTT) as the difference
between the pulse arrival times (PAT) at location a and b in the arterial tree.
(PAT) – at both locations. PTT is then simply obtained as the difference between both
times:
PTT = PATb − PATa. (2.10)
Both PAT values are usually computed relative to a given timing reference t0 = 0. A
typical choice for t0 is the timing of the R-wave peak of the electrocardiogram (ECG), as
the feature is robustly identiﬁable. Figure 2.7 illustrates a measurement of the PTT in
the pulmonary arterial tree (provided one has access to the pressure waveforms in both
locations depicted).
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3 State of the art in cardiovascular
monitoring techniques
In the previous chapter, we have emphasized the current clinical need for safe and
continuous solutions for monitoring the cardiac output (CO) and the pulmonary artery
pressure (PAP). The purpose of the present chapter is to provide an overview of the
existing modalities and techniques for CO (Section 3.1) and PAP (Section 3.2) monitoring,
and to highlight their strengths and limitations.
3.1 Cardiac output
3.1.1 Gold standards
The gold standard CO measurement method uses the Fick principle, which computes
CO as the rate of oxygen consumption divided by the difference between arterial and
venous oxygen concentrations [97]. However, its clinical applicability remains limited,
as this method is time-consuming – with a time resolution of 5 to 10 minutes [97] – and
only valid in a steady hemodynamic and respiratory state [121].
In clinical settings, the gold standard CO monitoring technique uses the pulmonary
artery catheter (PAC) thermodilution method: a known mass of cold saline is injected
into the right heart, and CO is computed from the area under the temperature curve
measured at a point downstream [97]. PAC thermodilution offers a better time resolu-
tion (∼ 30 s) than the Fick principle, but requires averaging 4 to 5 measurements for
comparable accuracy [80].
3.1.2 Partial rebreathing methods
Partial rebreathing methods, as implemented in the NICO system (Respironics, Mur-
rysville, USA), are derived from the Fick principle and use carbon dioxide as indicator
instead of oxygen [79]. An extension loop is added to the circuit of a ventilator and al-
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lows estimating the venous carbon dioxide content [54]. The system is thus non-invasive
but restricted to intubated and ventilated patients [36].
Clinical studies evaluating its accuracy have reported good trending ability (high cor-
relation coefﬁcients) but signiﬁcant bias in several patient populations. The approach
remains untested in hemodynamically unstable patients [54].
3.1.3 Pulse contour methods
Pulse contour methods are a family of CO estimation methods based on the morpho-
logical analysis of arterial pressure waveforms [131]. As the relation between pressure
and ﬂow is not constant, pulse contour methods require periodic recalibration maneu-
vers, more frequently in case of varying CO [54, 131]. They rely on the joint estimation
of stroke volume (SV) and heart rate to estimate CO, as CO is the product of both
parameters.
The PiCCO system (Pulsion Medical Systems, Feldkirchen, Germany) measures the
pressure waveform in a large (e.g. femoral or axillary) artery and uses transpulmonary
thermodilution for calibration [131]. The working principle of transpulmonary ther-
modilution is similar to that of PAC thermodilution, but uses a central venous line for
injection and the temperature curve is measured at the arterial catheter. Beat-to-beat SV
estimation is obtained by computing the area under the curve of the ﬂow waveform
estimated from the pressure waveform via a so-called Windkessel model (later described
in Section A.2) [36].
The LiDCO system (LiDCO Ltd, Cambridge, UK) is slightly less invasive as it relies
on peripheral venous and arterial lines. Calibration is performed via lithium dilution,
with the advantage of a high signal-to-noise ratio (SNR) as lithium is naturally absent
in blood [54]. However, frequent recalibration maneuvers are limited in presence of
muscle relaxation drugs [131]. For beat-to-beat SV estimation, the LiDCO system does
not use a pulse contour method per se, as it relies on a power analysis of the pressure
waveform and not on its morphology [131].
The FloTrac system (Edwards Lifesciences, Irvine, USA) measures the pressure wave-
form in the femoral or radial artery. As opposed to the PiCCO and LiDCO systems,
FloTrac uses a self-calibration procedure. Beat-to-beat SV estimation is obtained from
the pulse pressure (PP) as SV = χ · PP. PP is estimated as the standard deviation of the
pressure waveform, while the χ factor is automatically re-estimated every minute using
waveform morphological features and anthropometric data of the patient. Although
appealing, this calibration maneuver is of limited accuracy [161].
Non-invasive systems such as the Nexﬁn system (BMEYE, Amsterdam, The Nether-
lands) measure the pressure waveform at the digital artery via the volume-clamp
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method [36, 131]. The peripheral waveform is transformed into a central waveform using
a generalized transfer function [180] and a Windkessel model is used to estimate a central
ﬂow waveform, and thus estimate SV [131]. The Windkessel parameters are obtained
from empirical relationships with pressure derived from population averages [131].
The reliability of pulse contour systems in anesthesia and intensive care units is ques-
tioned because of their inability in tracking changes in peripheral resistance [36]. Inva-
sive recalibration maneuvers are necessary whenever changes in vascular tone and/or
CO may have occurred [14, 131].
3.1.4 Ultrasound methods
Ultrasound methods are based on the measurement of the mean blood velocity across
the aorta via the Doppler ultrasound technique. The area under the velocity-time curve
provides the so-called stroke distance, or velocity time integral (VTI) [97]. SV is obtained
by multiplying the VTI with the cross-sectional area of the aorta.
The USCOM system (USCOM Ltd, Sydney, Australia) uses transthoracic Doppler ul-
trasound: the VTI is obtained non-invasively by directing the Doppler probe at the
ascending aorta. The CardioQ-ODM system (Deltex Medical, Chichester, UK) uses
transesophageal Doppler ultrasound: the VTI is obtained by inserting the probe through
the patient’s esophagus and directing it at the descending thoracic aorta [97, 106]. The
transesophageal approach is invasive and thus limited to anaesthetized patients [36],
but beneﬁts from two main advantages over its transthoracic counterpart: it is more
conducive to continuous monitoring [106], and has a better signal-to-noise ratio due to
the proximity of the probe with the source of the signal [131]. However, both approaches
depend strongly on the operator [36] and are very sensitive to probe positioning [106].
In both systems, the area of the aorta is estimated from the patient’s anthropomet-
ric data [36]. Alternatively, the area can be assessed by measuring the diameter of
the aorta using echocardiography, either non-invasively (transthoracic) or invasively
(transesophageal) [106].
Another non-invasive ultrasound-based approach consists in estimating the end-diastolic
and end-systolic volumes of the ventricles from echocardiograms of the ventricles using
an assumed chamber geometry [97]. SV is obtained as the difference between both
volumes. Alternatively, cardiac magnetic resonance imaging (MRI) scans can be used
instead [166].
3.1.5 Impedance-based methods
Impedance cardiography (ICG) systems, such as the BioZ system (Cardiodynamics, San
Diego, USA), measure thoracic electrical bioimpedance through electrodes located at
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speciﬁc locations at the neck and the abdomen [54]. In this conﬁguration, the injected
electrical currents are assumed to pass mostly through the aorta, and therefore the
pulsatile (cardiogenic) component of the measured impedance signal is assumed to
be representative of aortic blood volume [36]. Its ﬁrst time derivative – the so-called
ICG signal – is thus expected to be representative of aortic ﬂow. Therefore the peak
amplitude of the ICG signal is expected to be linked to SV. The method has not gained
widespread acceptance in clinical practice because of its contested accuracy and the lack
of understanding of the phenomena being measured [71, 106, 177].
Another impedance-based approach has been proposed more recently and is imple-
mented in the NICOM system (Cheetah Medical, Inc., Newton Center, USA). The method
is known as bioreactance and makes use of the phase shift of the thoracic bioimpedance
signal [106]. Using the phase shift induced by aortic pulsatility (instead of its modulus
as in ICG) is thought to reduce the inﬂuence of factors affecting the ICG signal, such as
lung water; however, as for ICG, there is a lack of understanding of what the bioreac-
tance signal actually measures [36]. Its ﬁrst time derivative is used to estimate cardiac
parameters in a similar fashion to ICG. The performance of the bioreactance approach
for beat-to-beat SV estimation remains unclear [36], with poor accuracy reported in
critically ill patients [44, 91].
3.1.6 Limitations of current CO monitoring techniques
In their review, Shephard et al [153] described the eight ideal characteristics for CO mon-
itoring techniques: accuracy, reproducibility, fast response time, operator independency,
ease of use, absence of morbidity, measurement continuousness, and cost effectiveness.
To this day, no existing CO monitoring technique has been able to meet all of these
requirements [131]. In particular, beat-to-beat and continuous monitoring techniques,
which are of paramount importance for patients in circulatory shock, suffer from poor
trending ability in case of hemodynamic instability.
3.2 Pulmonary artery pressure
3.2.1 Gold standard
The gold standard PAP measurement technique is the invasive PAC. An accurate mea-
surement of the PAP implies some technical requirements to be followed with caution.
In particular, verifying the dynamic response of the PAC is necessary due to the risk of
under- or overdamped pressure waveforms [57]. Moreover, the system must be properly
leveled and re-zeroed after each change in position. For every 1 cm shift above right
atrial level (atmospheric pressure), 0.74 mmHg of hydrostatic pressure is subtracted
from the pressure measured [89, 110].
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3.2.2 Implantable hemodynamic monitors
Wireless implantable hemodynamic monitors (pressure sensors implanted in the pul-
monary arteries) such as the CardioMEMS HF System (CardioMEMS Inc., Atlanta, USA)
have been recently introduced for the management of heart failure patients [1]. They are
able to provide beat-to-beat PAP readings with good accuracy [2].
3.2.3 Ultrasound methods
The main ultrasound-based method for PAP estimation is based on the Doppler mea-
surement of the peak velocity vmax of the tricuspid regurgitation (TR) jet, i.e. the velocity
of the small blood backﬂow pushed from the right ventricle back through the tricuspid
valve into the right atrium during ventricular ejection. Trivial or mild TR occurs in
50–80 % of normal subjects [16, 37, 40, 112]. Its prevalence (70–80 %) and severity is
higher in cardiac patients [37, 40]. As right ventricular pressure and PAP are virtually
equal during systole, systolic PAP (SPAP) can be estimated using the so-called modiﬁed
Bernoulli equation [37]:
SPAP = 4v2max + RAP, (3.1)
where RAP is right atrial pressure. When estimated non-invasively, RAP can only be
obtained in a semi-quantitative manner from the change in diameter of the inferior vena
cava assessed by echocardiography [56]. Alternatively, RAP can also assumed to be
constant, for instance 10 mmHg [112]. The latter option has the advantage of simplicity
and provides comparable results [30, 37]. Comparison of TR-derived SPAP estimates
with PAC-derived measurements show good agreement [10, 37, 108]. However, in
the individual patient, the measurement of vmax can be inaccurate, depending on the
strength of the TR signal [56].
TR velocity is currently considered the main echocardiographic variable for estimating
the likelihood of PH in symptomatic patients [56]. Other echocardiographic variables
such as the time to peak right ventricular outﬂow (acceleration time) are known to corre-
late with the PAP [30]; their use in conjunction with vmax for assessing the probability of
PH is recommended [56].
Other ultrasound-based approaches have been proposed for measuring PAP-related
variables. In [96], intravascular ultrasounds were used for the real-time imaging of
the proximal pulmonary artery for estimating pulmonary arterial distensibility and
compliance, both of which show an inverse exponential relation with the PAP. Similar
ﬁndings were obtained non-invasively using MRI [148].
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3.2.4 Phonocardiography-based methods
Various approaches based on the spectral analysis of the second heart sound have been
proposed to estimate the PAP [31, 156, 184]. Xu et al [184] estimated the PAP indirectly
using as feature the time interval between the aortic and pulmonary components of the
second heart sound. There is however no direct physiological link between the PAP and
this feature. Besides, the feature can be affected by diseases such as systemic arterial
hypertension, or aortic/pulmonary valve stenosis. The trending ability of the proposed
approach in the individual patient was not reported by the authors. Smith et al [156]
used a larger feature space (N = 10). Large inter- and intra-dataset variances were
obtained in the selection of the optimal feature subset, depending on the algorithm or
selection method used. Their PAP estimation approach was even more indirect given
the larger number of features used and the lack of direct physiological link between any
of them and the PAP. The trending ability of the proposed approach in the individual
patient was not reported neither.
3.2.5 Limitations of current PAP monitoring techniques
An optimal PAP monitoring modality should be non-invasive (free of any risks or
complications associated with cardiac catheterization) and unsupervised (able to operate
continuously without supervision of a medical doctor). Besides, it should be able to
monitor short-term trends (trending ability), e.g. with a time resolution of 30 seconds or
less. While the gold standard PAC and implantable monitors lack the ﬁrst requirement,
ultrasound-based methods lack the two last ones. Phonocardiography-based approaches
have the advantage of complying with the two ﬁrst requirements. However, their
trending ability remains to be tested. Furthermore, their limited physiological basis,
their invalidity under certain pathophysiological conditions, and the sensitivity of the
measurement to background noise [184] strongly hinders their applicability for routine
PAP monitoring in a clinical context.
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tomography
Electrical impedance tomography (EIT) is a non-invasive, non-ionizing and low-cost
functional imaging technique allowing real-time visualization of impedance changes
within the thorax. First tested for medical applications in 1978 [70] and originally
introduced as applied potential tomography [11], EIT has been a growing center of
attention since the mid-90s in ﬁelds such as thoracic imaging of lung and cardiac
function, as well as brain and gastrointestinal tract imaging [6, 73]. The present thesis
focuses on the use of EIT for thoracic imaging.
4.1 Thoracic imaging by EIT
4.1.1 Working principle
A typical EIT monitoring system consists in a belt of electrodes placed in a ring around a
given medium of interest. Small electrical currents are injected into the medium and the
resulting voltages are measured on its surface. A reconstruction algorithm then estimates,
from these surface measurements, the most likely distribution of internal impedance
changes. The result is a 2D tomographic image depicting the internal distribution of
impedance change in the medium, and is commonly referred to as EIT frame, or simply
EIT image. The technology is characterized by a low spatial resolution, but its strength
resides in its high time resolution. Frame rates up to 50 images per second are common.
In thoracic imaging by EIT, the medium of interest is the thoracic cavity. The belt of
electrodes is placed around the chest and images of the intra-thoracic distribution of
bioimpedance changes are reconstructed.
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4.1.2 Factors affecting thoracic bioimpedance
In thoracic EIT, most system measure local changes in bioimpedance (with respect to a
given reference spatial distribution)1. In the thorax, changes in the internal distribution
of bioimpedance are mainly induced by respiratory and cardiovascular activity. Figure 4.1a
shows an example of an EIT image measured at the heart level in a healthy 28-year-old
male subject during normal breathing, illustrating the effects of respiratory activity on
the EIT signal. The measurements were obtained with a Goe MF II device (CareFusion,
Höchberg, Germany) and the images reconstructed with the GREIT algorithm [5]. The
effects induced by cardiovascular activity are hardly visible in that image as their
amplitude is typically 10 times smaller than their respiratory counterparts. Figure 4.1b
shows an EIT image measured in the same conditions but during breath-hold, illustrating
the effects of cardiovascular activity on the EIT signal.
4.1.3 Separation of the respiratory- and cardiovascular-related components
Estimating parameters related to cardiovascular activity with EIT – one of the aims of
the present thesis – requires the EIT signal to show minimal inﬂuence from breathing-
related conductivity changes. Various methods have been proposed in the literature
to isolate the cardiovascular component. Although not appropriate for continuous
monitoring in contexts such as intensive care units, acquiring the EIT data during
breath-hold remains the simplest and most effective approach [49]. Separation methods
exploiting principal component analysis have been proposed [41, 130]. More commonly
used, frequency ﬁltering techniques (e.g. high-pass ﬁltering) are a simple and effective
alternative for strongly reducing the inﬂuence of the respiratory component. Another
well-known approach is ECG-gated ensemble averaging, which consists in exploiting
the physiological synchrony of cardiovascular-related EIT signals with the ECG signal.
This method provides a more selective ﬁltering than a simple high-pass ﬁlter by acting
as a comb ﬁlter with increasingly wider lobes at higher cardiac harmonics [139]. The
process can be performed in post-processing or in real-time by using the ECG signal as
trigger during the data acquisition process.
4.2 EIT for bedside monitoring of the cardiorespiratory system
4.2.1 Current situation and challenges
The aforementioned qualities of EIT, in particular its non-invasiveness and its ability
to provide continuous measurements, make of this technology an ideal candidate for
1We explain later the rationale for reconstructing distributions of intra-thoracic impedance changes
instead of absolute impedance values. Moreover, as impedance is mainly resistive at EIT frequencies [47, 73],
EIT images are often depicted as distributions of conductivity changes (the inverse of resistance). We use
this convention in the present thesis.
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Figure 4.1 – Internal distribution of conductivity changes measured by EIT in a healthy
subject: (a) at end inspiration with respect to end expiration, and (b) during breath-hold
at end systole with respect to end diastole. Color scales are not the same between both
images, as cardiovascular-related changes are of much smaller amplitude. Warm colors
depict conductivity increases; cool colors depict conductivity decreases. The dashed
lines highlight the pulmonary regions of interest; the dotted line highlights the cardiac
region of interest. In (a), the conductivity decreases in the lung regions at inspiration
due to the inﬂow of air, which deforms the cells of the alveolar walls and changes
their dielectric properties [122]. In (b), the ejection of highly conductive blood from the
ventricles to the lungs induces a decrease in conductivity in the heart region and an
increase in the lungs.
patient monitoring at the bedside (e.g. in intensive care units), as illustrated in Figure 4.2.
However, before EIT can make its way into routine clinical practice, several challenges,
in particular a proper deﬁnition of standardized EIT protocols, ﬁndings, interpretations
and diagnostic tools, need to be overcome [52].
4.2.2 Clinical outlook
At the current state of research, the most promising ﬁeld of application of EIT is thought
to be the monitoring and optimization of ventilation [6] as signiﬁcant advances have
been achieved in terms of EIT-based assessment of end-expiratory lung volume and
ventilation distributions over the last decades [51]. Besides, cardiovascular applications
have received increasing attention as well. In particular, the clinical potential of EIT
has been investigated for the estimation of hemodynamic parameters such as cardiac
output [129, 174], aortic blood pressure [157], pulmonary perfusion [21, 49, 120] or stroke
volume variations [104].
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Figure 4.2 – Concept of bedside EIT monitoring. (a) A belt of equidistantly spaced
electrodes is attached around the patient’s chest. (b) Impedance measurements are
performed and supplied to an image reconstruction algorithm, resulting in sequence of
EIT images. (c) Regions of interest (ROI) characteristic of particular organs or anatomi-
cal structures are identiﬁed and (d) ROI-wise or pixel-wise functional analysis of the
impedance signals is performed. (e) The estimated cardiorespiratory parameters result-
ing from the analysis are provided to the clinician.
4.3 Technical aspects of EIT
4.3.1 Measurement of bioimpedance
Formally, bioimpedance is a measure of the opposition presented by biological tissue
to an electrical current when a voltage is applied. Electrical currents ﬂow through a
biological tissue via the movement of ions among its cells [47]. The path taken by the
current will depend on its frequency. Low-frequency currents will hardly penetrate
the cells, as their membranes are mostly capacitive [13]. The currents thus primarily
travel through the viscous extra-cellular ﬂuid, which behaves as a resistor. At higher
frequencies however, the currents will be able to charge the cell membranes and ﬂow
through them and the intra-cellular ﬂuid [47]. This aspect is illustrated in Figure 4.3. A
cell suspended in extra-cellular ﬂuid can be modeled as a capacitor C in series with a
resistor R1, both of which are in parallel with another resistor R2 [13]. More generally,
the entire human body can be electrically modeled as a combination of capacitive and
resistive elements, with reasonable accuracy for low-voltage levels [47].
Considering the abovementioned aspects, the choice of frequency of the injected currents
38
4.3. Technical aspects of EIT
Rm Cm
Ri
Rm Cm
Re
C
R1
R2
Low-frequency current path
High-frequency current path
Figure 4.3 – Path of electrical currents through a suspension of cells. Low-frequency
currents can hardly penetrate the cells due to the dominantly capacitive behavior of their
membrane. High-frequency currents are able to pass through the membrane and the
intra-cellular space. Cm: membrane capacitor; Rm: membrane resistor; Ri: intra-cellular
ﬂuid resistor; Re: extra-cellular ﬂuid resistor; C, R1, R2: capacitor and resistors of the
equivalent circuit. Adapted from [13].
in EIT is a matter of compromise. The skin-electrode impedance is large at lower frequen-
cies (up to 1 MΩ at 1 Hz and 100 kΩ at 100 Hz), but drops as frequency increases (down
to 220 Ω at 100 kHz and 120 Ω at 1 MHz) [144]. Large skin-electrode impedances induce
a substantial voltage drop on the injecting electrodes, and impedance imbalance on the
measuring electrodes, thus degrading the common-mode rejection of instrumentation
ampliﬁers [73]. This aspect favors higher frequencies. Furthermore, maximal allowed
RMS amplitude of so-called patient leakage currents are very restricted at lower frequen-
cies (0.1 mA at 100 Hz according to the current international electrical safety standards
IEC 60601–1:2005) [77], which limits the signal-to-noise ratio. Beyond 1 kHz, the risk
decreases rapidly and current amplitude can be increased, up to 10 mA at 100 kHz [77].
This aspect also favors higher frequencies. However, as frequency increases, the inﬂu-
ence of capacitive effects (parasitic capacitances) increases, thereby limiting the possible
frequency range [73]. Taking all these elements into consideration, a frequency of
100 kHz can thus be considered typical for EIT and – more generally – bioimpedance
measurements, with most studies operating in the range 10 kHz – 1 MHz [47]. The
choice of the amplitude of the injected currents is then dictated by safety considerations
in function of the chosen frequency and the limitations of the device used.
4.3.2 Stimulation and measurement patterns
An EIT system typically consists of a belt of nS electrodes equidistantly spaced on the
periphery of the thorax. Small electrical currents are injected on pairs of electrodes and
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Figure 4.4 – Adjacent stimulation and measurement pattern: example for a 16-
electrode conﬁguration. (a) The current is injected on the ﬁrst pair of adjacent
electrodes ({1, 2}) and the resulting voltages are measured on the remaining pairs
({3, 4}, {4, 5}, . . . , {15, 16}). (b) The same process is repeated until each adjacent pair
has been used as injecting pair once. Adapted from [105].
the resulting voltages are measured on the remaining pairs according to a so-called
stimulation and measurement pattern. For instance, in the widely-used adjacent pattern
illustrated in Figure 4.4, the current is ﬁrst injected through the pair of electrodes
{1, 2}, while the resulting voltages are measured on the (nS − 3) remaining adjacent
pairs (Figure 4.4a). The current is then injected on the next pair of adjacent electrodes,
namely {2, 3}, and the resulting voltages are measured on the remaining pairs again
(Figure 4.4b). Once each pair of adjacent electrodes has served for current injection, a total
of nM = nS(nS − 3) voltage measurements have been performed. However, because of
reciprocity, only nM/2 of these voltage measurements are independent [105]. The choice
of stimulation and measurement pattern depends on the system and the application.
With the adjacent pattern, current density is larger near the injecting electrodes and
decreases rapidly as a function of distance [105]. Sensitivity is thus larger near the
boundaries, but weak near the center of the thorax, where most cardiorespiratory
phenomena of interest occur. Other patterns, where the pairs of injecting/measuring
electrodes are separated by one or more electrodes, allow a more uniform current density
and a better sensitivity in the central regions, at the cost of a decreased sensitivity near
the boundaries [81].
4.3.3 Image reconstruction
The generation of an EIT frame begins with the acquisition of nM voltages vm ∈ RnM
using a given stimulation and measurement pattern. The voltages are then supplied to
an image reconstruction algorithm and the distribution of intra-thoracic conductivity
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changes is reconstructed. We present hereafter the underlying physics concepts and
working principles of EIT image reconstruction, in particular of one-step linearized
reconstruction as commonly used in difference EIT for clinical applications.
Let us consider the thorax as a medium of complex admittance γ(x) (the inverse of
impedance) into which electrical currents are injected at a ﬁxed angular frequency ω.
(The dependence on the spatial variable x is implicit in the following for simplicity of
notation.) As mentioned earlier, in the range of frequencies used by EIT, the reactive
part of γ is negligible [47, 73], and therefore the medium can simply be characterized by
its real-valued conductivity σ. During current injection, an electric ﬁeld E is set up in
the medium and induces a conduction current density J [8]. Both quantities are related
by a continuum version of Ohm’s law [73]:
J = σE. (4.1)
In absence of internal sources, the total current density in the medium is J, and it is
divergence-free [20]:
∇ · J = 0. (4.2)
Equation (4.2) is the continuity equation and basically states that the amount of charge
entering the medium is equal to the amount of charge leaving it: as the medium is
conductive, there is no accumulation of charge in it [8]. Furthermore, ω being sufﬁciently
low in EIT for magnetic effects to be negligible, a quasi-electrostatic assumption (constant
magnetic ﬁeld) allows us to express E purely in terms of a scalar electric potential φ [8, 73]:
E = −∇φ. (4.3)
Combining (4.1), (4.2) and (4.3), we ﬁnd the continuum version of Kirchhoff’s law
(Laplace equation) [73]:
∇ · σ∇φ = 0. (4.4)
From (4.4), ﬁnding a unique solution for φ given σ is then possible, given appropriate
boundary conditions [73]. This is known as the forward problem. This system can only be
solved analytically in cases of very simple medium geometries and conductivities [7].
However, for more general medium geometries and conductivity distributions, numeri-
cal methods are needed and therefore a discretization of the medium is required. This is
typically performed using the ﬁnite element method, by approximating the medium
geometry with a mesh of nE tetrahedral elements [7]. Using the ﬁrst-order ﬁnite element
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method, the conductivity of the medium is discretized into a vector of element-wise
constant conductivity values σ ∈ RnE . The potential φ can then be approximated by
functions which are linear on each element and continuous across the faces (by analogy
with Kirchhoff’s law) [73]. The potential φ being thus piecewise-deﬁned is not differ-
entiable, which prevents solving (4.4). However, using the weak form of the equation
allows circumventing the issue and leads to a solvable linear system of equations [73].
The process of obtaining the surface voltages v resulting at the electrodes given a
supposedly known internal distribution of conductivity σ can be described via the
so-called forward operator F : RnE 
→ RnM :
v = F (σ). (4.5)
Obviously, in EIT the problem is reversed (inverse problem): the internal distribution of
conductivity σ is unknown and the EIT reconstruction process aims at assessing it from
a set of nM voltages vm ∈ RnM measured at the surface electrodes. The simplest solution
is to ﬁnd the conductivity distribution that minimizes the difference between F (σ) and
vm in a least square sense (‖ · ‖ is the standard 2-norm) [73]:
σ̂ = argmin
σ
‖F (σ)− vm‖2. (4.6)
However, solving (4.6) is doomed to fail as the problem is ill-posed [73]: there are more
unknowns than measurements (nE > nM) and the solution is not unique. Moreover,
the problem is ill-conditioned: as current density is larger near the surface, EIT is more
sensitive to unwanted information (e.g. skin-electrode impedance imbalance) than to the
phenomena of interest (intra-thoracic conductivity changes). Addressing these issues is
done by regularizing the problem, i.e. by introducing some assumptions and restrictions
in order to ensure numerical stability and smoothness of the solution [73]. To do so, the
usual approach is to use Tikhonov regularization:
σ̂ = argmin
σ
‖F (σ)− vm‖2 + λ2‖Γ(σ − σr)‖2. (4.7)
The positive scalar λ is called the regularization parameter, and controls the trade-off
between accuracy of the solution (low λ) and numerical stability (high λ). The term
‖Γ(σ − σr)‖2 allows penalizing solutions that differ too much from an a priori reference
conductivity distribution σr. The regularization matrix Γ ∈ RnE×nE may be chosen to be
the identity matrix to penalizes large conductivity deviations from σr, or a difference
operator to ensure smoothness of the solution [73]. The choice of σr can for instance be
based on a priori knowledge of the internal distribution of anatomical structures and of
their average electric properties.
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As mentioned earlier, it is convenient in medical EIT to make use of difference data,
namely conductivity and voltage changes around reference working points σr and vr,
that is Δσ = σ − σr and Δv = v− vr. The use of difference data provides several advan-
tages, such as a reduced variance between acquisition channels (e.g. due to component
variability and aging) and skin-electrode impedances [8], and the possibility to linearize
the EIT problem around the aforementioned working points. Besides, obtaining abso-
lute conductivity values is not only of great complexity but typically not necessary for
EIT-based biomedical applications, which are more interested in functional information
(conductivity variations around a working point are thus sufﬁcient for that purpose). In
practice, the voltage working point vr is typically estimated by averaging the voltages of
a few frames of an EIT recording when the physiology is presumed stable and, by deﬁni-
tion, is hypothesized to correspond to the conductivity working point σr, i.e. vr = F (σr)
via equation (4.5). It follows:
Δv = F (Δσ),
≈ SΔσ, (4.8)
where S ∈ RnM×nE is the so-called sensitivity matrix and is obtained through the
linearization of the forward operator F around the working point σr [8]. In practice,
S is calculated from the ﬁnite element mesh as the sensitivity of each i-th voltage
measurement to a change in conductivity in the j-th mesh element:
[S]ij =
∂[Δv]i
∂[Δσ]j
∣∣∣∣∣
σr
. (4.9)
Equation (4.7) can now be rewritten as:
Δ̂σ = argmin
Δσ
‖SΔσ − Δvm‖2P + λ2‖Δσ‖2Q. (4.10)
The matrix P ∈ RnM×nM is a weighting matrix controlling the inﬂuence each measure-
ment has in the computation of the errors, by giving less weight to noisier or erroneous
measurements. It is often determined automatically (e.g. by measuring reciprocity er-
rors) and/or from a priori considerations (e.g. knowledge of faulty electrodes) [66]. The
matrix Q ∈ RnE×nE is a regularization matrix that favors smooth solutions, as the limited
number of measurements in EIT prevents resolving high spatial frequency details [8]. Q
can for instance be implemented as a discrete Laplacian ﬁlter [168]. Other choices exist,
such as the NOSER prior [32], which scales Q with the sensitivity of each element using
S to cope with the larger sensitivity of EIT at the boundaries [5]. By solving (4.10), a
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linearized one-step solution is obtained as [73]:
Δ̂σ = (STPS+ λ2Q)−1STPΔvm
= RΔvm (4.11)
where R ∈ RnE×nM is the so-called reconstruction matrix for one-step linearized EIT.
One-step linearized reconstruction algorithms, as opposed to most non-linear and/or
iterative algorithms, allow real-time imaging of the thorax, with image sampling rates
typically ranging between 10 and 50 frames per second, depending on the system and
the application [6].
4.4 Commercially available EIT systems
Many research-oriented EIT systems dedicated to lung monitoring have been developed
over the last decades (see [55] for an exhaustive list). At present only few systems are
commercially available (see Table 4.1).
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Table 4.1 – Commercial EIT systems.
System: ENLIGHT R© 1800
Distributed by: Timpel, São Paulo, Brazil
Electrodes: individual, passive
Number of electrodes: 32
Current frequency: 125 kHz
Imaging rate: 50 images/s
System: Goe MF II
Distributed by: CareFusion, Höchberg, Germany
Electrodes: individual, passive
Number of electrodes: 16
Current frequency: 5−500 kHz
Imaging rate: 13, 25, 33, or 48 images/s
System: PulmoVista R© 500
Distributed by: Dräger Medical, Lübeck, Germany
Electrodes: stretchable elastic belt, passive
Number of electrodes: 16
Current frequency: 80−130 kHz
Imaging rate: 10, 20, 30, 40, or 50 images/s
System: Shefﬁeld MK 3.5
Distributed by: Maltron International, Rayleigh, UK
Electrodes: individual, passive
Number of electrodes: 8
Current frequency: 2−1600 kHz
Imaging rate: 25 images/s
System: Swisstom BB2
Distributed by: Swisstom AG, Landquart, Switzerland
Electrodes: textile belt, active
Number of electrodes: 32
Current frequency: 125−175 kHz
Imaging rate: ﬂexible, up to 50 images/s
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5.1 Introduction
5.1.1 Objectives
In Chapter 3, we have introduced the limitations of current CO monitoring solutions.
The use of the gold standard PAC thermodilution method in clinical settings has, for
the last two decades, become controversial due to the lack of evidence of improved
patient outcomes following its use [67, 107]. Besides, its time resolution is insufﬁcient to
provide continuous monitoring during hemodynamic instability [36, 131]. Finally, cur-
rent non-invasive beat-to-beat monitors are limited by their sensitivity to physiological
phenomena unrelated to CO, thus requiring frequent recalibration maneuvers, whenever
changes in the patient’s hemodynamic status may have occurred [91, 131, 177].
In the present study, we investigate the potential and accuracy of EIT for the non-invasive
and continuous measurement of CO.
5.1.2 Measurement principle and study goal
We have seen in Section 3.1 that several modalities for CO measurement are based on
the joint estimation of stroke volume (SV) and heart rate, as CO is the product of both
parameters. Thus, the main technical challenge resides in the non-invasive estimation of
SV, as heart rate is easy to assess non-invasively. In the present study, we investigate
the feasibility of using EIT for SV estimation. This approach is based on the hypothesis
illustrated in Figure 5.1, i.e. that the EIT-derived conductivity change in the ventricular
region Δσ – hereafter referred to as “EIT heart signal” – is representative of changes
in ventricular blood volume, and therefore its peak-to-peak amplitude Δσmax over the
cardiac cycle, representative of SV. The goal of the present study is to investigate the
validity of this hypothesis.
Previous work. The determination of SV by means of EIT was ﬁrst reported by Vonk-
Noordegraaf et al [174]. Through multivariate regression, an indirect correlation between
SV and Δσmax was found. Zlochiver et al [185] proposed a parametric approach where
the axes of an ellipsis representing the left ventricle were iteratively optimized from
the analysis of the impedances measured. High correlation with the reference was
found despite some limitations: the use of impedance cardiography as reference, and
the dependency of their approach on anatomical and conductivity a priori assumptions.
A similar approach was used by Rashid et al [140] who expressed the boundary of the
left ventricle as truncated Fourier series coefﬁcients, and used a ﬁrst-order kinematic
model as state evolution model. A recent publication [129] found signiﬁcant correlation
coefﬁcients between SV and a cardiac impedance change derived from principal compo-
nent analysis. However, due to unresolved issues in their results (unexpected scaling
effects), the authors highlighted the need for further investigations before considering
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Figure 5.1 – Stroke volume (SV) monitoring by EIT: measurement principle and hypoth-
esis. The EIT heart signal Δσ is hypothesized to be representative of changes in left
ventricular volume (LVV), or ventricular volume in general. As a consequence, its peak-
to-peak amplitude Δσmax is assumed to be representative of SV, i.e. the peak-to-peak
change in LVV.
the transfer of their technique into clinical practice.
These studies differ in their approach for computing an SV-related quantity. In particular,
the non-parametric approaches in [129] and [174] did not ﬁnd a direct relation between
Δσmax and SV, suggesting that the hypothesis in Figure 5.1 might be incorrect, or at
least incomplete. The exact sources contributing to the genesis of Δσ appear to be
still unclear and subject to interpretation. Yet, the correct interpretation of impedance-
derived parameters requires a fundamental understanding of the physiological origin of
the signals being measured.
Origins of pulsatile EIT signals in the heart region. The exact origin of pulsatile con-
ductivity changes in EIT remains subject to interpretation [52]. Many potential cardio-
synchronous sources of conductivity change (such as atrial and ventricular blood volume
changes, arterial distensibility and pulsatility, or blood ﬂow) act in concert within the
thorax. In the heart region, the hypothesis in Figure 5.1 assumes Δσ to be solely induced
by changes in ventricular blood volume. However, recent investigations in pigs [23]
suggest that heart motion (cardioballistic effects) may play a signiﬁcant role in the genesis
of Δσ. Indeed, as myocardial deformation occurs over the cardiac cycle, interactions
between the myocardium and low conductivity tissues (mostly adipose and lung tissues)
at the periphery of the heart generate cardio-synchronous conductivity changes that
directly contribute to the genesis of Δσ, but are not caused directly by variations in
blood volume. Isolating these motion-induced changes from those caused by variations
in blood volume is virtually impossible, as strong mechanical (e.g. myocardial deforma-
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Figure 5.2 – Overview of the simulation and analysis process for the present study. See
text (beginning of Section 5.2) for details.
tion and ventricular volume change) and physiological (e.g. cardiac inotropy and SV)
interdependencies link both of these two factors [86]. Simulations on a dynamic model
to quantify the contribution of each factor to the genesis of Δσ are therefore suggested.
The goal of this study is thus twofold: (1) to provide, through simulations on a dynamic
model, a better understanding of the origins of the EIT heart signal Δσ, in particular
by quantifying and characterizing the inﬂuence of heart motion in its genesis; and (2)
to evaluate via the model the validity of using Δσ as an estimator of left ventricular
volume (LVV), and thus of using Δσmax for SV estimation.
Section 5.2 describes the creation of the model and the EIT simulations performed. The
simulation results are presented in Section 5.3 and discussed in detail in Section 5.4.
5.2 Methods
Figure 5.2 shows an overview of the simulation and analysis process used in the
present study. From segmented magnetic resonance imaging (MRI) scans, a dynamic
bioimpedance model is created. The model can be adapted via two parameters: the SV
value to be simulated, and the “scenario”, which controls the amount of heart motion
in the cardiac region. The adapted model is then used to perform EIT simulations for
each SV value and scenario considered, and the EIT heart signal Δσ is automatically
assessed from the EIT images. The inﬂuence of heart motion on Δσ and on Δσ-based SV
estimation is then investigated.
5.2.1 Inﬂuence of heart motion: three scenarios
The scenario is one of the two parameters of the model (along with the simulated
SV value), and controls the amount of heart motion. Throughout the whole study,
three scenarios are considered. Two of them (scenarios A and B) are physiologically
unrealistic. In A, only blood volume changes are occurring in the heart, but no heart
motion is present, i.e. there is no mechanical interaction of the outer myocardial surface
with its surrounding tissues. Scenario B is the opposite of A: only heart motion is
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present, and no blood volume changes occur in the heart. Finally, scenario C is the
physiologically realistic scenario. In C, both blood volume changes and heart motion
are present.
Scenarios A and B will allow us to isolate and thus quantify the individual effects
that blood volume changes and heart motion have on Δσ. Scenario C will allow us to
evaluate the performance of EIT for SV estimation in physiologically realistic conditions,
i.e. when the EIT heart signal is a mixture of blood volume- and motion-related changes.
The way these three scenarios are implemented will be detailed in the next section.
5.2.2 Dynamic bioimpedance model creation
MRI data acquisition and segmentation
The healthy subject enrolled in this experiment was an 83-kg, 183-cm, 50-year-old male
with an under-bust girth of 100 cm. MRI scans were acquired with a 3T Philips Achieva
instrument. ECG-gated scans were performed during breath-hold in an oblique plane
along the long axis of the heart. A full cardiac cycle was imaged with a time resolution of
43 ms, resulting in a total of 20 2D image slices. The spatial resolution in the mediolateral
and anterioposterior directions was 0.94 mm/pixel, and slice thickness 8 mm.
The cardiac cavities (atria and ventricles), the outer boundary of the myocardium, and
the aorta were segmented manually in each of the 20 MRI frames representing the
cardiac cycle. The lungs, fat, skeletal muscle, spine, and thorax contour were segmented
manually in the ﬁrst frame only. The aortic wall thickness was assumed to be 12 % of
the segmented aortic radii [121] and the pericardium uniformly 2 mm thick [176]. The
resulting segmentation can be seen in Figure 5.3a (for one frame of the cardiac cycle).
In addition, the segmented area and length of the left ventricle in each frame were used
to compute the reference left ventricular volume LVVMRI via the single-plane area-length
method [166] (see Figure 5.3b).
Simulation of scenarios A, B, and C
Simulating the three scenarios described earlier in Section 5.2.1 can be done by modifying
adequately the segmentation of the inner boundary of the myocardium (i.e. the boundary
of the cardiac chambers), as well as its outer boundary. This process is illustrated in
Figure 5.4. In short:
a) In scenario A (where the EIT heart signal Δσ is caused by changes in blood volume
only), the segmentation of the myocardial outer boundary is “frozen” to its end-
diastolic state for all 20 frames of the cardiac cycle. This suppresses conductivity
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Figure 5.3 – (a) Example of an MRI-derived segmented frame of the dynamic model. For
illustration purposes, each organ or tissue is colored using a gray level proportional to its
electrical conductivity value. (b) Reference MRI-derived left ventricular volume LVVMRI.
The reference end-diastolic, end-systolic and stroke volumes are EDVMRI = 128 mL,
ESVMRI = 51.7 mL and SVMRI = 76.3 mL.
changes related to heart motion.
b) In scenario B (where Δσ is caused by heart motion only), the myocardial inner
boundary is “frozen” to its end-systolic state for all 20 frames of the cardiac cycle.
This suppresses conductivity changes related to blood volume variations.
c) In scenario C, no modiﬁcation is made to the segmentation, as scenario C depicts
the realistic scenario.
Our segmentation can therefore be adapted depending on which scenario (A, B, or C)
is to be simulated. However, just as our 20 MRI frames, the segmentation covers one
cardiac cycle and therefore one corresponding SV value only (SVMRI). Investigating the
possibility of tracking changes in SV with EIT requires the possibility of changing this
SV value. This can be done through appropriate modiﬁcation of the segmentation, as
described in the next section.
Simulation of SV changes
Simulating a different SV value can be achieved by morphing the segmentation of the
heart at end diastole and end systole to different end-diastolic and end-systolic volumes,
respectively. This process is detailed hereunder. It is worth mentioning that this only
needs to be done for 2 frames of the cardiac cycle, namely frame 0 (end-diastolic frame)
and frame 7 (end-systolic frame), since only the peak-to-peak amplitude of Δσ, namely
Δσmax, is needed for SV estimation, as illustrated earlier in Figure 5.1. The morphing
process operates as follows.
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Figure 5.4 – Zoom on the segmentation of the ventricular region for each scenario at end
diastole and end systole. The inner and outer boundaries of the myocardium at end
diastole are shown in light blue in all images. In scenario A, the outer boundary of the
myocardium is “frozen” to its end-diastolic state. In scenario B, the inner boundary of
the myocardium is “frozen” to its end-systolic state. In scenario C (realistic scenario), no
modiﬁcation is made to the segmentation.
a) For each 2D point located on the inner or outer boundary of the segmented my-
ocardium at frame 0 (end-diastolic frame), its corresponding point is manually
identiﬁed at frame 7 (end-systolic frame).
b) Aggregating all these 2D boundary points into matrices at frame 0 and 7 leads to
X0 and X7, respectively.
c) We then obtain a displacement matrix Y = X7 − X0.
d) Introducing the pair of parameters {κ, λ} (both being equal to 1 for the moment),
we can write X0 = X7 − κY and X7 = X0 + λY.
e) Simulating different SV values can then be done by morphing the segmentation X0
to a different end-diastolic volume value using X0 = X7 − κY with κ = 1, and/or
by morphing the segmentation X7 to a different end-systolic volume value using
X7 = X0 + λY with λ = 1.
Applying the procedure described above allows easily simulating SV values different
from SVMRI. For scenario A, the procedure is applied only for the inner boundary of the
myocardium. For scenario B, it is applied only for its outer boundary.
A given segmentation is thus characterized by two parameters: the SV value and the
scenario simulated. The next section describes how – for a given segmentation – the
corresponding bioimpedance model is created.
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(a) (b)
Figure 5.5 – Mesh of the 2.5D dynamic bioimpedance model before (a) and after (b)
assigning a conductivity value to each of its ﬁnite element.
Table 5.1 – Conductivity value of tissues at 100 kHz [68].
Tissue Conductivity (S/m) Tissue Conductivity (S/m)
Blood 7.03 · 10−1 Lungs See Figure 5.6a
Blood (aorta) See Figure 5.6b Spinal cord 8.08 · 10−2
Skeletal muscle 3.62 · 10−1 Fat 2.44 · 10−2
Aortic wall 3.19 · 10−1 Vertebrae 2.08 · 10−2
Myocardium 2.15 · 10−1
Model creation
The model creation process and all ensuing EIT simulations are carried out using Matlab
(MathWorks, Natick, USA) and the framework of the EIDORS toolbox [4]. A 2.5D (2D
extruded) ﬁne mesh ﬁtting the subject’s segmented thorax contour is generated using
the dedicated function [62] of the EIDORS toolbox (Figure 5.5a). A total of ∼ 4.6 · 105
tetrahedral elements with an average edge length of 5.1 mm are obtained. At each k-th
frame, each ﬁnite element of the mesh is assigned an electrical conductivity value of the
organ or tissue its center belongs to (by considering an extrusion of the segmentation to
3D) in the time laps of the current frame (Figure 5.5b). The biological values of electrical
conductivity used in this model are listed in Table 5.1.
Pulmonary and aortic conductivity changes. The model implements conductivity
changes purely related to cardiovascular activity, as the MRI scans were acquired during
breath-hold using ECG gating. The conductivity changes in the lungs are thus purely
induced by the pulsatility of the pulmonary arteries, and their conductivity varies ac-
cording to the curve depicted in Figure 5.6a. In the aorta, the conductivity depends both
on the distension-induced change in blood volume, and the ﬂow-induced change in
blood conductivity [170]. While the former is directly determined in the model by the
MRI-obtained area change of the aorta over the cardiac cycle, the later is controlled by
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Figure 5.6 – (a) Pulmonary conductivity change over the cardiac cycle, based on the
waveform measured by [173], set to a baseline (end-diastolic) conductivity value of
1.07 · 10−1 S/m [68] and scaled in order to produce a conductivity change of 10 % [27].
(b) Aortic conductivity change over the cardiac cycle, computed via Visser’s model [170]
using an MRI-based blood ﬂow curve and aortic radii measured in a healthy subject.
The conductivity curve is set to a baseline value of 7.03 · 10−1 S/m [68] and scaled in
order to produce a conductivity change of 15 % [138].
the conductivity curve in Figure 5.6b.
5.2.3 EIT simulations
EIT data generation: the forward problem
EIT relies on the application of small alternating electrical currents and peripheral volt-
age measurements v to estimate the intra-thoracic conductivity distribution σ. In the
present study, EIT voltages v are obtained using EIDORS with a 32-electrode stimulation
and measurement pattern where each injecting or measuring pair of electrodes is sepa-
rated by four non-injecting or non-measuring electrodes, respectively [55]. The default
EIDORS ﬁrst-order forward solver is used to generate the voltages v.
EIT image reconstruction: the inverse problem
As is convenient for biomedical applications of EIT, we make use of difference EIT recon-
struction (previously introduced in Chapter 4) in the present study. Image reconstruction
is performed using the GREIT algorithm with the recommended parameters [5]. Differ-
ence data are obtained by using the ﬁrst frame (representing end diastole) as reference
data set, resulting in sequences of 40× 60 pixel images after image reconstruction.
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Figure 5.7 – Automatic segmentation of the ventricular ROI. (a) A sign image is computed
as the sign of the average conductivity value at each pixel over the cardiac cycle. As
the reference EIT frame corresponds to end diastole, a negative sign indicates that
– on average – conductivity decreases over the course of the cardiac cycle. As the
ventricles are ﬁlled with blood at end diastole and empty during systole, a negative
sign is expected in the ventricular ROI. (b) A power image is then computed as the
pixel-wise variance of the conductivity change across time and (c) is segmented using
the watershed algorithm [113] as proposed by Ferrario et al [45]. (d) The watershed
region containing the negative-sign pixel with maximal cardiac power is deﬁned as the
ventricular ROI (green dotted line). (e) For visual comparison, a segmented frame (the
same as in Figure 5.3a) is shown.
5.2.4 Automatic extraction of Δσ in EIT image sequences
Automatically obtaining Δσ from an EIT image sequence ﬁrst requires the automatic
extraction of the ventricular region of interest (ROI). The ROI is computed in scenario C
(realistic scenario). This process is illustrated and detailed in Figure 5.7. At each k-th
frame, the total conductivity change in the ventricular region Δσ[k] is computed by
summing the conductivity change of all pixels within the ROI.
5.2.5 Simulated SV values
As explained earlier, the model is controlled by two parameters: the SV value and
the scenario (A, B, or C) simulated. In the present study, 11 physiologically realistic
stroke volumes1 are simulated, and listed in Table 5.2. They are hereafter referred to as
SVi (i ∈ {1, . . . , 11}), with SV1 corresponding to SVMRI, the original SV value obtained
from the MRI scans. SV2 to SV11 simulate SV values induced by changes in cardiac
preload, afterload, or inotropy. Hereafter, the Δσ curve obtained with SVi and scenario X
(X ∈ {A,B,C}) will be referred to using the notation Δσ(X)i . The peak-to-peak amplitude
of Δσ(X)i will be referred to as Δσ
(X)
i,max.
1The physiological interdependent effects of preload, afterload and cardiac inotropy on SV (described
earlier in Section 2.2.5) are taken into account [86].
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5.2.6 Analysis protocol
Analysis 1: Contribution of heart motion to the genesis of Δσ
This ﬁrst analysis aims at quantifying the inﬂuence (i.e. the contribution in terms of
amplitude) of heart motion to the genesis of Δσ. To do so, the peak-to-peak amplitudes
Δσ(A)1,max and Δσ
(B)
1,max of the EIT heart signal in scenarios A and B are compared. The
contribution (percentage of the total amplitude change) of heart motion to the EIT heart
signal is estimated as Δσ(B)1,max
/(
Δσ(A)1,max + Δσ
(B)
1,max
)
.
Analysis 2: Impact of heart motion on the morphology of Δσ
This analysis aims at evaluating the closeness of ﬁt between the EIT heart signal Δσ
and left ventricular volume (LVV) at various levels of heart motion, as using Δσmax
for SV estimation implicitly requires Δσ to be representative of LVV. To do so, for each
scenario X, Δσ(X)1 is ﬁtted onto LVVMRI (least-square linear ﬁt); the root mean square error
(RMSE) and Pearson’s correlation coefﬁcient between both curves are then computed.
Analysis 3: Impact of heart motion on EIT-based SV estimation
This analysis aims at evaluating the accuracy of EIT-based SV estimation at various levels
of heart motion. To do so, Pearson’s correlation coefﬁcient between the simulated SVi
values and their corresponding Δσ(X)i,max in all three scenarios is evaluated. Furthermore,
using a 1-point calibration (the MRI-derived SV1 value and its corresponding Δσ
(X)
1,max
value), all Δσ(X)i,max values are converted to milliliters, resulting in an EIT-based estimate
of SV for each scenario as follows:
SVEIT
(X)
i = Δσ
(X)
i,max ·
SV1
Δσ(X)1,max
, (5.1)
where SV1/Δσ
(X)
1,max is the 1-point scaling (calibration) factor. The error (mean± SD),
both absolute (in milliliters) and relative (as a percentage), is calculated between SVEIT
(X)
i
and SVi for each scenario.
5.3 Results
For illustrative purposes, examples of reconstructed EIT images for various SVi values
and for the three scenarios are shown in Figure 5.8.
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Figure 5.8 – End-systolic reconstructed EIT frame for the three scenarios in various
conditions (see Table 5.2): the baseline condition (1) and the two conditions (4 and 7)
showing the most extreme SVi values. The blue and red colors respectively depict
decreases and increases in conductivity with respect to the reference (end-diastolic)
frame. The color scale is the same for all images.
60
5.3. Results
Table 5.2 – Simulated SV values (adapted from [86]). EDV and ESV represent the end-
diastolic and end-systolic volumes, respectively. The “Baseline” condition represents
the original volumes obtained from the MRI data (Figure 5.3b).
i Description EDVi (mL) ESVi (mL) SVi (mL)
1 Baseline 128.0 51.7 76.3
2 Preload (small increase) 144.0 54.3 89.7
3 Preload (moderate increase) 160.0 56.9 103.1
4 Preload (large increase) 176.0 59.5 116.5
5 Preload (small decrease) 114.6 46.5 68.1
6 Preload (moderate decrease) 101.3 41.3 60.0
7 Preload (large decrease) 88.0 36.2 51.8
8 Afterload (increase) 138.7 67.2 71.5
9 Afterload (decrease) 122.7 41.4 81.3
10 Inotropy (increase) 117.3 36.2 81.1
11 Inotropy (decrease) 144.0 72.4 71.6
5.3.1 Contribution of heart motion to the genesis of Δσ (Analysis 1)
The EIT heart signal Δσ(X)1 is depicted for each scenario in Figure 5.9a. The peak systolic
amplitude Δσ(X)1,max is found to be 0.84, 1.08, and 1.99 A.U. for scenarios A, B, and C,
respectively. The contribution of heart motion to the EIT heart signal is therefore
Δσ(B)1,max
/(
Δσ(A)1,max + Δσ
(B)
1,max
)
= 1.08/(0.84+ 1.08)  56.3 %.
5.3.2 Impact of heart motion on the morphology of Δσ (Analysis 2)
The linear least-square ﬁt of Δσ(X)1 onto LVVMRI is shown in Figure 5.9b (only for the
realistic scenario C for the sake of clarity). The RMSE between both curves is found to
be 27.7 mL, 25.4 mL, and 21.6 mL for scenarios A, B, and C respectively. In the same
order, Pearson’s correlation coefﬁcients of 0.973, 0.978, and 0.984 between both curves
are obtained.
5.3.3 Impact of heart motion on EIT-based SV estimation (Analysis 3)
The correlation between Δσ(X)i,max and SVi is shown in Figure 5.10a (for the realistic
scenario C only). Figure 5.10b depicts the error on SV estimation for all three scenar-
ios after converting Δσ(X)i,max into SVEIT
(X)
i using (5.1). The error (mean± SD) between
SVEIT
(X)
i and SVi is −0.66± 3.88 mL (−0.62± 4.43 %), 1.67± 2.48 mL (2.19± 3.38 %) and
0.57± 2.19 mL (1.02± 2.62 %) for scenarios A, B, and C, respectively. In the same order,
Pearson’s correlation coefﬁcients of 0.984, 0.991, and 0.996 between both quantities are
obtained.
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5.4 Discussion
A dynamic bioimpedance model was created for quantifying and characterizing the
inﬂuence of heart motion on the genesis of the EIT heart signal Δσ. The inﬂuence of
heart motion on the accuracy of EIT-based SV estimation was also evaluated.
5.4.1 Contribution of heart motion to the genesis of Δσ
From Analysis 1, the EIT heart signal Δσ was found to be dominated by heart motion-
induced changes, with a contribution of approximately 56 %. This joint presence of
blood volume-related and heart motion-induced changes to the genesis of Δσ can be
explained as follows. During ventricular ejection, as illustrated in Figure 5.11, the my-
ocardium contracts in the EIT ventricular ROI (light blue dashed line in the ﬁgure) and
is progressively substituted – spatially speaking – by adipose and/or lung tissue [60],
causing heart motion-related impedance changes. In the meanwhile, blood is substi-
tuted by myocardial tissue, causing blood volume-related changes. These two effects
act in concert and decrease the global conductivity in the ventricular ROI. The opposite
occurs in the atrial region, where the low-conductivity adipose and lung tissues are
progressively substituted by the myocardium (heart motion-related changes), and the
latter by blood (blood volume-related changes), thus increasing the global conductivity
in the atrial region. The ventricular and atrial regions are separated by a zone of negligi-
ble conductivity change (between the two green dotted lines of the right panel in the
ﬁgure). At end diastole, this zone is occupied by ventricular blood and is progressively
substituted by atrial blood as the atrioventricular plane moves towards the apex during
ventricular ejection [29]. Therefore, no signiﬁcant conductivity change occurs in this
region.
5.4.2 Impact of heart motion on the morphology of Δσ
Analysis 2 aimed at evaluating the inﬂuence of heart motion on the closeness of ﬁt
between LVVMRI and Δσ. It was found that both blood volume-related changes Δσ(A)
and heart motion-induced changes Δσ(B) strongly correlate with LVVMRI (r > 0.97). This
is also reﬂected by the very similar RMSE found in all scenarios after ﬁtting Δσ onto
LVVMRI, and the strong morphological resemblance between all curves in Figure 5.9a.
We explain this strong correlation between heart motion-induced conductivity changes
and LVVMRI as follows. The myocardium and blood are nearly incompressible [18, 83].
Therefore, in the ventricular region, the deformation of the myocardial outer boundary
must follow that of its inner boundary (i.e. the deformation of the ventricles), as no
volume loss can occur. Consequently, conductivity changes occurring outside of the
heart reﬂect changes occurring inside, i.e. changes in ventricular blood volume.
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Figure 5.11 – Schematic illustration of the conductivity change in the heart region be-
tween end diastole (ED) and end systole (ES). The rightmost image depicts the difference
of both aforementioned images, i.e. what difference EIT actually aims at reconstructing.
The black lines in ES depict the outlines of ED. See Section 5.4.1 for details. LA: left
atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; AV plane: atrioventricular
plane; MY: myocardium; LC: low-conductivity tissue (adipose or lung tissue).
5.4.3 Impact of heart motion on EIT-based SV estimation
Analysis 3 aimed at testing the feasibility of tracking changes in SV with EIT from
the peak-to-peak amplitude of the EIT heart signal Δσmax. To do so, a wide range
of physiologically realistic SV values were simulated. Strong correlation coefﬁcients
(r > 0.98) were found for all scenarios between Δσmax and SV. After conversion of Δσmax
to milliliters using a 1-point calibration, the resulting errors on SV estimation were small
enough to be clinically useful [36]. These results suggest that EIT can accurately monitor
SV variations despite the dominantly heart motion-related origin of the EIT heart signal.
In summary, our observations suggest that the EIT heart signal is not dominantly induced
by ventricular blood volume changes. However, it is representative of ventricular blood
volume changes, due to the strong correlation between heart motion- and blood volume-
induced impedance changes.
5.4.4 Implications of our observations
Impact of respiratory activity
We have explained in Section 5.4.1 that heart motion-induced impedance changes are
due to the conductivity contrast between the myocardium and its surrounding tissues,
mainly lung tissue. In our model based on ECG-gated MRI scans during breath-hold,
variations in lung conductivity were limited to small changes induced by arterial pul-
satility. However, in realistic scenarios, lung tissue conductivity varies much more
due to respiratory activity; therefore, the contrast with myocardial tissue varies much
more as well. In other terms, the amplitude of the motion-related component of the EIT
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heart signal is modulated by lung conductivity changes, and thus by respiratory activity.
This could affect the accuracy of the EIT-based measurement of SV. Similarly, other
respiration-induced phenomena, such as the in- and out-of-plane motion of the heart
or the deformation of the internal distribution of impedance volumes, may challenge
the measurement. A possible workaround could consists in performing respiration-gated
EIT measurements, for instance by only measuring Δσmax at end of expiration. Such a
solution could overcome the aforementioned respiration-induced limitations, at the cost
of limiting the responsiveness of the EIT-based measurement of SV.
Impact of particular pathological conditions
On the other hand, our observations call into question the feasibility of EIT-based
SV estimation in particular pathological conditions, such as large pericardial effusion
(accumulation of ﬂuid around the heart) [103]. In such cases, heart motion is not
limited to the normal deformation of the myocardium, but also to its disease-induced
displacements in the pericardial cavity. The resulting mechanical interactions of the heart
with its surrounding tissues – unrelated to SV – are likely to signiﬁcantly affect the EIT
heart signal.
It is also worth mentioning that other pathologies, such as valvular insufﬁciencies, are
likely to compromise the EIT-based measurement of SV. In such cases, SV is likely to be
overestimated, as part of the ejected volume is pushed back into the atria (mitral/tri-
cuspid regurgitation) or the ventricles (aortic/pulmonary regurgitation) at the end of
ventricular ejection.
5.4.5 Limitations and future work
The main limitations of the model and study are listed hereafter.
a) Given the aims of this study, only cardiovascular-related conductivity changes
were modeled. Therefore, the aforementioned effects of respiratory activity on
the accuracy of EIT-based SV estimation can only be described, but not formally
quantiﬁed. To include respiration in a model – and all its aforementioned effects
(such as in- and out-of-plane heart motion) – would require complex 4D modeling.
We rather suggest to investigate this aspect in real clinical data.
b) Another aspect not included in our model was the ﬂow-induced change in blood
conductivity in the cardiac chambers, due to the complexity of the modeling
process. A future extension of the present model should aim at taking these effects
into account.
c) The model is 2.5D. Electrical currents are known to propagate in three dimensions.
65
Chapter 5. Inﬂuence of heart motion on the EIT-based measurement of CO
Conductivity changes occurring above and below the electrode plane are thus not
necessarily considered adequately.
d) No noise was included in the simulations. Its inﬂuence on the accuracy of SV
estimation by EIT remains to be evaluated.
e) The simulation of the different SVi values (Table 5.2) using the morphing procedure
described in Section 5.2.2 is limited by the linearity assumption of the latter. Extrap-
olating the original end-diastolic and end-systolic volumes to larger – respectively
smaller – values is therefore only valid to a certain extent.
f) The model is based on the morphology of one single subject. The generalizability
of our observations should be veriﬁed in larger datasets.
g) The inﬂuences of atrial, pulmonary and aortic conductivity changes on the EIT
heart signal Δσ have not been formally quantiﬁed. They can however be assumed
to be small, given the spatial distance between the ventricular ROI and the other
structures, as well as the strong correlation found between Δσ and ventricular
blood volume.
In our opinion, this last point should be thoroughly investigated in the future, as the
plane imaged by EIT may not always be as optimal as the one used in the present study,
where both the imaged ventricular “area” and the atrioventricular distance were large.
In realistic clinical setups, managing to place the EIT electrode belt in that exact ﬁeld
of view without the assistance of another imaging modality seems hardly achievable.
Future work should therefore focus on investigating the inﬂuence of sub-optimal belt
placements and/or belt displacements, to quantify atrial, pulmonary and aortic pulsatile
inﬂuence on Δσ, and verify the SV trending ability of EIT in those conditions.
In a second phase, measurements on humans should be performed to conﬁrm our
observations and validate the potential of EIT for non-invasive SV and CO monitoring.
Particular attention should be given to the aforementioned inﬂuence of respiration on
the EIT heart signal. We suggest the use of respiration-gating in the analysis process.
5.4.6 Summary and conclusion
Simulations were performed on a dynamic bioimpedance model to investigate the
origins of the EIT heart signal Δσ. It was found that the main contributor to this
change is heart motion, by approximately 56 %. It was further found that the motion-
induced component of the EIT heart signal was strongly correlated (r = 0.978) with left
ventricular volume. This observation was explained by the quasi-incompressibility of
blood and myocardial tissue. Under those circumstances, EIT was found to be able to
estimate SV (and thus CO) over a wide range of physiologically realistic values with
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great accuracy. However, these observations were made using a model simulating intra-
thoracic bioimpedance changes during breath-hold and in a healthy heart. Respiratory
activity may affect the accuracy of the measurement, through its inﬂuence on the motion-
induced component of the EIT heart signal. This inﬂuence should be quantiﬁed in
clinical data. Furthermore, the feasibility of the measurement is called into question in
patients suffering from particular conditions such as large pericardial effusion.
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6.1 Introduction
In the previous chapter, the study was focused on the inﬂuence of heart motion on the
EIT heart signal Δσ. However, some key aspects regarding the origins of Δσ have not
been investigated. For instance, the inﬂuence of atrial blood volume changes on Δσ
remains unknown. Indeed, the model presented in the previous chapter was based
on MRI scans acquired along the long axis of the heart, where the spatial separation
between the ventricles and the atria is maximized and is assumed to allow minimizing
the inﬂuence of the atria on Δσ [171]. In practice, managing to position an EIT electrode
belt exactly along this axis can hardly be done without the use of another modality – such
as CT scans – to verify the position of the belt. It is therefore necessary to investigate and
quantify the inﬂuence of atrial conductivity changes on Δσ when the belt is not placed
in a plane maximizing atrioventricular separation. The same applies regarding the
inﬂuence of conductivity changes induced by the pulsatility of the proximal pulmonary
arteries or the aorta. These two sources were already included in our model, but their
inﬂuence on Δσ was negligible in the EIT plane considered.
This raises an important point, namely the extension of the model to the third dimension.
Indeed, the use of 2D or 2.5D models requires creating a fully new model when a
different belt position is investigated, as the plane imaged by EIT is different. A 3D
model solves this issue by easily allowing to investigate various belt positions. In
addition, it allows adequately considering the conductivity changes occurring above
and below the electrode plane. Last but not least, a 3D model would also allow the
investigation of another important aspect of SV by EIT, namely the repeatability of the
measurement, particularly in case of displacement or repositioning of the electrode belt
in-between measurements. Indeed, in a clinical context, the belt may occasionally be
displaced (shifted by a few centimeters) during patient handling, or not be repositioned
at the exact same place after having been momentarily removed. The inﬂuence of such
belt displacements on the accuracy of SV by EIT has not been investigated.
The goals of this preliminary study are thus the following:
a) To create a 3D dynamic (i.e. 4D) bioimpedance model of the human thorax easily
allowing to investigate different belt positions;
b) To quantify the contribution of the ventricles, the atria, the lungs and the aorta on
the EIT heart signal Δσ;
c) To conﬁrm our previous ﬁndings, i.e. the feasibility of tracking changes in SV by
EIT during breath-hold, on this complete 4D model;
d) To investigate the inﬂuence of belt displacement or repositioning on the repeatabil-
ity of the measurement.
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6.2 Methods
The purpose of this section is to provide a summarized description of the 4D
bioimpedance model. A detailed description of the various structures and functional-
ities of the model can be found in [22, 24, 25]. Similarly, the various simulations and
analyses performed – extensively described in the three aforementioned studies – will
be provided in a summarized form here.
6.2.1 Thoracic bioimpedance model
The anatomy of the model was based on MRI recordings performed on a healthy male
volunteer (62 kg, 178 cm, 28 years old) during expiratory breath-hold. The outer surfaces
of the thorax and the lungs were segmented from static whole-thorax 3D scans, whereas
the geometrical deformations of the cardiac chambers and the aorta were segmented
from 4D ECG-gated scans. While the conductivity changes induced by the pulsatility of
the heart and the aorta were directly dictated by their geometrical deformations over
the cardiac cycle, the conductivity changes induced by the pulsatility of the pulmonary
arterial tree was modeled using a time- and location-dependent curve of conductivity
change based on a simpliﬁed model of the pulmonary circulation. Finally, in order to
investigate the inﬂuence of belt displacements, six EIT belts – each comprised of 32
electrodes – were applied onto the thorax mesh (see Figure 6.1). (1) The TM (transversal
middle) belt was placed at the average level of the heart, which is in between the 9-th
and 10-th thoracic vertebra. The belts (2) TH (transversal high) and (3) TL (transversal low)
were placed 3.5 cm higher and lower than TM, respectively. This corresponds to the level
of the 8-th (for TH) or in between the 10-th and 11-th (for TL) thoracic vertebrae. The
belts (4) TLM and (5) THM were placed midway between TL and TM, and TH and TM,
respectively. Finally, (6) the OB (oblique) belt was obtained by tilting the TM belt by 25◦
from transverse to coronal as suggested for cardiac EIT by Vonk-Noordegraaf et al [171],
who hypothesized this angle to be optimal for imaging the heart along its longitudinal
axis, and thus for optimizing the separation between the atria and the ventricles. To
ensure accurate calculations, the mesh was reﬁned in the vicinity of the electrodes as
described in [63].
6.2.2 Bioimpedance simulations and EIT reconstruction
All simulations were performed with Matlab (MathWorks, Natick, USA) using the
framework of the EIDORS toolbox [4]. All impedance measurements were simulated
using a quasi-adjacent stimulation pattern with four inactive electrodes in between the
two ones actively measuring voltage/injecting current [55]. The simulated impedance
measurements were reconstructed to EIT images with the GREIT algorithm [5] and
inverse models generated at the height of each belt from a coarser version of the static
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Figure 6.1 – 4D thoracic bioimpedance model. The model includes MRI-based dynamic
models of the heart and the aorta, and a simpliﬁed dynamic model of the pulmonary
vasculature. The small rectangles on the periphery of the thorax depict the EIT electrodes.
TH: orange belt; TM: green belt; TL: gray belt; OB: black belt. TLM and THM not shown
for easier visualization.
thorax model.
6.2.3 Analysis protocol
Analysis 1: Sources contributing to Δσ
The purpose of this analysis was to allow quantifying the contribution of each pulsatile
source (ventricles, atria, lungs, aorta) to the EIT heart signal Δσ, in particular for two
electrode belt placements commonly used in cardiac EIT, namely TM and OB (see
Figure 6.1). For each belt, one heart cycle was simulated with all structures (atria,
ventricles, lungs and aorta) contributing to the intra-thoracic impedance change. In each
case, an image representing the RMS amplitude of the time signal at each pixel – hereafter
referred to as RMS image – was calculated, as shown in Figure 6.2 (left). From this RMS
image, the ventricular ROI (solid red line in the Figure) was automatically segmented in
a similar fashion as the one described earlier in Section 5.2.4. Then, to investigate the
individual inﬂuence of each source of impedance change (atria, ventricles, lungs, aorta),
each structure was simulated independently, with the other structures frozen to their
end-diastolic state. Again, in each case, an RMS image was calculated (such as Figure 6.2,
right). From these RMS images, the contribution of each individual structure to the
EIT heart signal was determined by summing up all pixels of the corresponding RMS
image in the ventricular ROI. Evaluating the contribution of each individual structure in
this manner involves that the superposition hypothesis is true, i.e. that simulating each
individual structure (ventricles, atria, lungs, aorta) separately and computing the RMS
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Figure 6.2 – Example of RMS images when simulating all structures (left) or the lungs
only (right). The contribution of the lungs to the EIT heart signal Δσ is determined by
summing up all pixels of the lung RMS image falling into the ventricular ROI.
amplitude of the sum of their respective EIT image sequences, is similar to simulating all
structures together and computing the RMS amplitude of the resulting sequence directly.
This was veriﬁed to be true, with a relative absolute error of 3.2± 1.7 % (for TM) and
2.3± 1.4 % (for OB) between the RMS images of both cases in the ventricular ROI.
Analysis 2: Inﬂuence of belt displacement on EIT-based SV estimation
By deforming the heart model in a fashion similar to the one described in Section 5.2.2 in
the previous chapter, 11 different SV values were simulated. The correlation between the
peak-to-peak amplitude Δσmax of the EIT heart signal and the simulated stroke volumes
was then evaluated for all belt placements, in order to conﬁrm/inﬁrm the validity of
Δσmax as a correlate of SV.
In a second phase, the inﬂuence of belt displacement was investigated as follows. (1)
Δσmax as obtained using the TM belt placement was ﬁtted (least-square linear ﬁt) onto
the reference simulated SV values, leading to a “baseline” Δσmax-to-SV calibration. (2)
Up-, down-, left-, and rightwards realistic electrode shifts were then applied to the TM
belt, and Δσmax was recalculated with these shifted belt conﬁgurations. (3) Finally, all
calculated Δσmax were converted to SV value using the previously obtained Δσmax-to-
SV calibration, and the error with respect to the reference simulated SV values was
calculated in each case.
6.3 Results
This section presents the results of this study in a summarized form. A detailed descrip-
tion of the results can be found in [24] and [25].
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6.3.1 Sources contributing to Δσ
In both belt placements, the main contributor to the EIT heart signal Δσ was found
to be the ventricles, by approximately 70 %, followed by the lungs (∼ 15 %) and the
atria (∼10 %) [24]. The ventricular contribution was slightly stronger using the OB belt
placement than with the TM placement.
6.3.2 Inﬂuence of belt displacement on EIT-based SV estimation
For all belt positions investigated, strong correlation coefﬁcients (r > 0.99) were found
between the peak-to-peak amplitude change Δσmax and the simulated SV values, thereby
corroborating the results obtained in Chapter 5 on the 2.5D model. However, signiﬁcant
errors (up to 30 mL) were found between the EIT-derived SV estimates and the simulated
SV values after inducement of realistic belt displacements [25].
6.4 Discussion
The goals of this preliminary study were multiple. In a ﬁrst step, a 4D bioimpedance
model of the human thorax was created in order to investigate the inﬂuence of various
belt positions. In this regard, the ﬁrst ﬁnding of this study has shown that the EIT heart
signal Δσ is dominated by conductivity changes induced by ventricular activity, and that
this contribution increases slightly when the belt is placed in an oblique plane. This can
easily be explained by the larger ventricular “surface” imaged by an oblique EIT plane.
However, contrary to observations in [171], a reduced contribution of the atria using
the oblique belt placement instead of the transverse placement could not be observed.
This needs to be explored further by comparing different reconstruction strategies and
measurement settings.
This preliminary study has also allowed to corroborate the ﬁndings made earlier in
Chapter 5, namely that tracking amplitude changes (Δσmax) in the EIT heart signal
during breath-hold indeed allows tracking changes in SV. However, this ability to track
SV changes seems to be signiﬁcantly affected by belt displacements. These ﬁndings
call into question the intra-subject repeatability of SV values obtained with the current
setup. Future work should focus on ﬁnding an improved setup less sensitive to electrode
displacements. A possible but limiting workaround could be to recalibrate the EIT signal
using another modality after each displacement.
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7.1 Introduction
7.1.1 Objectives
In Chapter 3, we have introduced the current limitations of PAP monitoring solutions in
hemodynamically unstable patients and patients with chronic pulmonary hypertension
(PH). The pulmonary artery catheter provides continuous readings but is associated with
non-negligible morbidity and mortality rates, whereas transthoracic Doppler echocar-
diography is not conducive with continuous monitoring. The need for a safer solution
for the clinical management of PH is thus strong. An optimal PAP monitoring modality
should be non-invasive (free of any risks or complications, and thus compatible with
frequent measurements) and unsupervised (able to operate without supervision of a
medical doctor) [1].
In the present study, we propose and investigate the potential of a novel non-invasive,
continuous and unsupervised PAP monitoring method based on the use of EIT.
7.1.2 Measurement principle
In Section 2.5, we have introduced the physiological relation linking blood pressure
and the pulse wave velocity (PWV), the speed of propagation of pressure waves in the
arterial tree. Monitoring changes in PAP using this relation implies measuring the PWV
in the pulmonary arteries, and therefore to have access to the pulsatile signal of the
pulmonary arteries. Hence the proposed use of EIT, as further detailed hereafter.
Let us consider the ejection of blood by the right ventricle starting with the opening
of the pulmonary valve at time t = 0. The resulting pressure pulse propagates at a
certain velocity (the PWV) to the various branches of the pulmonary arterial tree. At any
downstream arterial site x, the passage of the pressure pulse distends the arterial wall
(Figure 7.1a) with a pressure p(x, t) (Figure 7.1b). The local distension of the arterial wall
induced by p(x, t) induces a local variation in electrical conductivity σ(x, t) (Figure 7.1c).
Consequently, assuming that σ(x, t) is entirely induced by p(x, t), they are inherently
synchronous. Therefore p(x, t) and σ(x, t) are expected to have identical pulse transit
times (PTT), i.e. the time required by the pressure pulse to reach location x in the arterial
tree (see dashed line in Figure 7.1b and 7.1c). The PTT being, by deﬁnition, inversely
proportional to the PWV, we hypothesize that tracking changes in pulmonary PWV, and
therefore in PAP, can be done by tracking changes in the PTT of σ(x, t) assessed by EIT:
PAP ↗ ⇐⇒ PWV ↗ ⇐⇒ EIT-derived PTT ↘ .
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Figure 7.1 – Measurement principle of the pulmonary pulse transit time (PTT) by EIT. (a)
At each cardiac cycle, the wall of each artery is distended by the passage of a pressure
pulse. (b) The pressure exerted by blood at a given location x along the arterial wall
is described by p(x, t). (c) The local distension of the arterial wall induced by p(x, t)
creates a small increase in electrical conductivity σ(x, t). Both waveforms (p(x, t) and
σ(x, t)) being inherently synchronous, their timing information – namely their PTT – is
identical.
7.1.3 Previous work and study goal
The use of EIT for monitoring patients with PH has previously been proposed by the
group of Smit et al [155]. They observed a decreased maximal pulmonary systolic
impedance change (ΔZsys) in patients suffering from advanced stages of idiopathic
pulmonary arterial hypertension. ΔZsys was hypothesized to represent pulmonary
perfusion and its decrease to originate mostly from the reduction of the vascular bed.
However, the physiological link between the amplitude information of the pulmonary
impedance change and the PAP remains to this day unclear, as ΔZsys may not unequivo-
cally be representative of perfusion [21, 52, 69]. Conversely, the timing information of
the pulmonary impedance change has a direct physiological link to the PAP through the
PWV, hence the PWV-based approach proposed in the present study.
We have previously demonstrated the feasibility of this EIT- and PWV-based approach
experimentally for blood pressure monitoring in the systemic circulation [157, 159].
In the present study, we investigate its feasibility for the pulmonary circulation using
simulations on a 4D bioimpedance model of the human thorax.
7.2 Methods
We test our approach using a model as this offers several advantages over clinical data:
(1) we can easily simulate various PAP-affecting pathological conditions, in particular
different types of PH, and thus avoid protocol- or pathology-speciﬁc results that could
arise from clinical data; (2) we can freely induce PAP variations, be they small or
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large; (3) we do not depend on reference hemodynamic variables measured in clinical
settings, which can be difﬁcult to obtain (e.g. pulmonary PWV) or affected by transient
hemodynamics (e.g. PAP) [142].
Section 7.2.1 presents in detail the 4D bioimpedance model. Section 7.2.2 describes how
the model can simulate various types of pulmonary hypertensive pathologies. Finally,
the EIT simulations performed with the model and the signal processing approach for
estimating a pulmonary PTT are detailed in Section 7.2.3.
7.2.1 Thoracic bioimpedance model
Main components and functionalities
We use a modiﬁed version of the 4D bioimpedance model presented in Chapter 6. This
model, shown in Figure 7.2, consists in a mesh of a human thorax where each mesh
element is at a ﬁxed location x and has a conductivity value σ(x, t) that varies over time,
in function of the organ or anatomical structure occupying the location of the element
at time t. The model includes conductivity changes induced by the main sources of
cardiovascular activity in the thorax during breath-hold, namely the heart, the aorta and
the pulmonary arterial tree. The geometrical deformations of the cardiac chambers and
the aorta are directly based on 4D magnetic resonance imaging (MRI) scans of a healthy
male volunteer (62 kg, 178 cm, 28 years old). The same could obviously not be done
for the pulmonary arterial tree, due to the size of its microvasculature and the limited
resolution of MRI scans, which is why a simpliﬁed model of the pulmonary vasculature
was implemented in Chapter 6. In the present study, we replace this pulmonary model
by a complete 4D bioimpedance model of a realistic pulmonary arterial tree.
To build this pulmonary model, we start by building an anatomically realistic static 3D
model of the whole pulmonary arterial tree. Then, in order to dynamize it (i.e. to make
it 4D by simulating the pressure-induced distension of its arteries over time), we use a
circulatory model of the pulmonary circulation. Finally, we transform this 4D model
into a 4D bioimpedance model by describing how the pressure-induced distension of the
pulmonary arteries affects the conductivity σ(x, t) at each location x in the lungs.
Anatomical model of the pulmonary arterial tree
This section describes the creation of the 3D anatomical model of the pulmonary ar-
terial tree used in this work. The goal was to obtain a tree that is geometrically and
morphometrically accurate. In other words, the tree should ﬁll the lung cavities with
realistic branching patterns, and the number and dimensions of all arterial segments in
the tree should match those of actual human lungs. To that end, we will be using the
study by Huang et al [74], which provides, for each order of arteries, their estimated
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Figure 7.2 – 4D thoracic bioimpedance model. Each mesh element is at a ﬁxed location
and its conductivity σ(x, t) varies over the time course of the cardiac cycle, in function
of the organ or anatomical structure occupying the location of the element at time t. The
small rectangles on the periphery of the thorax depict the EIT electrodes.
number, average radius and length. They obtained these reference morphometrical data
by measuring a pulmonary cast of a left pulmonary arterial tree. It is to be noted that the
arterial radius measurements reported by Huang et al [74] were obtained in arteries at
quasi-atmospheric pressure (i.e. zero pressure in medical applications, as blood pressure
is standardly expressed in mmHg above atmospheric pressure). This is convenient in
our case as our circulatory model (see the next section) needs to deal with zero-pressure
radiuses.
As a ﬁrst step in the tree creation process, an anatomically accurate model of the large
pulmonary arteries by Reymond [141] – based on contrast-enhanced magnetic resonance
angiography scans – was rigidly registered onto our corresponding MRI-based arteries.
These arteries were imaged in vivo and were thus subjected to a distending PAP > 0.
Thus we scaled down their radiuses in order to ﬁt the reference zero-pressure arterial
radiuses reported by Huang et al [74].
As a second step, the remaining (medium and small) arteries were generated using
the volume-ﬁlling branching algorithm by Burrowes et al [28] described in detail in the
Appendix (Section A.1): the lung volumes were automatically ﬁlled with a branching
tree using the end segments of the large arteries as seed points for the tree growing
procedure.
In the whole tree, the ratio between the radius of each artery and those of its two
daughters was controlled using equation (A.3), which depends on the branching (ξ)
and asymmetry (γ) ratios. The branching ratio was set to the average value ξ = 3.2
for pulmonary arterial trees in humans [74]. The asymmetry ratio γ was then adjusted
in order for the generated tree to accurately match the morphometrics reported by
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Figure 7.3 – Radius of all generated arterial segments in the left pulmonary tree as a
function of their order: comparison with reference morphometrical values of an actual
left pulmonary arterial tree (Huang et al [74]). The values are given as mean± SD.
Huang et al [74], as illustrated in Figures 7.3, 7.4 and 7.5, which respectively show
the radius, length and number of arterial segments in the generated left arterial tree
against reference morphometrical values. In the ﬁgures, the arterial segments are sorted
according to their order, as is usual for tree-like structures: we use the so-called diameter-
deﬁned Strahler ordering system as it is the system used by Huang et al [74]. The ﬁnal
generated 3D pulmonary arterial tree is shown in Figure 7.6.
Circulatory model of the pulmonary arterial tree
The purpose of the circulatory model is to determine the pressure-induced distension
undergone by each arterial segment in the pulmonary arterial tree during the cardiac
cycle. We describe in detail the inner workings and principles of so-called 1D distributed
parameter models in the Appendix (Section A.2). In short, these models consider the arte-
rial tree as a vast network of interconnected arterial segments through which pressure
and ﬂow waves propagate. By analogy with electrical circuits, transmission line theory
can be applied and provides analytical solutions for pressure and ﬂow. However, this
analogy is only truly valid in the smaller arterial segments, which do not taper (narrow
along their length) signiﬁcantly. In the larger (tapering) segments of the arterial tree,
non-linear effects prevent the use of transmission line theory and numerical solutions are
required to assess pressure and ﬂow. Therefore two models are necessary for obtaining
the distribution of pressure and ﬂow in the pulmonary arterial tree: a non-linear and
numerically-solved model for the large arteries, and a linear and analytically-solved
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Figure 7.4 – Length of all generated arterial segments in the left pulmonary tree as a
function of their order: comparison with reference morphometrical values of an actual
left pulmonary arterial tree (Huang et al [74]). The values are given as mean± SD.
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Figure 7.5 – Number of generated arterial segments in the left pulmonary tree as a
function of their order: comparison with reference morphometrical values of an actual
left pulmonary arterial tree (Huang et al [74]). The values of the reference are given as
mean± SD.
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Figure 7.6 – Anatomical model of the pulmonary arterial tree. To help the visualization,
not all smaller arteries are shown and a color code is used to illustrate the distance from
the pulmonary valve (dark blue = close; light green = far).
model for the small arteries. In order to solve both of these models, proper boundary
conditions must be deﬁned. In particular, each model requires:
a) An inﬂow boundary condition: most often, a ﬂow waveform is used. Alternatively,
a pressure waveform or model of the right ventricle (varying elastance model) can
be used [141], but only one of those or the system will be overdetermined;
b) An outﬂow boundary condition: most often, an output impedance is used, by
analogy with transmission line theory [123]. The impedance mimics the load “seen”
beyond the arterial tree (or portion of the tree) under consideration.
Figure 7.7 illustrates the structure of the global circulatory model of the pulmonary
circulation. In the present study, the so-called transition sites are the arterial sites in the
tree where the transition between the large and the small arteries occurs, i.e. the sites
where the transition between the non-linear and the linear model will take place. In
the present study, the 1D distributed parameter model by Reymond [141], adapted by
Billiet [17] for the pulmonary circulation, will be used as non-linear model for the large
arteries, whereas the standard linear solutions based on transmission line theory will be
implemented for the smaller arteries. As mentioned above, both models are described
in detail in the Appendix (Section A.2).
Determination of the transition sites. The transition sites are those segments in the
arterial tree where the transition between the so-called “large” and “small” arteries
occurs. From a hemodynamic viewpoint, large arteries are dominated by inertial effects,
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Figure 7.7 – Structure of the global circulatory model of the pulmonary circulation. A
non-linear and numerically-solved model is used for the large arteries, and a linear
and analytically-solved model is used for the small arteries. The transition between the
so-called “large” and “small” arteries occurs at the transition sites. Each model requires
proper boundary conditions to be solved. At the level of the transition sites, the outﬂow
boundary conditions for the large artery model need to be consistent with the inﬂow
boundary conditions for the small artery model, for continuity purposes.
whereas small arteries are dominated by viscous effects [180]. Therefore, as a dimen-
sionless ratio of inertial over viscous forces, the so-called Womersley number α is a
well-suited criterion for classifying arteries either as large or small [180]. Milnor [115]
measured Womersley numbers at multiple arterial sites and found that large elastic ar-
teries typically show Womersley numbers α ≥ 4. Therefore, we can deﬁne our transition
sites as the last arterial segments in the tree (starting from the heart) for which α ≥ 4.
Furthermore, as the linear circulatory model will be used beyond these sites, we can
verify that the linearization condition is met for the small arteries, i.e. that the non-linear
convective acceleration term in the x-momentum Navier-Stokes equation (equation (A.6)
in Section A.2) becomes negligible [154]. This is the case if U/PWV  1, where U is the
characteristic velocity (average axial velocity) of blood [35, 167]. Even in the worst-case
scenario (highest ﬂow, lowest PWV), we found U/PWV to be systematically < 0.04 in
the small arteries, which satisﬁes the linearization condition.
Boundary conditions. We deﬁne hereafter the inﬂow and outﬂow boundary conditions
for both the large and small artery circulatory models. At the level of the transition sites,
the outﬂow boundary conditions for the large artery model need to be consistent with
the inﬂow boundary conditions for the small artery model, for continuity purposes.
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As inﬂow boundary condition for Reymond’s large artery model, we use the waveform
proposed by [124], which can easily be scaled to any desired cardiac output (CO) and
heart rate:
q(0, t) =
CO · t
τ2p
exp
(
− t
2
2τ2p
)
, (7.1)
with t ∈ [0, T[, where T is the cardiac period, and τp is the time to peak ﬂow (also known
as acceleration time). This time is inversely related to the PAP and can be empirically
derived from it as [85]:
τp =
1
6.8
[
2.1− log10(PA)
]
, (7.2)
where PA is the mean PAP.
As outﬂow boundary condition, Reymond’s model uses 3-element Windkessel models
(Section A.2.1) at all transition sites [141]. These models are frequently used to mimic the
afterload of the heart [179]. In Reymond’s model, they are used to mimic the equivalent
impedance of the tree branches “seen” from each transition site downstream. These
equivalent impedances are known in our study from the 3D anatomical model of the
pulmonary arterial tree. With both its inﬂow and outﬂow conditions thus deﬁned,
Reymond’s model can now be solved.
Solving Reymond’s model provides us directly with the inﬂow boundary conditions
for the small arteries, as it determines the ﬂow waveforms entering each transition site,
i.e. entering the small arteries. On the other hand, the outﬂow boundary conditions for
the small arteries in linearized circulatory models are typically set by controlling the
value of the pressure downstream of the arterial tree [123] (let us call it PW). Formally
speaking, PW represents the pressure of the capillaries or the venous microvasculature,
which is difﬁcult to measure in clinical practice. It is however essentially the same
as pulmonary capillary wedge pressure if we neglect the small transvenous pressure
gradient [109], and is assumed to be continuous in the model; we discuss the validity of
this assumption in Section 7.4.
Setting PW to a given desired value in structured tree models is typically done through
the use of Nt terminal impedances Zti (i ∈ {1, · · · , Nt}) at the leaves of the tree [123]
(see Figure 7.8). The value of each terminal impedance Zti must be properly set in order
to ensure its upstream pressure to equal PW. This requires ﬁnding the ﬂow qi running
through each i-th leaf of the tree, as Zti = PW/qi, ∀i ∈ {1, · · · , Nt}. These ﬂow values
can easily be obtained by momentarily setting Zti = 0 for all terminal impedances and
imposing the desired transarterial pressure gradient (PA − PW) at the input of the tree.
With both its inﬂow and outﬂow conditions now deﬁned, the linear model for the small
arteries can be solved as well.
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Figure 7.8 – Schematic representation of the pulmonary arterial tree, by analogy with
electrical circuits. The tree is made of large and small arteries. In the large arteries,
non-linear effects are non-negligible and the distribution of pressure and ﬂow in the
arterial network requires a numerical solution. From the so-called transition sites and
beyond, the distribution of pressure and ﬂow in the arterial network can be solved
analytically after linearization of the problem. Each terminal arterial segment in the tree
(pre-capillary artery) is connected to a terminal impedance Zti that allows controlling
the value of the pressure PW at the output of the tree.
In this section, we have presented an anatomically realistic static 3D model of the whole
pulmonary arterial tree (Figure 7.6). We have then made it 4D by assessing the pressure-
induced distension of all pulmonary arteries over time via a circulatory model. As a last
step, we need to transform this 4D model into a 4D bioimpedance model by describing
how the pressure-induced distension of each artery at location x in the lungs induces
changes in pulmonary conductivity σ(x, t).
Assessment of pulmonary conductivity
During breath hold, the effective conductivity of lung parenchyma σ(x, t) is predom-
inantly affected by arterial pulsatility. The distension of the arterial bed makes the
conductivity of lung parenchyma slightly rise above its end-diastolic value σ(x, 0) dur-
ing systole (i.e. for t > 0), due to the high conductivity of blood (σblood ≈ 0.7 S/m at
EIT frequencies) [68]. This end-diastolic value of lung parenchyma σ(x, 0) is difﬁcult
to estimate as it depends on the conductivity of lung alveolar tissue σalv, which de-
pends on the fractional volume of air in the lungs. Several mathematical models have
been developed to express σalv as a function of the degree of deﬂation of the lungs.
Roth et al [145] compared several of these models and introduced their own, based on
3D alveolar microstructures. For lung tissue imaged at functional lung capacity as is
the case in our model, their observations suggest an average value σalv = 0.1 S/m [145].
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This conductivity value does not include extra-capillary blood vessels, i.e. the arteries
and veins. In order to obtain the effective conductivity of the whole lung parenchyma
σ(x, t) (including extra-capillary blood vessels), Nopp et al [122] suggested to consider
lung tissue as a mixture of a dielectric medium (alveolar tissue with conductivity σalv)
and conductive inclusions (extra-capillary blood vessels with conductivity σblood). The
Maxwell Garnett mixing rule states that [87]:
σ(x, t) = σm +
1
3 fi(σi − σm)∑3k=1 σmσm+Nk(σi−σm)
1− 13 fi(σi − σm)∑3k=1 Nkσm+Nk(σi−σm)
, (7.3)
where σm = σalv and σi = σblood are the conductivities of the dielectric medium and
the inclusions respectively, fi = fi(x, t) is the volume fraction of the inclusions, Nk
are the depolarization factors and k ∈ {1, 2, 3} corresponds to the three Cartesian
coordinates. For cylindrical inclusions such as arterial segments, N1,2 ≈ 0.5 and
N3 ≈ 0 [87]. By means of our anatomical model of the pulmonary arterial tree, the
volume fraction of blood vessels fi(x, t) can be assessed in each pulmonary voxel x over
time, as illustrated in Figure 7.9, with pulmonary venous blood volume approximately
equal to the non-pulsatile (end-diastolic) component of arterial blood volume [65]. For
instance, in a small pulmonary voxel at location x whose volume is occupied at 10 % by
arteries at end diastole (t = 0), the volume fraction of blood will be fi(x, 0) = 0.2 (10 %
of arterial blood and 10 % of venous blood). The remaining 80 % will be occupied by
lung alveolar tissue with conductivity σalv. Using (7.3), this gives us σ(x, 0) = 0.17 S/m
in that particular pulmonary voxel.
As the cardiac cycle unfolds (t > 0) and systole occurs, the arteries distend with the
increase in pressure. We can precisely determine the extent of this arterial distension
thanks to the circulatory model. With this distension, the increase in arterial blood
volume and therefore fi(x, t) is known at each instant of the cardiac cycle. As a conse-
quence, via (7.3), the value of σ(x, t) is also known for every location x in the lungs and
for the whole cardiac cycle, which completes the creation of our 4D bioimpedance model.
7.2.2 Simulation of pathologies
The hemodynamic behavior of our 4D thoracic bioimpedance model is controlled by a
set of hemodynamic parameters (PA, PW, CI, Rt, and Ct). In the following we describe
each these parameters, their physiological interdependencies, and their typical values in
normotensive (nonpathological) conditions. We will then detail how the values of these
parameters can be adjusted to simulate several pulmonary hypertensive pathologies.
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(a) (b)
Figure 7.9 – Assessment of the volume fraction of extra-capillary blood vessels in each
pulmonary voxel. Lung tissue can be considered as a mixture of a dielectric medium
(alveolar tissue) and conductive inclusions (extra-capillary blood vessels) [122]. The
pulmonary voxels should not be chosen too large in order not to exceed EIT resolution.
They should not be too small neither in order for most inclusions (arteries and veins) to
be of reasonably small size with respect to the voxels for the Maxwell Garnett mixing
rule (equation 7.3) to be applicable [87]. We consider 1 mL cubic voxels to be a good
compromise. The computation of the volume fraction fi(x, t) of conductive inclusions
for each voxel at location x and at time t is performed as follows. Consider the 2D
example shown in (a). An arterial segment passes through four cubic voxels. In order
to assess the percentage of the segment’s volume in each voxel, the segment is ﬁlled
with a grid of uniformly spaced points, with a grid resolution equal to one fourth of the
segment’s average radius. A voxel containing 30 % of all grid points will be assigned
30 % of the segment’s volume. Note that this point-to-cube assignment procedure is
largely sped up (in terms of computational time) by the choice of cubic voxels (instead
of tetrahedral voxels, for instance). After this procedure is performed for all arterial
segments of the pulmonary tree, the volume fraction fi(x, t) for each voxel is known
and is assigned to all tetrahedral elements of the mesh whose barycenters falls within
said voxel, as shown in (b).
Hemodynamic parameters description, interdependencies and normal values
We have earlier described in Section 2.3.2 a remarkable hemodynamic characteristic of
the pulmonary circulation, namely that the pulmonary RC time τRC, i.e. the product
of the pulmonary vascular resistance Rt and compliance Ct, is a constant (at a given
downstream left atrial pressure) [164]. In a retrospective study on large clinical datasets,
Tedford et al [164] derived the following relationship with pulmonary capillary wedge
pressure (PW), a surrogate measure of left atrial pressure:
τRC = −0.0063 · PW + 0.46. (7.4)
As a consequence, except for particular conditions affecting left atrial pressure and thus
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PW, the pulmonary RC time τRC remains constant in health and hypertension [93, 94, 149].
Although τRC is related to HR [94, 149], any reduction in Rt and related increase in Ct
during hypertension treatment has been shown not to be due to a change in HR, and
therefore the latter is constant in the model (HR = 80 bpm) [94].
In their literature review on pulmonary hemodynamics in normal subjects, Kovacs et al
[88] reported normal values for Rt of 0.056 ± 0.023 mmHg·s/mL. In our model, Rt
can directly be obtained from the anatomical model of the pulmonary arteries as the
equivalent resistance of the entire tree [180]. We obtain Rt = 0.048 mmHg·s/mL, which
is well in line with the aforementioned value reported by Kovacs et al [88]. They also
reported normal mean PAP (PA = 14.0 mmHg) and pulmonary capillary wedge pressure
(PW = 8.0 mmHg) values, which yields τRC = 0.41 s via (7.4). We can then obtain the
pulmonary vascular compliance Ct using the deﬁnition of the pulmonary RC time:
Ct = τRC/Rt, (7.5)
which gives us Ct = 8.478 mL/mmHg. Lastly, we can ﬁnd the cardiac index (CI), i.e. the
cardiac output (CO) normalized by the body surface area (BSA):
CI =
CO
BSA
=
PA − PW
Rt · BSA . (7.6)
With BSA = 1.78 m2 calculated using the Du Bois formula [42], we ﬁnd
CI = 4.19 L/min/m2, which is well in line with the value of 4.10 L/min/m2 reported by
Kovacs et al [88].
These normal (nonpathological) values for the hemodynamic parameters governing the
model are summarized in the ﬁrst row of Table 7.1.
Simulation of pulmonary hypertensive conditions
By modifying the values of the hemodynamic parameters controlling the model, several
hypertensive conditions can be realistically simulated and allow us to test our PAP
monitoring method in various forms of PH.
We have previously described the clinical classiﬁcation of PH into ﬁve groups (Sec-
tion 2.4.2): pulmonary arterial hypertension (PAH), PH due to left heart disease (PH-
LHD), PH due to lung diseases and/or hypoxia, chronic thromboembolic PH (CTEPH),
and PH with unclear and/or multifactorial mechanisms [56]. We aim at simulat-
ing one pathological case of each group, except for the last one, since its pathogen-
esis is unclear. For each pathological case considered, 5 levels of PAP above the
nonpathological value (14 mmHg) will be considered, by increments of 10 mmHg
(i.e. PA = {24, 34, 44, 54, 64} mmHg). The case PA = 24 mmHg simulates a borderline
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Table 7.1 – Normal and pathology-speciﬁc values of the hemodynamic parameters of
the model.
Pathology PA PW CI Rt Ct
(mmHg) (mmHg) (L/min/m2) (mmHg·s/mL) (mL/mmHg)
None 14.0 8.0 4.19 0.048 8.478
24.0 8.0 2.82 0.191 2.141
34.0 8.0 2.63 0.334 1.225
PAH 44.0 8.0 2.55 0.477 0.858
54.0 8.0 2.50 0.620 0.660
64.0 8.0 2.48 0.764 0.536
24.0 15.3 2.66 0.111 3.284
34.0 22.6 2.23 0.173 1.835
PH-LHD 44.0 29.9 2.02 0.236 1.154
54.0 37.2 1.91 0.298 0.758
64.0 44.5 1.83 0.360 0.499
24.0 12.0a 3.70 0.110b 3.107
34.0 17.0a 3.70 0.155b 1.813
HAPE 44.0 22.0a 3.70 0.201b 1.280
54.0 27.0a 3.70 0.246b 0.989
64.0 32.0a 3.70 0.292b 0.806
24.0 8.0 2.51 0.215 1.905
34.0 8.0 2.30 0.382 1.073
CTEPH 44.0 8.0 2.22 0.549 0.747
54.0 8.0 2.17 0.715 0.573
64.0 8.0 2.14 0.882 0.464
PAH: pulmonary arterial hypertension; PH-LHD: pulmonary hypertension due to
left heart disease; HAPE: high altitude pulmonary edema; CTEPH: chronic throm-
boembolic pulmonary hypertension; PA: mean pulmonary artery pressure; PW: mean
pulmonary capillary wedge pressure; CI: cardiac index; Rt: pulmonary vascular
resistance; Ct: pulmonary vascular compliance.
a These values actually represent capillary pressure PC, not pulmonary capillary
wedge pressure PW. As detailed in the text, PW in HAPE is actually normal
(10.0 mmHg) [101], whereas PC is abnormally elevated. Increasing PW in the
model can either simulate an increase in PW (as is the case in PH-LHD) or an
increase in transvenous pressure gradient (as is the case in HAPE).
b As the values provided for PW actually represent PC (see previous note), these Rt
values actually represent pulmonary arterial resistance only, not the true values
of the entire pulmonary vascular resistance. Those can be obtained using (7.6)
with PW = 10.0 mmHg for all levels of HAPE [101].
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pre-hypertensive stage, as PH is only formally diagnosed for PA ≥ 25 mmHg [56]. The
remaining cases (34 to 64 mmHg) represent mild to severe levels of PAP.
Pulmonary arterial hypertension (PAH). PAH is characterized by the vasoconstriction,
muscularization and ﬁbrosis of the small pulmonary arteries (< 0.5 mm of diameter) [56].
The loss of distensibility that results from this vascular remodeling process progressively
induces an overall decrease in arterial compliance in the whole tree [96, 148]. In our
model, PAH is simulated by reducing the diameter of the small arteries. This allows
us to increase Rt to any targeted value for simulating the various levels of PAH. The
remaining parameters are then adjusted accordingly, as detailed hereafter.
Let us ﬁrst consider the average hemodynamic parameter values in PAH reported
by Humbert et al [75] from a French national registry: PA = 55.0 mmHg, PW =
8.0 mmHg (unaffected in PAH) and CI = 2.5 L/min/m2. We ﬁnd the correspond-
ing Rt value (0.635 mmHg·s/mL) with (7.6). With the baseline PA (14.0 mmHg) and
Rt (0.048 mmHg·s/mL) values found earlier for the normal (nonpathological) case, we
now have two {PA,Rt} pairs, which allows us to predict Rt as a function of PA, as both
quantities are linearly related in the pulmonary circulation [149]. We obtain:
Rt = 0.0143 · PA − 0.1519. (7.7)
Finally, for each level of PAP, we obtain Ct via (7.5), and CI via (7.6).
The complete list of thus-obtained hemodynamic parameter values to simulate each
level of PAH is provided in Table 7.1.
PH due to left heart disease (PH-LHD). In the second group of pulmonary PH, the
failure of the left heart to pump blood efﬁciently – as in cases of valvular diseases or
advanced stages of heart failure – leads to an elevation of left heart pressures [64]. This
rise in PW causes an elevation of PA upstream [56]. Rt can remain normal, or signiﬁcantly
increase in cases of capillary and arterial remodeling [64]. In a retrospective study in
heart failure patients, Afshar et al [9] reported the following average hemodynamic
parameters: PA = 38.0 mmHg, PW = 25.5 mmHg and CI = 2.13 L/min/m2. From these
values and the baseline PA and PW values found for the above-described nonpathological
case, we can predict PW for all levels of PAP, as experimental data show a quasi-linear
relationship between PA and PW in PH-LHD [9]:
PW = 0.73 · PA − 2.21. (7.8)
Proceeding as for PAH, we then ﬁnd Rt, Ct and CI for all levels of PAP. The complete list
of thus-obtained hemodynamic parameter values to simulate each level of PH-LHD is
provided in Table 7.1.
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PH due to lung diseases and/or hypoxia. One example of the third PH group is the high
altitude pulmonary edema (HAPE), a potentially lethal condition affecting previously
healthy individuals rapidly going to high altitude [178]. The exact cause of HAPE
remains unknown [101]. The favored hypothesis regarding its genesis is a severe and
inhomogeneous vasoconstriction of the vasculature associated with a stress failure and
an increase in transmural pressure PC of the capillaries [178]. Rupture of the capillary
wall causes ﬂuid to ﬂow from the capillary lumen to the interstitial and alveolar spaces.
In order to simulate HAPE in our model, we start by randomly designating small
regions of the lungs as edemic while the others remain unaffected, thus mimicking the
typically patchy distribution of high altitude-induced edemas [178]. Vasoconstriction
is induced in the non-edemic regions only [178], thus increasing Rt and decreasing Ct
via (7.5). In the edemic regions, the presence of ﬂuid in the alveolar space causes the
electrical conductivity of the parenchyma to increase. We consider an increase in lung
water concentration by 75 % [152]. In the aforementioned model proposed by Roth et al
[145] for estimating the conductivity of lung parenchyma, this corresponds to using an
alveolar tissue conductivity σalv = 0.15 S/m.
In a study on control and HAPE-susceptible subjects at high altitude, Maggiorini et al
[101] concluded that HAPE is initially caused by an increase in PC. It stems from their
study that PA ≈ 2 · PC. The remaining hemodynamic variables of the model, namely
PW and CI, remain normal in case of HAPE [178]. Maggiorini et al [101] reported
values of PW = 10.0 mmHg and CI = 3.7 L/min/m2 for both control and HAPE-
susceptible subjects at high altitude [101]. In our model, the abnormal increase in PC can
be simulated simply by setting PW = PC. Indeed, increasing PW in the model can either
simulate an increase in left atrial pressure (as is the case in PH-LHD) or an increase in
transvenous pressure gradient (as is the case in HAPE).
The complete list of thus-obtained hemodynamic parameter values to simulate each
level of HAPE is provided in Table 7.1.
Chronic thromboembolic pulmonary hypertension (CTEPH). In the fourth group of PH,
the disease is characterized by the partial or complete obliteration of one or several
pulmonary arterial segments [128]. As a consequence, a part or the entirety of the ﬂow
is redirected towards the nonoccluded areas, thereby exposing them to higher wall
shear stresses [72]. An arteriopathy similar to that encountered in PAH (vasoconstriction
and vascular remodeling) progressively develops in these segments, while the arteries
downstream of the occluded areas typically remain unaffected [72, 128].
In the model we simulate this disease by occluding one of the daughter vessels of the left
interlobar artery and by inducing vasoconstriction in those parts of the microvasculature
that are not downstream of the occluded segment [72]. Pepke-Zaba et al [128] reported
average hemodynamic parameters in CTEPH from an international registry: PA =
47.0 mmHg and CI = 2.2 L/min/m2. Left atrial pressure remains unaffected in CTEPH;
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Nagaya et al [118] reported a value of 8.0 mmHg for PW. Following the same procedure
as the one used for PAH, we then ﬁnd Rt, Ct and CI for all levels of PAP.
The complete list of thus-obtained hemodynamic parameter values to simulate each
level of CTEPH is provided in Table 7.1.
7.2.3 EIT simulations and PTT estimation
With the ability to simulate various PAP-affecting pathologies in our 4D bioimpedance
model, we can now proceed to simulating EIT measurements using the model. All
EIT simulations were performed with Matlab (MathWorks, Natick, USA) using the
framework of the EIDORS toolbox [4].
EIT simulations
Obtaining surface voltage measurements (the forward problem). The cardiac cycle,
of duration T = 0.75 s, was discretized into 25 time instants of 30 ms each, thus
corresponding to an EIT image sampling rate of 33 frames/sec. At each k-th time instant
of the cardiac cycle, the ﬁrst-order forward solver of EIDORS was used to simulate the
propagation of small alternating electrical currents in the bioimpedance model (via the
electrode belt shown in Figure 7.2) and measure the resulting voltages vk. A voltage
matrix V was then obtained by concatenating horizontally all 25 column vectors vk.
Real EIT measurements are well-known to include noise. In order to model noisy
voltages, a realistic SNR was considered. In [151], the authors analyzed recordings from
a Goe MF II EIT device (CareFusion, Germany) and found SNRs ranging from 42 to
156 dB. We chose a worst-case scenario SNR of 42 dB (i.e. SNR = 15, 850). Following
their approach, noisy voltages Vn were thus obtained by adding a white Gaussian noise
of variance Pi/SNR to each i-th line of V, where Pi is the average power of the i-th line
[151].
So-called difference voltages Un were then obtained by subtracting the ﬁrst column (ﬁrst
frame) of Vn, i.e. the end-diastolic voltages, from all columns (all frames) of Vn, as is
usual in medical EIT applications [73]. Un thus describes voltage variations around
a reference state (end diastole) and allows the linearization of the EIT reconstruction
problem for small voltage variations around this working point.
Reconstructing the internal conductivity distribution (the inverse problem). Image
reconstruction was carried out on a coarser version of the thoracic mesh using the
widely-used one-step Gauss-Newton algorithm with the Laplace prior [100]. Difference
noisy EIT images Yn representing the intra-thoracic conductivity changes over time with
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Figure 7.10 – Example of reconstructed EIT frame (slice at the level of the EIT electrodes
shown in Figure 7.2) depicting the end-systolic distribution of conductivity change (with
respect to end diastole). Cool colors (heart region) depict conductivity decreases with
respect to end diastole, while warm colors (lung regions) depict conductivity increases.
The pulmonary region of interest is highlighted by dashed lines. EIT tomographs
provide functional information; they are known for not being anatomically accurate
references. A lack of symmetry between the left and right lungs – as is the case here – is
not unusual.
respect to the end-diastolic reference state were thus obtained as:
Yn = RUn, (7.9)
where R is the so-called reconstruction matrix. Figure 7.10 shows an example of an EIT
frame at end systole.
Pulmonary PTT estimation approach
In the following, the automatic procedure for estimating a pulmonary PTT value from a
25-frame EIT image sequence Yn is described.
First, a pulmonary region of interest (ROI), deﬁned as those pixels depicting a lung-like
behavior and a signiﬁcant pulsatility, was automatically segmented from the EIT images.
To do so, the cardiac frequency Fourier coefﬁcient zT of the EIT time signal s(t) at each
pixel was computed as:
zT =
1
T
∫ T
0
s(t)e−i
2πt
T dt. (7.10)
At any given pixel location, the modulus |zT| depicts the amplitude of the ﬁrst cardiac
harmonic, whereas the argument arg(zT) depicts its phase shift with respect to the
opening time of the pulmonary valve (t = 0). As the conductivity increases in the lungs
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Figure 7.11 – Estimation of the pulmonary pulse transit time (PTT). (a) In each pixel
of the pulmonary region of interest (ROI), the PTT is estimated using the intersecting
tangent method [33]. The ﬁrst tangent goes through the minimum of s(t) in (1), while the
second tangent passes through the maximum of its ﬁrst time derivative in (2). The PTT
is found at the intersection of both tangents. (b) Histogram of PTT estimates for all pixels
of the ROI, with ν and m the mean and the median of all PTT values, respectively. The
global PTT estimate is μ, the average of those PTT values falling within the m± λ ·MAD
interval, with λ = 2.5 and MAD the median absolute deviation [99].
and decreases in the heart shortly after cardiac ejection, the ﬁrst harmonic of s(t) is
expected to resemble a sine wave (π/2 phase shift) in the lungs, whereas it is expected
to resemble an antiphase sine wave (−π/2 phase shift) in the heart. Both types of
pixels were therefore separated by using a threshold value of 0 on arg(zT). Pixels with
signiﬁcant pulsatility were then identiﬁed by comparing |zT| to an automatic amplitude
threshold β obtained using Otsu’s method [125]. In the end, the pulmonary ROI was
obtained as those pixels for which |zT| > β and arg(zT) > 0 (Figure 7.10).
For each pixel belonging to the pulmonary ROI, a PTT was estimated from its EIT time
signal s(t) using the intersecting tangent method [33], as illustrated in Figure 7.11a. With
M pixels contained within the ROI, M estimates of the pulmonary PTT were obtained.
Erroneous PTT estimates were expected to arise in case of excessive noise or signiﬁcant
inﬂuence from sources not related to pulmonary pulsatility in s(t), particularly in ROI
pixels located near the cardiac region. In order to mitigate for these possible erroneous
PTT estimates, outliers were automatically rejected using the median absolute deviation
method [99] as illustrated in Figure 7.11b. Finally, a representative pulmonary PTT value
was obtained by averaging all non-rejected PTT estimates.
This whole process was carried out for all 21 vascular states summarized in Table 7.1.
For each of them, the pulmonary PTT value estimated from the EIT images was then
compared with the underlying PAP.
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Figure 7.12 – EIT-derived pulmonary PTT for different levels of PAP and for different
pathologies.
7.3 Results
Figure 7.12 shows the main ﬁndings of our study: for each type of hypertensive condition
considered (PAH, PH-LHD, HAPE, CTEPH), the relation between the mean PAP and the
PTT derived by EIT is shown. In the estimation of the PTT, an average of 6.9± 2.6 % of
pixels of the pulmonary ROI were rejected as outliers by the median absolute deviation
method.
The next ﬁgures aim at illustrating the inner workings of our model and approach.
Figure 7.13 illustrates the morphological differences that can be observed between the
pressure waveforms traveling in the pulmonary arterial tree and the resulting EIT signals.
The solid lines depict an example of the pressure waveforms found at various arterial
sites, from the main pulmonary artery to a pre-capillary artery, whereas the dotted line
depicts the average EIT signal in the pulmonary ROI obtained in the same pathological
condition.
Figure 7.14 (top panel) depicts an example of the pressure waveforms as found in a
distal artery for increasing levels of PAP. For each of them, their PTT value is highlighted
with a marker. Similarly, the bottom panel depicts the corresponding average EIT signal
in the pulmonary ROI, with their respective PTT values also highlighted. Comparing
the PTT values calculated from the pressure waveforms with those calculated from the
EIT signals, correlation coefﬁcients r > 0.99 (p < 0.001) were found for all pathologies
(PAH, PH-LHD, HAPE, and CTEPH).
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Figure 7.13 – Solid lines: Pressure wave propagating through the pulmonary arterial tree
in a borderline pre-hypertensive case of CTEPH (PA = 24 mmHg). Dotted line: Average
EIT signal obtained in the pulmonary ROI in the same pathological condition.
7.4 Discussion
In this study, we have hypothesized that changes in PAP could be monitored non-
invasively by tracking changes in pulmonary PTT via EIT. We have tested our approach
in an MRI-based 4D bioimpedance model of the human thorax. An anatomical model of
the entire pulmonary arterial tree was constructed using contrast-enhanced magnetic
resonance angiography scans [141] for the larger arteries, and a geometrically and mor-
phometrically accurate arterial tree growing algorithm [28] (Appendix Section A.1) for
the smaller arteries. The pulsatile behavior of each arterial segment of the tree was
assessed via validated hemodynamic models of the pulmonary circulation [123, 141]
(Appendix Section A.2). The local conductivity change occurring in each pulmonary
voxel over time was obtained from the pressure-induced change in pulmonary blood
volume. Our method was evaluated in several PH conditions. Simulated EIT measure-
ments were performed on the model and the pulmonary PTT was estimated from the
resulting EIT signals.
7.4.1 EIT-based PAP monitoring
On the PTT-PAP relation
Figure 7.12 shows the main ﬁndings of the present study: it can be observed that
increasing levels of PAP are associated with shorter PTT values for all forms of PH
pathologies, as expected from the physiological link between pressure and PWV (higher
pressures are associated with faster PWV, and thus shorter PTT). These results suggest
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Figure 7.14 – Top panel: Example of pressure waveforms found in a distal artery for
increasing levels of HAPE, as well as for the normal (nonpathological) case. Bottom panel:
Corresponding average EIT signals in the pulmonary ROI. In both panels, the PTT of
each waveform is highlighted by a marker. Note that the EIT signals have been given
arbitrary vertical offsets for easier visualization.
that EIT can be used to monitor changes in pulmonary PTT, and therefore in PAP.
It can be observed from the ﬁgure that the PTT value at a given PAP level (e.g. PA =
24 mmHg) is not necessarily the same for all pathologies. This is due to the physiological
link between PWV and the structural properties of the arterial wall [180], which can
strongly differ between pathologies. Conversely, in CTEPH, the arteriopathy in the
nonoccluded areas strongly resembles that of PAH [128], which explains why the PAP-
PTT relation is very similar for both pathologies.
Finally, the inverse exponential nature of the PTT-PAP relation shows that our PWV-
based method is particularly indicated for monitoring early changes in pulmonary
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hemodynamics and early stages of PH. Indeed, at lower PAP values, small changes in
PAP induce large changes in PTT. This is in line with the expected relationship between
the PTT and the PAP, given the PWV–PAP relationship illustrated earlier in Chapter 2
(Figure 2.6). PWV has a high sensitivity to small losses in arterial distensibility at lower
pressures. The same observation was drawn in intravascular ultrasound and MRI
studies [96, 148], demonstrating that PWV – even more than PAP itself – is a strong
predictor of survival [94, 95].
On the pressure and EIT waveforms
Several other observations, listed hereafter, can be drawn from the ﬁgures presented
in Section 7.3. Although the morphology of the EIT signal roughly resembles that
of the various pressure waveforms (Figure 7.13), it does not resemble one of them
predominantly. In particular, the slope of the EIT signal is less steep than that of the
pressure waveforms, which suggests that arteries of all sizes contribute to the generation
of the EIT signal. The contribution of the small arteries is not negligible in comparison
to that of the larger arteries as they are much more abundant [74].
Figure 7.14 shows how the PTT-related information carried by the pressure waveforms
remains present in the EIT signals despite the aforementioned morphological differences
between both types of waveforms. Note that all EIT signals depicted in Figure 7.14
(bottom panel) have similar peak-to-peak amplitudes, despite having been generated by
vastly different distending pressures (top panel). This can be explained by the inverse
exponential relationship between pressure (p) and arterial distensibility (δ) [180]. As
PAP rises to increasingly severe levels, arterial distensibility decreases due to vascular
remodeling. As a consequence, the product of p and δ, which determines the extent
of arterial distension, remains almost constant throughout the physiological range of
pressure values [96, 148]. Nevertheless, an amplitude decrease in the average EIT signal
can be expected with an increase in PAP in cases of reduced pulmonary microvascular
bed in advanced stages of PH [155].
7.4.2 Model assumptions validity, limitations, and future work
We discuss hereafter the validity of the main assumptions used in the creation of our
model, as well as its main limitations and those of our approach. We then mention
practical workarounds to overcome some of these limitations, and some suggested
future work.
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Model assumptions validity
Being based on MRI scans acquired during breath-hold, our 4D bioimpedance model
does not take into account impedance changes induced by respiratory activity. Respira-
tion does not only affect the dielectric properties of the lung parenchyma, it also deforms
the internal distribution of impedance volumes as well as the external thoracic contour.
However, we consider this simpliﬁcation in our model to be acceptable. Our method
being based on timing information (the PTT) rather than on amplitude, respiration-
induced conductivity changes have limited effect on our measurement. Besides, several
techniques (short apneas, respiration- and ECG-gating, frequency ﬁltering, etc.) allow
efﬁciently minimizing the inﬂuence of these respiratory artifacts in practice in cardiac
EIT [50, 73]. Moreover, the automatic tracking of the pulmonary ROI (Section 7.2.3) can
cope for possible respiration-induced changes in internal impedance distribution.
A second assumption of our model, mentioned earlier, is that the pressure downstream
of our pulmonary arterial tree, i.e. PW, is continuous, although it is known to be slightly
pulsatile [121]. In this study, we have considered the inﬂuence of the pulsatile component
of PW to be minor not only in terms of amplitude, but also because it occurs late in the
cardiac cycle: the early systolic part of the σ(x, t) waveform (Figure 7.1), which is of
interest to estimate the PTT, is not affected by the pulsatility of PW. For this reason,
its pulsatile component can, in our opinion, be neglected without any loss of relevant
information.
A third assumption of our model is that the pulmonary arterial wall, known to be much
thinner than its systemic counterpart [121], is of negligible thickness. The non-inclusion
of the arterial wall in the model is expected to only slightly affect the baseline value of
lung conductivity, but not its pulsatile behavior. The arteries will distend “at the same
time” regardless of the presence (or absence) of the wall in the model. Thus only the
amplitude of the EIT signal s(t) is affected; its timing information (its PTT), which is of
interest for PAP monitoring, remains unaffected.
Model and method limitations
A ﬁrst limitation of our method concerns the timing reference used for the estimation of
the PTT. In our study, t = 0 corresponds to the time of opening of the pulmonary valve.
However, in practice, this feature is difﬁcult to estimate non-invasively [117].
A second limitation concerns the possible inﬂuence of conductivity changes not related
to pulmonary pulsatility in those lung regions close to the heart, in particular sources
generating conductivity changes similar to those occurring in the lungs, such as atrial
or aortic changes. Heart motion-induced displacements of the pulmonary arteries may
also affect the pulmonary EIT signal in the most proximal regions of the lungs [133].
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A third limitation, intrinsic to models describing complex processes, is the use of physio-
logical parameters from multiple different studies, and therefore different sources.
Practical workarounds
It is important to mention that workarounds exist in practice to try and overcome
some of these limitations. For instance, PTT-based systemic blood pressure monitoring
systems often use the R-wave peak of the electrocardiogram – a robust feature to detect –
as surrogate timing reference (t = 0) for PTT estimation [117].
Erroneous PTT estimates resulting from the possible artifacts induced in the proximal
regions of the lungs by sources not related to pulmonary pulsatility are expected to be
automatically discarded by the outlier rejection method (Section 7.2.3) [99]. Alternatively,
they could be avoided by limiting the ROI to its most distal part.
Future work
Further improvement to the present model could aim at addressing the aforementioned
limitations. However, in our opinion, future work should predominantly focus on
evaluating our proposed non-invasive PAP monitoring approach in real EIT data.
7.4.3 Summary and conclusion
There is currently no practical solution for the non-invasive monitoring of PAP in
hemodynamically unstable patients and patients with chronic PH. We have previously
demonstrated experimentally the feasibility of a novel approach based on the use of
EIT for the monitoring of systemic blood pressure [157, 159]. In the present study, we
have evaluated its feasibility in the pulmonary circulation for the monitoring of PAP.
Our results, obtained from simulations on a 4D bioimpedance model of the human
thorax, suggest that changes in PAP can indeed be monitored by EIT under various
pathophysiological conditions. If conﬁrmed in clinical data, these ﬁndings could open
the way for a novel generation of non-invasive PAP monitoring solutions for patients
with PH.
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8.1 Introduction
8.1.1 Objectives
In the previous chapter, we have proposed and evaluated the feasibility of a novel
method for monitoring changes in PAP by EIT. Our simulations on a 4D bioimpedance
model have indicated that EIT was indeed capable of tracking changes in PAP. In the
present study, we aim at validating our method experimentally.
8.1.2 Measurement principle
As for our previous model-based study, changes in PAP will be assessed through the
physiological relation linking pressure and pulse wave velocity (PWV), by tracking
changes in the pulmonary pulse transit time (PTT) using EIT:
PAP ↗ ⇐⇒ PWV ↗ ⇐⇒ EIT-derived PTT ↘ .
Formally speaking, the pulmonary PTT is the time it takes for a pressure wave generated
at the pulmonary valve to reach a distal arterial location in the lungs. Since the time
of opening of the pulmonary valve (t = 0) is a feature that is difﬁcult to estimate
non-invasively, the PTT can, in practice, be approximated by the pulse arrival time
(PAT) [117]. The PAT uses the R-wave peak of the ECG as reference time (t = 0) instead
of the opening of the pulmonary valve1. In the present study, an ECG signal will thus be
measured along with the EIT data and the PAT will be used as a surrogate measure of
the PTT.
8.2 Materials and methods
A summary of the methods and experimental protocol is illustrated in Figure 8.1.
8.2.1 Subjects and experimental protocol
Sixteen healthy volunteers (14 male, 2 female) were enrolled in our study. Tricuspid
regurgitation – needed for the estimation of the reference PAP by Doppler echocardiog-
raphy (see Section 8.2.2) – was not measurable in two of them (1 male, 1 female), leaving
us with a total of fourteen subjects (age: 31 ± 6.1 years old, BMI: 24 ± 2.8 kg/m2).
The EIT data were acquired using the 16-electrode Goe-MF II device (CareFusion, Ger-
many). An ECG was recorded using the ECG100C module (Biopac Systems, Inc., USA)
1This approximation is equivalent to considering PTT ∝ PATb in Figure 2.7.
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Figure 8.1 – Summary of the methods and experimental protocol. The subjects lie
in supine position and pulmonary artery pressure (PAP) variations are induced by
means of an altitude simulator. Tomographic (EIT), electrocardiographic (ECG), and
echocardiographic measurements are performed. Pulmonary pulse arrival time (PAT)
values are obtained from the joint analysis of the EIT and ECG data, whereas reference
PAP values are obtained from the echocardiographic measurements. The correlation
between the PAP and the EIT-derived PAT is then evaluated.
Altitude
simulator
mask
ECG
electrode
EIT
electrode
Figure 8.2 – Experimental setup showing the mask of the altitude simulator and the
position of the electrodes on the subject’s chest area.
and was fed into the auxiliary input of the Goe-MF II device, thus allowing the syn-
chronous acquisition of both the EIT data and the ECG signal. The EIT measurement
process is further detailed in Section 8.2.3.
In order to induce PAP variations, during parts of the protocol the subjects were breath-
ing nitrogen-enriched air through a mask connected to an altitude simulator (AltiTrainer,
SMTEC, Switzerland), as shown in Figure 8.2. Normobaric hypoxia causes vasocon-
striction in the pulmonary arterial tree and therefore induces elevations of PAP. The
peripheral capillary oxygen saturation (SpO2) of the subjects was continuously mon-
itored using the Radical-7 device (Masimo, USA), whereas their systolic pulmonary
artery pressure (SPAP) was measured periodically by Doppler echocardiography (as
further detailed in Section 8.2.2). Each subject was lying in supine position and under-
went seven 2-minute EIT and ECG measurements at various oxygen saturation levels,
as depicted and detailed in Figure 8.3. Immediately after each EIT measurement, the
subjects were asked to turn on their left side in order for their SPAP to be measured by
Doppler echocardiography.
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Figure 8.3 – Experimental protocol for inducing PAP variations through normobaric
hypoxia: two baseline measurements in normoxia (∼540 m, SpO2 ≥ 95 %), two mea-
surements in mild hypoxia (∼4200 m, 90 % > SpO2 ≥ 80 %), two measurements in deep
hypoxia (∼5400 m, 80 % > SpO2 ≥ 65 %), and one baseline measurement in normoxia.
Immediately after each 2-minute EIT and ECG measurement, the subjects were asked to
turn on their left side and their SPAP was measured by Doppler echocardiography.
The study was approved by the institutional review boards on human investigation of
the University of Bern, Bern, Switzerland (BE 2016-00747) and registered at Clinical-
Trial.gov (NCT 0296 9486). All participants provided written informed consent.
8.2.2 Echocardiographic measurements
The echocardiographic measurements were performed with a real-time, phased-array
sector scanner (Acuson Sequoia 512, Siemens, Germany) with an integrated color
Doppler system and transducers containing crystal sets for 2-dimensional imaging
(5.0 MHz with second harmonic technology) and for continuous-wave Doppler record-
ing (2.5 MHz). After localization of tricuspid regurgitation via Doppler color ﬂow
imaging, the maximal tricuspid regurgitation velocity vmax was measured by means of
continuous-wave Doppler ultrasound. As previously validated by our group in hypoxia
against invasive measurements [10], the right atrioventricular pressure gradient ΔP was
estimated using the modiﬁed Bernoulli equation (ΔP = 4v2max). The SPAP was estimated
as ΔP+ RAP, where RAP (right atrial pressure) was assumed to be 10 mmHg [112].
Each reported SPAP value is the average of at least three measurements. The maximal
deviation among averaged values was found to be systematically ≤ 4 mmHg.
8.2.3 EIT measurements and image reconstruction
The EIT data were acquired with 16 gel electrodes (Ambu BR-50-K, Ambu, Denmark)
placed around the subjects’ chest in a transversal plane at the level of the ﬁfth intercostal
space. The EIT device was conﬁgured to inject currents at 100 kHz and acquire 25 images
per second. The ECG signal at the auxiliary input was sampled at 325 Hz. The EIT data
were reconstructed into images of 64×64 pixels with Matlab (MathWorks, Natick, USA)
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using the framework of the EIDORS toolbox [4]. The reconstruction was performed
using the 2.5D human thorax model of EIDORS and the GREIT algorithm with the
recommended settings [5].
8.2.4 EIT data processing
The following three sections describe the proposed automatic signal processing method
for estimating one global pulmonary PAT value from each 2-minute EIT recording.
Pixel-wise signal processing. As a ﬁrst step, the EIT time signal at each pixel was
ﬁltered using a high-pass (0.65 Hz) fourth-order Butterworth ﬁlter and zero-phase
ﬁltering in order to reduce the inﬂuence of respiration-related impedance changes.
These components and noise were then further attenuated through ECG-gated ensemble
averaging. As a result, each 2-minute EIT signal at each pixel was summarized by one
representative cardiovascular-related pulse s(t).
Automatic identiﬁcation of the pulmonary ROI. Then, the pulmonary ROI was au-
tomatically identiﬁed using the approach previously described in Section 7.2.3. In
short, at each pixel, the cardiac frequency Fourier coefﬁcient zT of s(t) was com-
puted (equation 7.10). As the pulmonary conductivity increases after cardiac ejec-
tion, the ﬁrst harmonic of s(t) was expected to resemble a sine wave in the lungs,
i.e. arg(zT) ≈ π/2, whereas it was expected to resemble an antiphase sine wave in the
heart, i.e. arg(zT) ≈ −π/2. Both types of pixels (pulmonary and cardiac) were thus sep-
arated by using a threshold value of 0 on arg(zT). The pulmonary ROI was then deﬁned
as those pulmonary pixels (arg(zT) > 0) with a signiﬁcant pulsatile amplitude, i.e. those
where the modulus |zT| of the ﬁrst cardiac harmonic was larger than an amplitude
threshold automatically set using Otsu’s method [125].
Estimation of the pulmonary PAT. The pulmonary PAT was also estimated as previously
described in Section 7.2.3. In short, a PAT value was estimated at each pixel from s(t)
using the intersection tangent method [33]. With M pixels contained within the ROI,
M estimates of the pulmonary PAT were thus obtained. Possible outliers were then
automatically rejected using the median absolute deviation method [99]. The ﬁnal
pulmonary PAT was obtained by averaging all non-rejected PAT estimates.
8.3 Results
8.3.1 EIT data processing
Before presenting the comparison between the EIT-derived PAT and the reference
echocardiography-derived SPAP (Section 8.3.2), the present section illustrates the var-
ious steps of the proposed EIT data processing method for estimating a pulmonary
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Figure 8.4 – Example of ECG-gated ensemble averaging. The “Raw EIT” curve depicts
an example of EIT time signal at a given pixel in the lung region. Its large ﬂuctuations are
due to respiration, while its smaller-amplitude oscillations are induced by pulmonary
arterial pulsatility. The main respiratory components of the signal are ﬁrst strongly
attenuated using a high-pass ﬁlter (“High-pass EIT” curve). Then, using the R-wave peak
of the ECG as cardiosynchronous trigger, all cardiovascular-related pulses are aligned
in time and averaged, leading to one “ensemble average” waveform representative of
pulmonary arterial pulsatility in that pixel.
PAT.
Pixel-wise signal processing. Figure 8.4 illustrates the process based on ECG-gated
ensemble averaging used for summarizing each 2-minute EIT time signal by one repre-
sentative cardiovascular-related pulse s(t) at each pixel.
Automatic identiﬁcation of the pulmonary ROI. Figure 8.5 shows examples of ensemble
average signals in the lung and heart regions and illustrates the discrimination between
both types of waveforms using the phase shift of the ﬁrst cardiac harmonic. In the
lung region, the harmonic is almost in phase with a sine wave at the cardiac frequency,
i.e. arg(zT) is slightly above π/2. In the heart region, the opposite occurs.
Figure 8.6 illustrates an example of pulmonary ROI segmentation (dotted lines). The left
panel depicts the pixel-wise modulus |zT| of the ﬁrst cardiac harmonic, and the right
panel its pixel-wise phase shift arg(zT).
Estimation of the pulmonary PAT. Figure 8.7 shows examples of pulmonary ensemble
average signals s(t) with their corresponding PAT estimations. Small vertical offsets
have been given to the signals for easier visualization.
8.3.2 EIT-based PAP monitoring
Figure 8.8 (left panels) shows the relation obtained between the EIT-derived PAT and
the reference echocardiography-derived SPAP (SPAPecho) for each subject. Figure 8.8
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Figure 8.5 – Examples of ensemble average signals s(t) in the lung (left) and heart (right)
regions, along with their ﬁrst cardiac harmonics. The phase shift arg(zT) is slightly
above π/2 in the lung region, where the harmonic resembles a sine wave at the cardiac
frequency. The opposite occurs in the heart region, where the harmonic resembles an
antiphase sine wave.
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Figure 8.6 – Examples of maps depicting (a) the pixel-wise modulus |zT| of the ﬁrst
cardiac harmonic and (b) its phase shift arg(zT). The dotted lines represent the automat-
ically extracted pulmonary region of interest. The medical image orientation (right side
on the left) is used.
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Figure 8.7 – Left panel: examples of pulmonary ensemble average signals in normoxia,
mild hypoxia and deep hypoxia. The estimated PAT of each curve is indicated by a dot.
Small vertical offsets have been added to the curves for easier visualization. Right panel:
zoom on the shaded area of the left panel.
(center panels) shows the relation between SPAPecho and SPAPEIT, the EIT-derived SPAP
estimate obtained using a least-square linear ﬁt of the PAT onto SPAPecho. Finally,
Figure 8.8 (right panels) shows the agreement between SPAPecho and SPAPEIT using a
Bland-Altman plot [19].
Each data point represents a 2-minute EIT recording and its corresponding echocardio-
graphic measurement. Note that the ﬁrst recording (ﬁrst measurement in normoxia)
in subject 1 and the third recording (ﬁrst measurement in mild hypoxia) in subject 3
could not be used due to ECG and EIT recording issues, respectively. As summarized
in Table 8.1, Pearson’s correlation coefﬁcients (r) in the range [−0.70,−0.98] (average:
−0.89) were obtained between the PAT and SPAPecho. Standard errors of the estimate
(SEE) in the range [0.9, 6.3] mmHg (average: 2.4 mmHg) were obtained between SPAPEIT
and SPAPecho.
Finally, Figure 8.9 shows the relation and agreement between SPAPEIT and SPAPecho for
all subjects together.
8.4 Discussion
8.4.1 Unsupervised and non-invasive PAP monitoring
In this study, we have presented experimental evidence of the feasibility of tracking
changes in PAP non-invasively via EIT. Changes in PAP were induced by hypoxic
vasoconstriction in fourteen healthy subjects, and reference SPAP values were obtained
from echocardiographic measurements.
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Figure 8.8 – EIT-based PAP monitoring: experimental results for each subject. Left-
side panels: comparison of the EIT-derived pulse arrival time (PAT) against the
echocardiography-derived systolic pulmonary artery pressure (SPAPecho). The Pearson’s
correlation coefﬁcient (r) between both quantities is indicated. The dotted lines depict
least-square linear ﬁts and their equations (y = a · x+ b) are given. Center panels: com-
parison of SPAPEIT – the EIT-derived estimate of SPAP obtained via a least-square linear
ﬁt of the PAT onto SPAPecho – with SPAPecho. The standard error of the estimate (SEE) is
indicated. Right-side panels: Bland-Altman plot [19] between SPAPEIT and SPAPecho. The
dotted lines indicate the 95 % limits of agreement.
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Figure 8.9 – EIT-based PAP monitoring: experimental results for all subjects. Top panel:
comparison of SPAPEIT with SPAPecho. Each type of marker corresponds to a subject.
The Pearson’s correlation coefﬁcient (r) and the standard error of the estimate (SEE)
between both quantities are indicated. Bottom panel: Bland-Altman plot [19] between
SPAPEIT and SPAPecho. The dotted lines indicate the 95 % limits of agreement.
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Table 8.1 – EIT-based PAP monitoring: experimental results for all subjects. “Pearson’s r”
column: Pearson’s correlation coefﬁcient between the EIT-derived PAT and the reference
echocardiography-derived SPAP (SPAPecho). “SEE (mmHg)” column: standard error
of the estimate between SPAPEIT and SPAPecho (SPAPEIT: EIT-based SPAP estimate
obtained via a per-subject linear least-square ﬁt of the PAT onto SPAPecho).
Subject
Pearson’s r SEE (mmHg)
PAT vs. SPAPecho SPAPEIT vs. SPAPecho
1 −0.98 1.4
2 −0.95 0.9
3 −0.88 1.7
4 −0.89 2.0
5 −0.70* 2.7
6 −0.93 1.3
7 −0.80 3.7
8 −0.96 2.6
9 −0.71* 6.3
10 −0.95 2.7
11 −0.89 1.2
12 −0.98 1.3
13 −0.86 2.9
14 −0.96 3.4
Average −0.89 2.4
Range [−0.70,−0.98] [0.9, 6.3]
*p < 0.1 (p < 0.05 otherwise).
Performance
For all subjects high correlation scores (r ∈ [−0.70,−0.98], average: −0.89) were found
between our EIT-derived PAT estimates and the reference SPAPecho values. Despite
the relatively small range of PAP variations induced through normobaric hypoxia
(< 10 mmHg in several subjects), the sensitivity of the EIT-derived PAT has shown to be
sufﬁcient for tracking these small variations.
For all subjects small standard errors of the estimate (SEE ∈ [0.9, 6.3] mmHg, aver-
age: 2.4 mmHg) were found between SPAPEIT and SPAPecho. In our study, SPAPEIT was
obtained using a least-square linear ﬁt of the PAT onto SPAPecho. Therefore, the reported
SEE values are the best achievable given the PAT values obtained. In practice, converting
measured PAT values to SPAPEIT would require an individual calibration to be trained
beforehand, possibly using three or four paired PAT-SPAPecho measurements to estimate
the regression line.
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Subject dependence of the PAT-SPAP relation
From Figure 8.8 (left panels), it can be observed that the relation between the PAT and
SPAPecho (y = a · x+ b) is different for each subject. This can be explained by several
subject-dependent factors inﬂuencing the PAT, in particular:
a) The duration of the pre-ejection period (PEP). As mentioned in Section 8.1, the PAT is
an approximation of the PTT and, formally speaking, is equal to PEP+ PTT [117].
The duration of the PEP is subject-dependent.
b) The dimensions of the lungs. The PAT depends on the length of the arterial pathway
traveled by the pressure pulse. This distance depends on the dimensions of the
lungs, which are also subject-dependent.
c) The compliance of the arteries. Arterial compliance, which is also subject-dependent,
affects both the PAP (by affecting the cardiac afterload) and the PAT (through its
link with PWV).
This is the reason why our approach is better suited for monitoring intra-subject trends
in PAP rather than absolute pressure values, which require an individual calibration
procedure to be performed.
Signal processing method
In this work we have proposed a fully unsupervised EIT-based method for the estimation
of the pulmonary PAT. This method makes heavy use of the cardiosynchronicity offered
by the ECG signal. ECG-gated ensemble averaging signiﬁcantly increases the signal-
to-noise ratio of the EIT signals without distorting them [139], while the use of the
phase shift with respect to the R-wave peak of the ECG for the segmentation of the
pulmonary ROI is simple, effective, and physiologically consistent. Furthermore, the
proposed method is resilient to erroneous or inaccurate PAT estimates through the use
of the median absolute deviation method in the estimation of the pulmonary PAT. In
this respect, one particular source of erroneous PAT estimates may be the thoracic aorta,
which is known to produce impedance changes that are detectable by EIT [157]. Their
quasi-synchronicity with the pulmonary cardiovascular-related impedance changes
might allow some pixels depicting aortic inﬂuence to be mistakenly included in the
pulmonary ROI. Our approach is expected to be resilient against such pixels for two
reasons: (1) as mentioned above, pixel-wise PAT estimates that are not consistent with
the majority are rejected by the median absolute deviation method; (2) because of the
small size (in the transverse EIT plane) of the thoracic aorta in comparison with the
lungs, only a small percentage of all ROI pixels will/might be inﬂuenced by the aortic
signal. Therefore, if not rejected as outliers, their inﬂuence is severely reduced by the
averaging of all non-rejected PAT estimates.
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8.4.2 Limitations and future work
Even though this study reveals novel and promising results, it is mainly limited by
the use of Doppler echocardiography as reference instead of the invasive pulmonary
artery catheter. In some subjects, echocardiography-derived SPAP measurements can be
inaccurate, depending on the strength of the tricuspid regurgitation signal [56]. A future
clinical validation of our approach should therefore use the gold standard pulmonary
artery catheter as reference.
Furthermore, it would also be interesting to investigate the long-term monitoring capa-
bilities of our EIT-based PAP estimation method. In particular, the two following aspects
should be examined:
a) The inﬂuence of the position of the EIT belt. We can assume that a belt positioned
slightly higher or lower would inﬂuence the PAT since the average distance trav-
eled by the pressure waves to reach the EIT plane would have changed. For
instance, assuming that a 2 cm vertical belt displacement changes the average
traveled distance by the same extent, a pressure wave traveling at 2 m/s would see
its PAT change by 10 ms. Given the PAT-SPAP relations found in this study, this
would translate to an error of 4.8± 2.8 mmHg in SPAP. We believe that quantifying
this error experimentally is of particular importance, as it is probably the main
factor impacting the repeatability of EIT measurements.
b) The stability of the PAT-to-SPAP calibration over time. Many systemic blood pressure
monitors based on the measurement of PWV require to be frequently recalibrated
due to their dependence on signals measured at the periphery [158]. Peripheral
arteries are subjected to vasomotion (spontaneous change in vascular tone), which
affects the PWV by a change in arterial compliance. Conversely, central elastic
arteries – such as the aorta or the pulmonary arteries – are not subjected to vaso-
motion [121]. The PAT-to-SPAP calibration should therefore – in theory – remain
unaffected over days/weeks. Again, we believe that verifying this assumption
experimentally is of particular importance.
8.4.3 Summary and conclusion
The measurement of PAP in hemodynamically unstable patients or patient with chronic
pulmonary hypertension is currently limited to invasive solutions (pulmonary artery
catheter) or solutions that are not conducive with continuous monitoring (Doppler
echocardiography). We have proposed a novel non-invasive and unsupervised PAP
monitoring method based on the use of EIT. The feasibility of our approach was evalu-
ated in fourteen healthy subjects undergoing hypoxia-induced PAP variations. Strong
correlation scores (r ∈ [−0.70,−0.98]) between echocardiography-derived SPAP mea-
surements and our EIT-derived parameter were found in all subjects, suggesting that
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EIT is a candidate technology for the non-invasive and continuous monitoring of PAP.
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9 Synthesis
The purpose of this thesis was to investigate the clinical potential of electrical impedance
tomography (EIT) as an hemodynamic monitor for the measurement of cardiac output
(CO) and pulmonary artery pressure (PAP).
More precisely, this thesis aimed at determining and quantifying the inﬂuence of heart
motion and belt position/displacement on the accuracy of the EIT-based measurement of
CO (Part II). Furthermore, this thesis aimed at proposing and investigating the feasibility
of a novel method for the EIT-based measurement of PAP, and to test it in vivo (Part III).
9.1 On the EIT-based monitoring of cardiac output
Over the course of this dissertation, we have highlighted the clinical importance of
being able to continuously monitor changes in CO – particularly in hemodynamically
unstable patients – and the need for a non-invasive alternative to the controversial
pulmonary artery catheter (PAC). We have then emphasized the limitations of current
non-invasive CO monitors, especially their dependence on peripheral signals, resulting in
the requirement of frequent recalibration. In this context, EIT – which measures central
signals – appeared as an attractive alternative solution.
9.1.1 Inﬂuence of heart motion
In the literature, the measurement of CO by EIT is implicitly based on the hypothesis that
the EIT heart signal (the ventricular component of the EIT signals) is generated exclusively
by changes in blood volume in the ventricles. However, heart motion (cardioballistic
effects) is suspected to have a non-negligible inﬂuence in the genesis of this signal due
to its ability to generate ventricular-like impedance changes. Therefore, in Chapter 5,
we aimed at quantifying the contribution of heart motion in the genesis of the EIT heart
signal and at determining its impact on the accuracy of EIT-based stroke volume (SV)
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estimation. Our investigations have revealed that heart motion, through the interaction
of the myocardium with its surrounding tissues, is the main contributor to the genesis
of the EIT heart signal (by ∼ 56 %). Moreover, our simulations showed that a strong
correlation (r > 0.97) exists between the impedance changes induced by heart motion
and those induced by the variations in ventricular blood volume. We explained this
correlation by the quasi-incompressibility of blood and myocardial tissue, which forces
these two effects to act in concert. As a result – although dominated by effects related
to heart motion – the amplitude of the EIT heart signal was found to remain strongly
correlated with changes in SV (r > 0.99), thereby demonstrating the feasibility of
monitoring CO changes using EIT with high accuracy (error of 0.57 ± 2.19 mL, or
1.02 ± 2.62 %, on the estimation of SV).
Besides, our observations suggested that the amplitude of the motion-related component
of the EIT heart signal is modulated by respiratory activity, which could affect the
accuracy of the EIT-based measurement of SV. As a practical workaround, we have
suggested the use of respiration-gated EIT measurements. Such a solution could solve
the aforementioned issues, at the cost of limiting the responsiveness of EIT for CO
monitoring, of particular importance during hemodynamic instability.
Importantly, our results also suggest that the EIT-based measurement of CO may be
compromised in particular pathological conditions, such as large pericardial effusion. In
such cases, heart motion is not limited to the normal deformation of the myocardium, but
also to its displacements in the pericardial cavity. The resulting mechanical interactions of
the heart with its surrounding tissues – unrelated to SV – are likely to signiﬁcantly affect
the EIT heart signal. We have also explained that other pathologies, such as valvular
insufﬁciencies, are likely to compromise the EIT-based measurement of CO, as the EIT
heart signal does not account for the volume of blood being pushed back through the
faulty valve.
9.1.2 Inﬂuence of belt position and displacement
In Chapter 6, we investigated a practical difﬁculty inherent to the measurement of CO
by EIT, namely the adequate placement of the belt along the long axis of the heart.
This position is assumed to minimize the inﬂuence of pulsatile sources unrelated to
ventricular activity on the EIT heart signal [171], but is hardly achievable in practice
without the use of another imaging modality to verify the placement.
For less optimal belt placements commonly used in cardiac EIT, our experiments have
shown that the EIT heart signal is still dominated by ventricular activity, but is also
inﬂuenced by non-negligible pulmonary, atrial and – to a lesser extent – aortic pulsatile
components. According to our preliminary ﬁndings, these non-ventricular inﬂuences
on the EIT heart signal do not compromise the measurement of CO by EIT.
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Our investigations have also revealed a limiting aspect concerning the placement of the
belt, namely the inﬂuence of a displacement on the accuracy of the estimation of CO. This
inﬂuence was found not to be negligible, with errors up to 30 mL on the estimation of SV.
Our results suggest that even small displacements (1-2 cm) may require the EIT signal
to be recalibrated if absolute CO values are necessary.
9.1.3 Summary
In summary, our CO-related studies indicate that:
a) It is possible to monitor changes in CO non-invasively by EIT, despite the domi-
nantly motion-related origin of the EIT heart signal.
b) The accuracy of EIT-based CO estimation may be affected by respiratory activity.
Furthermore, the measurement could even be compromised under speciﬁc patho-
logical conditions such as severe pericardial effusion and valvular insufﬁciencies.
c) Belt placements commonly used in cardiac EIT – although suboptimal for the
measurement of CO – can reliably track changes in SV. Oblique placements, which
allow obtaining a larger ventricular contribution in the EIT heart signal, should be
preferred over transverse placements.
d) When absolute CO values (rather than just trends) are needed, a recalibration of
the measurement is strongly advised in events of displacement or repositioning of
the EIT belt.
9.2 On the EIT-based monitoring of pulmonary artery pressure
In clinical settings, the continuous monitoring of PAP is currently limited to the invasive
PAC, with the known non-negligible risks associated with its use. Doppler echocar-
diography, although non-invasive, is not conducive with continuous monitoring due
to its dependence on a medical doctor to perform the measurement. Moreover, only
50–80 % of patients have sufﬁcient tricuspid regurgitation for the measurement to be
performed [37, 40]. Thus, the clinical need for a non-invasive and unsupervised solution
to monitor the PAP is strong.
9.2.1 Feasibility of a novel non-invasive method
We have proposed a novel method for monitoring the PAP from EIT measurements. The
method is based on the physiological relation linking blood pressure and the pulse wave
velocity (PWV), the speed of propagation of the pressure waves in the arteries.
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In Chapter 7, we demonstrated via simulations the validity of our method for several
types of pulmonary hypertensive conditions and various degrees of disease severity.
Our results, which demonstrate a logarithmic relation between the pulmonary PWV
and the PAP, are in line with physiological expectations (see Section 2.5). PWV has a
high sensitivity to small losses in arterial distensibility at lower pressures. The same
observation was drawn in intravascular ultrasound and MRI studies [96, 148], demon-
strating that PWV – even more than PAP itself – is a strong predictor of survival [94, 95].
Our PWV-based method is therefore particularly indicated for monitoring early changes
in pulmonary hemodynamics.
9.2.2 In vivo evaluation
In Chapter 8, we tested our novel PAP monitoring method in vivo. To that end,
we induced elevations in PAP in fourteen healthy volunteers by subjecting them to
various levels of normobaric hypoxia. Our results demonstrated strong correlations
(r ∈ [−0.70,−0.98], average: −0.89) between our EIT-derived PWV-related parameter –
the pulse arrival time (PAT) – and measurements of systolic PAP obtained by echocardio-
graphy, thereby allowing a ﬁrst experimental validation of our method. When converting
the measured PAT values to pressure units using per-subject calibrations, small standard
errors of the estimate were obtained (SEE ∈ [0.9, 6.3] mmHg, average: 2.4 mmHg).
From a signal processing perspective, the proposed method has the advantage of being
simple, robust and fully unsupervised, particularly regarding the selection of the region
of interest – often a critical task in EIT given the fact that electrical tomographs are poor
anatomical references.
Besides, it is important to note the subject-dependent relation between the PAT and
the PAP, which prevents any inter-subject PAT comparison at similar PAP levels. We
explained these differences by the anatomical (e.g. lung dimensions) and physiolog-
ical (e.g. duration of the pre-ejection period, compliance of the pulmonary arteries)
differences existing between individuals.
Finally, it is worth mentioning that our studies on PAP have not investigated the in-
ﬂuence of a displacement of the EIT belt, likely to be the main factor affecting the
repeatability of the measurement. We can assume that the PAT would be different since
the average distance traveled by the pressure waves to reach the EIT plane would have
changed. The extent of this difference – that we roughly estimated to be ∼5 mmHg for
a 2 cm vertical belt displacement – remains to be formally quantiﬁed experimentally.
Similarly, the stability of the per-subject PAT-to-PAP calibration over time – hypothesized
to be guaranteed due to the absence of vasomotion (spontaneous changes in vascular
tone) in the pulmonary arteries – remains to be veriﬁed experimentally.
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Figure 9.1 – Perspectives of EIT in intensive care units for the monitoring of CO and
PAP. In patients undergoing right heart catheterization (“PAC patients”), EIT could be
used to extend the measurement after removal of the PAC, and to allow the monitoring
of short-term trends in-between the intermittent CO measurements by the PAC. In
patients not undergoing right heart catheterization (“Non-PAC patients”), EIT could be
used to monitor otherwise unknown trends and, when possible and necessary, could
be calibrated using a non-invasive modality such as transthoracic echocardiography to
provide absolute values of CO or PAP.
9.2.3 Summary
In summary, our PAP-related studies indicate that:
a) It is possible to monitor changes in PAP non-invasively by EIT.
b) The pulmonary PWV being a strong predictor of survival [94, 95], our PWV-based
method is particularly indicated for the detection of early changes in pulmonary
hemodynamics. In contrast, our method is likely to be less sensitive to small
changes in PAP at higher pressures (i.e. in case of severe pulmonary hypertension).
c) The monitoring of absolute pressure values requires an individual calibration
(e.g. by echocardiography). A universal (population-wise) calibration is unlikely to
be found given the numerous subject-speciﬁc factors inﬂuencing the PAT.
d) The effects of a displacement of the EIT belt on the estimation of the PAP and the
stability of per-subject PAT-to-PAP calibrations remain to be investigated experi-
mentally.
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9.3 Perspectives in intensive care units
The use of EIT in clinical settings is still in its early stages. In this section we aim at
determining what its main area of use could be as a non-invasive CO and/or PAP
monitor, particularly in intensive care units. Figure 9.1 illustrates this concept. We
consider two situations/scenarios, depending whether the patient is equipped with a
PAC (“PAC patients”) or not (“Non-PAC patients”).
In PAC patients, CO is obtained intermittently from the PAC. EIT could therefore be used
to track short-term CO variations in-between consecutive PAC measurements, using the
latter as a calibration means to provide continuous absolute CO trends. Furthermore,
EIT could allow extending the monitoring after removal of the PAC. Its calibration being
independent of peripheral effects such as vasomotion, it is expected to remain valid over
a sustained period of time.
Regarding the measurement of PAP in PAC patients, the utility of EIT would be to
provide a continuous monitoring after removal of the PAC, using the latter as a cali-
bration means to provide continuous absolute PAP trends. Here also, the calibration is
expected to remain valid over a sustained period of time, as the pulmonary arteries are
not subjected to vasomotion [97].
In non-PAC patients, EIT by itself (uncalibrated) could be used to provide otherwise
unavailable CO and PAP trends. Trends (rather than absolute values) are of particular
clinical importance in events of circulatory shock. A non-invasive access to such trends
could also have a signiﬁcant impact for vulnerable patients, such as newborns or children.
For instance, for conditions such as persistent newborn pulmonary hypertension, there
is a strong reluctance in exposing the patients to invasive procedures, and alternatives
are limited [51]. When needed and possible, a calibration by means of an alternative
modality (e.g. transthoracic echocardiography) could allow translating the measured
EIT values to absolute units of CO or PAP (green blocks in Figure 9.1).
9.4 Original contributions
The original contributions of the present thesis can be summarized as follows.
a) The creation of a dynamic 2.5D bioimpedance model dedicated to investigating
the inﬂuence of cardioballistic effects (heart motion) on the EIT heart signal.
b) The demonstration via simulations on the model of the feasibility of tracking
changes in CO by means of EIT with good accuracy – despite the dominantly
cardioballistic origin of the EIT heart signal – and the identiﬁcation of factors that
may affect this accuracy.
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c) The creation of a 4D bioimpedance model of the pulmonary vasculature capable of
realistically simulating pulmonary hemodynamics in various cases of pulmonary
hypertension.
d) The development of a novel non-invasive and unsupervised PAP monitoring
method based on the use of EIT and the measurement of changes in pulmonary
pulse wave velocity.
e) The demonstration, via simulations on the aforementioned model, of the feasibility
of tracking changes in PAP by means of the proposed method in various cases of
pulmonary hypertension.
f) The validation in vivo of the proposed method in healthy subjects undergoing acute
changes in PAP through hypoxia.
9.5 Limitations and future work
9.5.1 EIT-based CO monitoring
Our investigations have provided novel insights about the genesis of the EIT heart
signal, and helped to determine the physiological and metrological requirements for
an accurate measurement of CO by EIT. However, our observations remain limited by
the absence of experimental validation. In our opinion, future work should therefore
mainly focus on carrying out a clinical trial, e.g. before and after anesthesia in patients
undergoing cardiac surgery, using PAC thermodilution CO measurements as reference.
Patients with valvular insufﬁciencies or large pericardial effusion should be excluded.
Changes in SV could be induced using the passive leg raising maneuver, used to predict
ﬂuid responsiveness in critically ill patients [116]. This maneuver consists in elevating
the legs of the patient from the supine position by a 30–60◦ angle, which allows increasing
the cardiac preload and thereby increasing SV. The so-called semi-recumbent position
has the opposite effect: the patient’s trunk is raised from the supine position by a 30–60◦
angle, thus decreasing the cardiac preload and thereby decreasing SV. Using these two
maneuvers along with the baseline supine position would therefore allow generating SV
variations to evaluate the trending ability of EIT. These maneuvers are non-invasive and
easy to perform, and could therefore be repeated twice to increase the number of paired
EIT-PAC measurements. Furthermore, they could also be repeated after anesthesia, as
the baseline CO is likely to have changed. As a results, a series of 6 to 12 paired EIT-PAC
measurements would be obtained for each patient, which is sufﬁcient to assess trending
ability [36].
According to our observations, careful consideration should be given to the following
aspects regarding the EIT measurements:
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a) The EIT belt should be placed in the oblique plane as described in [171] to maximize
ventricular contribution to the EIT heart signal.
b) If feasible during the experimental protocol, typically before anesthesia at baseline
condition, the belt should initially be placed ∼1.5 cm below the desired position,
then ∼ 1.5 cm above, and ﬁnally at the desired position. At each position, EIT
measurements paired with PAC measurements should be performed. These mea-
surements should allow quantifying the inﬂuence of belt displacements on SV
estimation experimentally.
c) During the remainder of the protocol, particular attention should be paid to mini-
mize the displacements of the belt.
d) During data analysis, we suggest the use of respiration-gating. The inﬂuence of
respiratory activity on the accuracy of the EIT-based measurement of CO should be
formally quantiﬁed by comparing the estimation errors obtained when respiration-
gating is or not used.
9.5.2 EIT-based PAP monitoring
A novel method for the non-invasive monitoring of PAP by EIT has been proposed and
validated both through simulations and experimentally. However, our experimental
study comprises some limitations, such as the use of Doppler echocardiography as
reference instead of the gold standard PAC. Although validated against PAC measure-
ments [10, 37, 108], echocardiographic measurements of the PAP can still be inaccurate
in the individual patient [56]. A future clinical study in patients should therefore use the
PAC as reference.
In such a study, PAP variations could for instance be induced after anesthesia by de-
creasing the inspired oxygen fraction in the ventilator, causing hypoxic pulmonary
vasoconstriction and increases in PAP. Alternatively, decreases in PAP could be induced
via inhaled nitric oxide, a selective pulmonary vasodilator used for the treatment of
patients with pulmonary hypertension and hypoxemia [76]. As the PAC and EIT both
provide continuous beat-to-beat readings, a large amount of paired PAC-EIT measure-
ments could thus be obtained and allow testing the beat-to-beat trending ability of EIT
for PAP monitoring.
Another particularly important aspect to be investigated is the stability over time of
the PAT-to-PAP calibration, in particular for the long-term monitoring of patients with
chronic pulmonary hypertension. This implies testing:
a) The inﬂuence of a different positioning of the EIT belt, which directly affects the
calibration itself as it affects the PAT;
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b) The repeatability of the calibration at intervals of weeks/months on a same subject.
To test both of these aspects, a study should be conducted in patients with chronic
pulmonary hypertension undergoing right heart catheterization during at least two
different visits at the clinic. During the ﬁrst visit, the following experimental protocol
should be performed:
a) The belt placement should be precise and easily reproducible. We suggest a
placement at the level of the ﬁfth intercostal space, as was done in our experimental
study. Distance measurements between the belt and anatomical reference points
should be performed, in order to facilitate the placement of the belt at the exact
same location during the next visit.
b) Once the belt in place, simultaneous PAC and EIT measurements should be per-
formed.
c) If not occurring naturally, small PAP variations should be induced in order for a
calibration function to be trainable. To do so, using the aforementioned passive leg
raising maneuver and semi-recumbent positions may be sufﬁcient to induce small
PAP variations (∼6 mmHg) [97, 98]. Alternatively, inhalation of nitric oxide via a
face mask could be performed. During the procedure, PAC and EIT measurements
should be performed continuously and a PAT-to-PAP calibration function trained.
d) Then, the belt should be shifted vertically by a small amount (e.g. 1.5 cm) above
the original position, and simultaneous PAC and EIT measurements should be
performed. The procedure should be repeated with a downward shift of the belt.
The measured PAT values should then be converted to pressure units using the
previously trained calibration function, and compared with the PAC-derived PAP
values. This should allow quantifying the inﬂuence of changes in belt position on
the accuracy of EIT-based PAP estimation.
e) Finally, during the next visit of the patient to the clinic, the belt should be po-
sitioned as close as possible to the initial placement. EIT measurements should
be performed and the PAT values obtained – converted to PAP values using the
previously trained calibration function – should be compared to the PAC-derived
PAP values. This should allow assessing the long-term stability of the calibration
function.
9.6 Conclusion
In conclusion, this thesis has – on the one hand – identiﬁed the dominantly cardioballistic
origin of the EIT heart signal. We have described how the impedance changes induced
by these cardioballistic effects correlate with ventricular volume, and identiﬁed several
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factors and conditions susceptible to affect the accuracy of the measurement. The
inﬂuence of belt position and displacements on the accuracy of the measurement of
CO have also been described and quantiﬁed. We have laid the foundation for future
investigations, and identiﬁed the clinical perspectives and main challenges ahead in the
EIT-based measurement of CO.
On the other hand, this thesis has proposed a novel non-invasive method for the EIT-
based measurement of PAP. We have developed a 4D model of the human thorax and
demonstrated the validity of our approach in various pulmonary hypertensive disorders.
We have explained its capability of being a stronger predictor of outcomes than PAP
itself due to its high sensitivity to small pressure changes in mild to moderate pulmonary
hypertension. Finally, we have demonstrated the validity of our method in vivo, thereby
paving the way for the development of a new branch of non-invasive PAP monitors
based on the use of EIT.
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A Anatomical and circulatory models
of the pulmonary arterial tree
The 4D bioimpedance model of the pulmonary arterial tree created in the present thesis
is based on the junction of two models:
a) A 3D anatomical model of the pulmonary arterial tree;
b) A 1D circulatory model of the pulmonary circulation.
In Section A.1, we present the algorithm on which our method for the creation of the 3D
geometrical model is based. In Section A.2, we introduce two circulatory models, our
circulatory model being based on the junction of both.
A.1 Anatomical model
A.1.1 Volume-ﬁlling branching algorithm
Let us suppose that we segment CT scans to extract the outer contour of the lungs and
the major pulmonary arteries of a subject. The limited resolution of medical imagery
techniques does not allow the segmentation of the entire pulmonary arterial tree. It
is therefore necessary to “generate” the remaining arteries in an automatic manner.
In other terms, if the incomplete imagery-obtained tree contains N terminal arterial
segments, the remainder of the tree can be grown in the unoccupied pulmonary volume
by using these N terminal segments as seed points for the tree growing procedure.
This is the principle behind the so-called volume-ﬁlling branching algorithm proposed by
Burrowes et al [28]. Its working principle is explained in detail in Figure A.1.
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(a) (b) (c)
Figure A.1 – Schematic illustration of the volume-ﬁlling branching algorithm [28] with
N = 2 terminal arterial segments. (a) The pulmonary cavities are ﬁlled with a uniform
3D grid of points (not shown). Each grid point is assigned to the closest terminal
segment, resulting in N clusters of points (separated by the straight line in the ﬁgure).
The center of mass of each cluster is calculated (black dots). (b) Each cluster is divided
into two subclusters using the plan (here, a dashed line) that contains its center of mass
and the terminal segment it is assigned to, resulting in a total of 2N subclusters. The
center of mass of each subcluster is calculated (white dots). (c) The, the two daughter
arteries of each terminal segment are generated by connecting its extremity to the centers
of mass of the two corresponding subclusters and by stopping at 40 % of the distance.
The 2N newly generated arterial segments are then considered as the new terminal
segments, and the whole procedure can start all over again. The procedure stops for a
given terminal segment when its length goes below a predeﬁned threshold lmin or when
the cluster it is assigned to contains less than two grid points.
A.1.2 Geometry and morphometry of the tree
Although the length and the spatial distribution of the arteries in the volume of the
lungs are determined by the volume-ﬁlling branching algorithm itself, their radius is
not. The relationship between the radiuses rd1 and rd2 of two sister arteries with the
radius rp of their parent artery is controlled by three parameters, namely an asymmetry
ratio γ, an area ratio η and a branching ratio ξ [123]:
γ =
r2d2
r2d1
, η =
r2d1 + r
2
d2
r2p
, rξp = r
ξ
d1
+ rξd2 . (A.1)
These parameters are not independent as:
η =
1+ γ
(1+ γξ/2)2/ξ
. (A.2)
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From (A.1) it follows:
rd1 = rp · (1+ γξ/2)−1/ξ , rd2 = rd1 ·
√
γ. (A.3)
Thus, as the radiuses of the ﬁrst arteries of the tree are known (by imaging), it is possible
to deduce iteratively the radiuses of all arteries in the tree, provided that γ, η and ξ are
known as well. The values of these parameters are adjusted such that the morphometry
of the generated tree matches that of actual pulmonary arterial trees.
Another important geometrical aspect of the arteries is their tapering (radius narrowing
along their length), a characteristic that is particularly signiﬁcant in the larger pulmonary
arteries [123, 154]. Their tapering follows an exponential curve of the form [124]:
r(x) = rin · exp(−kx), (A.4)
where k = ln(rout/rin)/l is the tapering factor, rin and rout are the radiuses of the artery
at its input and output, l is its length, and x is the location along the artery. The factor
k is determined empirically using average values from morphometrical data of the
pulmonary arteries [17, 124].
A.2 Circulatory models
As mentioned in the previous section, a 1D circulatory model of the pulmonary circu-
lation is used in the present thesis. The purpose of so-called 1D distributed parameter
models is to describe the propagation and distribution of pressure and ﬂow waves in
the arterial tree. The main idea behind these models is to solve the Navier-Stokes equa-
tions describing the motion of a viscous ﬂuid (blood) in tubes (arteries) as a function
of pressure and ﬂow in each arterial segment of the tree. Comparing the pulmonary
arterial tree to a vast network of interconnected segments through which pressure and
ﬂow waves propagate, parallels with transmission line theory can be drawn, where:
a) Each arterial segment is a transmission line and can be modeled using a longitudi-
nal (ﬂuid resistance and inertance) and a transverse (wall compliance) impedance
(see Figure A.2);
b) The pressure gradient across an arterial segment is analogous to electrical voltage;
c) The ﬂow running through the segment is analogous to electrical current.
The relationship between voltage and current in transmission line theory is described
by the so-called Telegrapher’s equations, which have analytical solutions in case of
sinusoidal steady state. Thus, assuming the pressure gradient (voltage) and the ﬂow
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Figure A.2 – Upper panel: Model of a non-tapering arterial segment of length l. Lower
panel: Electrical analog, with R′, L′ and C′ the electrical resistance, inductance and
capacitance per unit length, respectively mimicking their hydraulic counterparts.
(current) to be periodic in the cardiovascular system, analytical solutions can be found for
pressure and ﬂow. However, this implies that each arterial segment can be represented
as in Figure A.2, i.e. with uniform anatomical and structural properties (resistance,
inertance, compliance) over the entire segment. This is not true in the larger pulmonary
arteries, which – as mentioned earlier – taper signiﬁcantly along their length. The
tapering of the large arteries induces non-linear effects (convective acceleration), which
prevent the direct use of transmission line theory [123]. Numerical approaches are
therefore required to solve the Navier-Stokes equations in these segments of the tree.
However, the aforementioned non-linear effects tend to become negligible at smaller
scales [167]. Analytical solutions based on transmission line theory can therefore be
used for the smaller arteries of the pulmonary tree, which is convenient as solving the
problem numerically in the smaller vasculature becomes computationally infeasible due
to the size of the tree [123].
We introduce hereafter the 1D distributed parameter model developed by Reymond [141]
for the systemic circulation, and adapted by Billiet [17] for the pulmonary circulation.
This model focuses on the larger segments of the arterial tree and uses a numerical
solving scheme. We will then introduce the linearized model for the smaller arteries
and its analytical solutions based on transmission line theory. In the present thesis,
both model are jointly used to assess the distribution of pressure and ﬂow in the entire
pulmonary arterial tree.
A.2.1 Non-linear model for the large arteries
In 1D distributed parameter models for the large arteries such as Reymond’s [141], the
arteries are considered as long straight tapering segments of constant length l and time-
and location-dependent cross-sectional area A(x, t) = πR(x, t)2 (see Figure A.3). The
blood running through the artery is subjected to a pressure p(x, t) and ﬂows at a rate
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Figure A.3 – Model of a large arterial segment (tapering tube) of length l and cross-
sectional area A(x, t).
q(x, t). Both quantities are assessed by solving the integral form of the continuity and
x-momentum Navier-Stokes equations in each arterial segment [123, 141]:
∂q
∂x
+
∂A
∂t
= 0, (A.5)
∂q
∂t
+
∂
∂x
(∫
A
u2dA
)
+
A
ρ
∂p
∂x
− 2πRμ
ρ
∂u
∂r
∣∣∣∣∣
r=R
= 0, (A.6)
where μ and ρ are the dynamic viscosity and the density of blood, respectively. Both
the convective acceleration term ∂∂x
(∫
A u
2dA
)
and the wall shear stress term μ ∂u∂r |r=R
depend on blood velocity u(x, r, t), which is a priori unknown. In his model, Reymond
uses oscillatory ﬂow theory (see the next section) to obtain good approximations of these
terms [141]. The system of equations (A.5+A.6) then only consists of three unknowns,
namely pressure (p), ﬂow (q) and arterial cross-sectional area (A). A so-called state
equation describing the sensitivity of the cross-sectional area of an artery to a change in
its distending pressure is used to complete the system [123]:
∂A
∂p
= f (A, p), (A.7)
where C′ = ∂A∂p is a quantity known as area compliance (or capacitance per unit
length) [180], and f (·) is an empirically-derived non-linear relation describing the vis-
coelastic properties of the arterial wall [17, 141]. The three-unknown system
(A.5+A.6+A.7) is then solved numerically, using appropriate boundary conditions.
Boundary conditions. The concept of boundary conditions for 1D distributed parameter
models is illustrated in Figure A.4. As inﬂow boundary condition, an “excitation” signal
(typically a ﬂow waveform) is inputted at the entry of the arterial tree. Alternatively, a
pressure waveform or a model of the right ventricle (varying elastance model) can be
used instead [141], but only one of them in order not to overdetermine the system [123].
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Figure A.4 – Boundary conditions for 1D distributed parameter models. As inﬂow
boundary condition, a ﬂow waveform (qin) is typically used. As outﬂow boundary con-
ditions, each terminal segment of the arterial tree is connected to an output impedance
(Zout,i) which mimics the hydraulic load “seen” beyond each segment down to venous
pressure (pv).
Figure A.5 – Electrical representation of the 3-element Windkessel (WK3) model. The
WK3 model mimics the load “seen” downstream from a given arterial site. Rp is the
so-called proximal resistance and represents the characteristic impedance of the arterial
site [141]. Rd (the distal resistance) and C respectively represent the global resistance
and compliance attributed to all peripheral arteries downstream of the site [179].
Reymond’s model can use both a ﬂow waveform and a varying elastance model [141].
As outﬂow boundary conditions, a typical choice is the use of output impedances at
the leaves of the tree [123]. Each impedance mimics the load “seen” beyond the arterial
tree (or portion of the tree) under consideration. These impedances, referred to as zero-
dimensional (lumped parameter) models, consist of resistive, capacitive and inertial
components connected in series and parallel, by analogy with electrical circuit theory.
One example is the 3-element Windkessel model (see Figure A.5), which consists of two
resistive and a capacitive element, and is capable of accurately mimicking the cardiac
afterload [179]. This is the choice made by Reymond in his model [141].
A.2.2 Linear model for the small arteries
For the small arteries, the complexity required for solving the aforementioned three-
unknown system (A.5+A.6+A.7) becomes computationally infeasible due to the size
of the arterial tree [123]. However, as smaller arteries do not taper signiﬁcantly, the
140
A.2. Circulatory models
convective acceleration term in the x-momentum Navier-Stokes equation (second term
in (A.6)) becomes negligible [35, 154]. Furthermore the state equation (A.7) can be
simpliﬁed [123]. The linearization of the governing equations becomes possible [123]
and an analytical solution for pressure and ﬂow can be found in every small arterial
segment of the tree, as will be detailed hereafter. These solutions make heavy use of
transmission line theory (by analogy with electrical circuits) and oscillatory ﬂow theory
(also known as Witzig-Womersley theory, or simply Womersley theory) [167].
Let us start with the simpliﬁcation of the state equation (A.7). As small arterial segments
do not taper, their cross-sectional area is constant. Neglecting viscoelastic effects [123],
the area compliance C′ = ∂A∂p can be obtained using [180]:
C′ = δA0, (A.8)
where A0 is the zero-pressure cross-sectional area of the arterial segment and δ is the
distensibility of its wall. For the small arteries, the continuity equation (A.5) remains
unchanged and can be merged with (A.8) since ∂A∂t =
∂A
∂p
∂p
∂t = C
′ ∂p
∂t [123, 181]:
∂q
∂x
+ C′
∂p
∂t
= 0. (A.9)
Furthermore, neglecting the convective acceleration term [35, 154], the linearized version
of the x-momentum equation (A.6) can be rewritten as [123, 181]:
R′q+ L′
∂q
∂t
+
∂p
∂x
= 0, (A.10)
where R′ and L′ are the ﬂuid resistance and inertance per unit length, respectively. Based
on pioneering work by Witzig [182], Womersley showed, in his oscillatory ﬂow theory,
that R′ and L′ are given by [181, 183]:
R′ =
ρω
A0M
sin(θ), (A.11)
L′ =
ρ
A0M
cos(θ), (A.12)
where ω is the angular frequency. The quantities M and θ were deﬁned by Womersley
as follows:
Meiθ = 1− 2J1(αi
3/2)
αi3/2 J0(αi3/2)
, (A.13)
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where J0 and J1 are the zeroth and ﬁrst order Bessel functions, i =
√−1 is the imaginary
unit, and α is the so-called Womersley number [167]. In an arterial segment of radius r0,
α = r0(ρω/μ)1/2.
Equations (A.9) and (A.10) are analogous to the Telegrapher’s equations in transmission
line theory, which describe the relationship between voltage and current along a trans-
mission line [146]. The problem can be formulated in the frequency domain because of
the pulsatile nature of pressure and ﬂow waveforms. Let us ﬁrst rewrite both equations:
∂Q
∂x
+ C′iωP = 0, (A.14)
Q(R′ + iωL′) +
∂P
∂x
= 0. (A.15)
where P = P(x, ω) and Q = Q(x, ω) are the complex Fourier series of p(x, t) and
q(x, t), respectively. The sinusoidal steady-state solutions of the system of equations
(A.14+A.15) are [146]:
P(x, ω) = P(0, ω)
[
Z(0, ω) + Zc
2Z(0, ω)
e−γx +
Z(0, ω)− Zc
2Z(0, ω)
eγx
]
, (A.16)
Q(x, ω) = Q(0, ω)
[
Z(0, ω) + Zc
2Zc
e−γx +
Zc − Z(0, ω)
2Zc
eγx
]
, (A.17)
where Z(x, ω) = P(x, ω)/Q(x, ω). The quantities Zc and γ are the characteristic
impedance and the propagation coefﬁcient of the arterial segment, respectively. From
transmission line theory, these two quantities are given by [146]:
Zc =
√
R′ + iωL′
iωC′
, (A.18)
γ =
√
iωC′(R′ + iωL′). (A.19)
The relation linking the input impedance Z(0, ω) of any arterial segment of length l to
its output impedance Z(l, ω) is derived from transmission line theory by combining
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equations (A.16) and (A.17). It follows that:
Z(0, ω) = Zc
Zc + Z(l, ω)− [Zc − Z(l, ω)] e−2γl
Zc + Z(l, ω) + [Zc − Z(l, ω)] e−2γl . (A.20)
Furthermore, by analogy with electrical circuit theory, the relation linking the output
impedance Z(l, ω)p of a parent artery to the input impedances Z(0, ω)dj (j = {1, 2}) of
its two daughters is given by:
1
Z(l, ω)p
=
1
Z(0, ω)d1
+
1
Z(0, ω)d2
. (A.21)
Therefore, provided that proper outﬂow boundary conditions have been deﬁned, as
previously described for the large arteries, we can iteratively apply equations (A.20)
and (A.21) and recursively compute the input and output impedances of all small arterial
segments in the tree in a bottom-up fashion.
Finally, using an appropriate inﬂow boundary condition at the entry of the small arterial
vasculature, such as ﬂow or pressure waveforms, the distribution of pressure and ﬂow
in all small arterial segments can be obtained.
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